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ABSTRACT OF THE DISSERTATION 
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by 
 
Elizabeth Jane Videlock 
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University of California, Los Angeles, 2019 
Professor Charalabos Pothoulakis, Chair 
 
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by 
abdominal pain associated with alteration in stool form and/or frequency. The pathophysiology 
of IBS is poorly understood. Although structural or histological changes in the gastrointestinal 
tract are absent in IBS, changes in intestinal function (e.g. increased intestinal permeability, 
increased neuronal sensitivity) and changes at the molecular level (e.g. gene methylation, 
gene/protein expression) have been described. 
This dissertation describes a translational research project which began with data from 
gastrointestinal biopsies and concluded with studies in cell culture models.  We performed a 
microarray gene expression profiling analysis of colonic mucosal biopsies in patients with IBS 
and healthy controls. I analyzed the differential gene and described the pathways involved in the 
regulation of IBS. These studies have direct clinical impact to patient care. Since data in the 
literature suggests a role for epigenetic changes (changes affecting gene expression) in IBS, I 
next focused on the role of differentially expressed long non-coding RNAs in IBS. The long non-
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coding RNA afadin-divergent transcript (AFDN-DT), which was up-regulated in IBS, was 
selected for further in vitro studies. I generated intestinal epithelial cell lines capable of inducible 
expression of AFDN-DT and tested the hypothesis that overexpression of AFDN-DT resulted in 
altered epithelial permeability.  
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Chapter 1: 
 
Introduction 
 
  
 2 
ABSTRACT 
Irritable bowel syndrome (IBS) is a common disorder characterized by abdominal pain 
associated with alterations in stool form and/or frequency. IBS is prevalent and accounts for 
significant cost and morbidity. While there have been significant advances in the field, there is 
still no reliable biomarker for IBS, nor is there a unified pathophysiologic mechanism. Therefore, 
both diagnosis and treatment are based on symptoms. The goal of the research presented in 
this dissertation was to improve understanding of IBS at the molecular level. Ultimately, my aim 
was to advance progress toward development of diagnostic tools and specific therapies for IBS 
and thereby improve quality of life for IBS patients. 
  
 3 
IRRITABLE BOWEL SYNDROME 
Definition of irritable bowel syndrome 
Irritable bowel syndrome (IBS) is characterized by abdominal pain associated with alterations in 
stool form and/or frequency. It is frequently diagnosed in both primary care and specialty 
practice.(1) IBS occurs in the context of a grossly and histologically normal gastrointestinal (GI) 
tract. For this reason, it has been referred to as a “functional” GI disorder. Over the past decade, 
the traditional dichotomy between “functional” and “organic” has been called into question by the 
growing body of evidence for changes at the molecular level associated with IBS and other 
functional disorders. Furthermore, there is a biochemical basis for all symptoms at the 
peripheral (gut-based) or central (brain, spinal cord) level. The current preferred classification of 
IBS is a Disorder of Gut-Brain Interaction.(2) It has also been suggested that IBS could be 
viewed as multiple "organic" diseases.(3) Despite the increasing identification of molecular 
differences in IBS, there is not a unifying putative mechanism and patients are grouped clinically 
by symptoms, so that IBS is appropriately designated as a syndrome rather than a disease. 
Epidemiology 
Prevalence and cost 
The worldwide prevalence of IBS is around 11%.(4) Patients with IBS have been consistently 
shown to have poor health-related quality of life (HRQOL), comparable to other chronic 
disorders such as gastroesophageal reflux disease (GERD), diabetes, hypertension and 
depression.(5-7) In comparison to patients with end-stage renal disease dependent on dialysis, 
patients with IBS score lower on domains assessing bodily pain, energy/fatigue, and social 
functioning.(6) Detriments in HRQOL are severe enough that, in tertiary care settings, there is 
an increased risk of suicidal ideation in IBS that is independent of psychological 
diagnoses.(8,9).  IBS accounts for significant health care costs,(10) as patients with IBS are 
more likely to have blood tests, radiologic tests, endoscopic procedures, and abdominal or 
 4 
pelvic surgeries than those without IBS.(11) In addition to direct medical expenses, costs to 
society come in the form of work absenteeism and impaired work productivity.(10) 
IBS is more prevalent in women. In a meta-analysis pooling data from population-based studies 
(total N=188,229), the odds of having IBS were higher among women with an odds ratio (OR) of 
1.7 and a 95% confidence interval of 1.5 to 1.8.(12) The increased prevalence was stable 
across geographic regions. Women with IBS were more likely to have IBS with constipation 
(IBS-C) with an odds ratio of 2.38 (95% confidence interval: 1.45-3.92), and less likely to have 
IBS with diarrhea (IBS-D) with an odds ratio of 0.45 (95% confidence interval: 0.32-0.65).(12) 
IBS is also more commonly diagnosed in patients under the age of 50 (13-15), and is more 
prevalent among patients with lower income.(13,15) 
Risk factors 
Family history 
Although IBS aggregates in families,(16-19) and twin studies suggest heritability,(20,21) a 
strong influence of environment and parental response to a child's abdominal pain may also be 
influential.(22-26) 
Prior GI infection 
Post-infection IBS (PI-IBS) is the onset of IBS symptoms following resolution of acute infectious 
gastroenteritis, characterized by two or more of the following: fever, vomiting, diarrhea, or a 
positive bacterial stool culture, in an individual without a history of IBS.(27) GI infection is the 
strongest risk factor for IBS and is associated with an approximately 4-fold increase in risk of 
IBS-symptoms at twelve months in comparison to uninfected individuals.(28) 
Stressful life events 
There is an association between IBS symptoms and current life stress for many patients with 
IBS.(29) IBS patients also have a higher prevalence of early adverse life events (EALs), or 
traumatic experiences during childhood including, but not limited to, maladjusted relationships 
 5 
with a parent or primary caregiver, severe illness or death of a parent, and physical, sexual or 
emotional abuse.(30,31) The development of PI-IBS is also associated with stressful life 
events.(32) 
Symptom-based diagnosis 
In the absence of a validated biomarker, diagnosis is based on symptoms. The rationale for the 
use of symptom-based criteria are that patients present to health care providers with symptoms 
(33,34) and symptom clusters are consistent across clinical samples and in population 
studies.(35,36) The key symptom of IBS is chronic or recurrent abdominal pain associated with 
altered bowel habits. The current criteria for diagnosis of IBS are the Rome IV criteria.(37) The 
patients included in the studies in this dissertation were diagnosed according to the previous, 
Rome III, criteria, which were published in 2006.(1) Both criteria are listed in Table 1. The main 
differences in the current (Rome IV) criteria are increased symptom frequency, and removal of 
the term “discomfort.” In addition, language was revised to be less restrictive regarding the 
timing of pain and bowel symptoms and whether pain was improved with defecation. These 
changes are emphasized by bold text in Table 1. Rome IV were slightly less sensitive but more 
specific (Table 1) in classifying IBS patients with both negative evaluation for alternative 
diagnoses and diagnosis of IBS by an experienced clinician.(38) Supportive symptoms that are 
not used for diagnosis include: abnormal stool frequency (> 3 bowel movements/day or < 3 
bowel movements/week), abnormal stool form (types 1−2 or 6−7 of the Bristol scale), excessive 
straining during defecation, defecatory urgency, feelings of incomplete evacuation, and mucus 
with bowel movements. In addition, an unpredictable bowel pattern (≥3 different stool form 
types/week) reinforces the diagnosis of IBS-D (39), while consecutive days without a bowel 
movement is associated with IBS-C.(40) Although the majority of patients have bloating, it is not 
required for diagnosis. IBS is sub-grouped by predominant bowel habit. Because stool form was 
the best predictor of predominant bowel habit in IBS, stool form rather than frequency 
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determines bowel habit sub-classification according to both the Rome III and Rome IV 
criteria.(1,37) These criteria are outlined in Table 2 and Figure 1. 
Table 1: Diagnostic criteria for IBS 
Rome IV (37) Rome III (1) 
Recurrent abdominal pain, on average, at 
least 1 day per week in the last 3 months, 
associated with 2 or more of the following 
criteria: 
1. Related to defecation 
2. Associated with a change in 
frequency of stool 
3. Associated with a change in form 
(appearance) of stool 
Criteria fulfilled for the last 3 months with 
symptom onset at least 6 months before 
diagnosis. 
Recurrent abdominal pain or discomfort at 
least 3 days per month in the last 3 
months that is associated with 2 or more of 
the following: 
1. Improvement with defecation 
2. Onset associated with a change in 
frequency of stool 
3. Onset associated with a change in 
form (appearance) of stool 
Criteria fulfilled for the last 3 months with 
symptom onset at least 6 months prior to 
diagnosis. 
 
Sensitivity/Specificity (38) 
62.7%/97.1% 73.1%/93.1% 
Differences are highlighted in bold text. 
Table 2: IBS subtyping 
 Percent of stools that meet the description  
(over the preceding 3 months) 
Subtype* Hard or lumpy stools 
(Bristol type 1-2) 
Loose or watery stools 
(Bristol type 6-7) 
IBS with constipation (IBS-C) ≥ 25% < 25% 
IBS with diarrhea (IBS-D) < 25% ≥ 25% 
Mixed IBS (IBS-M) ≥ 25% ≥ 25% 
Unsubtyped IBS (IBS-U)** < 25% < 25% 
*For Rome IV, percent of stools refers to days with at least one abnormal bowel movement.(37) 
**Patients who meet diagnostic criteria for IBS but whose bowel habits cannot be accurately categorized 
into 1 of the 3 groups above should be categorized as having IBS unclassified. 
Reprinted from Videlock EJ, Chang L. “Irritable Bowel Syndrome”. In: Talley NJ, Kane SV, Wallace MB, 
editors. Practical Gastroenterology and Hepatology: Small and Large Intestine and Pancreas. 1 ed. 
Oxford, United Kingdom: Wiley-Blackwell; Copyright 2010 with permission from John Wiley and Sons. 
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Figure 1: Bowel habit subtypes 
This figure demonstrates the types of stool based on consistency and can be used as a guide 
for subtyping by predominant bowel habit. 
BM; bowel movement 
Reprinted from Gastroeneterology:150(6), Lacy BE at al., Bowel Disorders, page 1396; Copyright 2016, 
with permission from Elsevier and the Rome Foundation. 
Pathogenesis 
Gut sensation and function are influenced by the state and activity of multiple domains, 
including the gut lumen, mucosa, enteric nervous system (ENS) and central nervous system 
(CNS), as well as communication between these domains.  A unifying theory in the 
pathogenesis of IBS is that there is a dysregulation in the complex interplay among these 
domains, which collectively constitute the “gut-brain axis.”(41) There is not a consensus on the 
underlying etiology of this dysregulation, and the disorder may represent a combination of 
factors involving different mechanisms.  
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This section starts with an overview of visceral sensation, and a discussion of enhanced visceral 
perception in IBS. This is followed by a more detailed discussion of peripheral putative 
pathogenic mechanisms in IBS, including how peripheral mechanisms may affect the gut-brain 
axis. There is significant overlap and interrelatedness of the discussed concepts, which is 
summarized in Figure 2. The section concludes with a summary of evidence for a potential role 
of genetic factors. The contribution of central nervous system (CNS) mechanisms to enhanced 
visceral perception is only briefly discussed, as the focus of this dissertation is on peripheral 
mechanisms. 
 
Figure 2: Interrelatedness of IBS pathophysiology concepts 
 
Introduction to visceral sensation 
Mechanical, chemical and other stimuli are detected in the gut by primary afferent neurons, 
which are extrinsic, intrinsic or intestinofugal. The primary nociceptors in the colon and rectum 
are the spinal primary afferent neurons.(42) Spinal afferents have variable thresholds for 
activation, which can change in response to injury and inflammation, and there are also silent 
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nociceptors, responding only in the presence of injury or inflammation.(43) The process of 
increased sensitivity of primary afferent neurons is referred to as peripheral sensitization, and it 
can occur via mediators released by various cell types including platelets, lymphocytes, mast 
cells and epithelial cells, and may also occur via alterations in second messenger systems or 
changes in gene expression.(44,45) 
Spinal primary afferent neurons have cell bodies in the dorsal root ganglion (DRG).(46) Their 
central processes synapse in the dorsal horn, and input is conveyed along the ipsilateral dorsal 
column to the contralateral ventroposterolateral nucleus of the thalamus. The CNS can 
modulate the response to visceral input and can change the responsiveness of reflexes 
controlling gut function in response to input from visceral afferents.(41) The degree to which 
input results in conscious sensation can also be moderated. For example, injury or 
inflammation, in addition to increasing sensitivity of primary afferent neurons, can change the 
sensitivity of central circuits,(47) leading to decreased thresholds for sensation and increased 
responsiveness.(48) 
Enhanced visceral perception 
Enhanced perception of visceral stimuli (Figure 3), a reproducible finding in a significant subset 
of IBS patients,(49) can occur either as a result of greater sensitivity of visceral afferent 
pathways or central amplification of visceral afferent input.(50) There is strong evidence for a 
role of the CNS in enhanced visceral perception through central sensitization. The important 
brain regions can be grouped into those associated with visceral sensation (in healthy controls 
as well), those involved in endogenous pain modulation, and those involved in emotional 
circuits. A quantitative meta-analysis of brain regions activated in response to rectal distention in 
IBS patients and controls, revealed that IBS patients have increased activation of areas 
associated with emotional arousal (pregenual anterior cingulate cortex, amygdala) as well as a 
midbrain cluster associated with endogenous pain modulation, while controls showed more 
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consistent activation of the medial and lateral prefrontal cortex.(51) Areas associated with 
endogenous pain modulation, such as the prefrontal cortex, have also consistently shown 
altered activation in response to rectal distention in IBS.(52,53) There is also evidence for 
peripheral factors in enhanced visceral perception. Sensitivity can be reduced by intrarectal 
lidocaine (54) and can be increased by rectal glycerol.(55) 
 
Figure 3: Enhanced visceral perception 
Reprinted from Videlock EJ, Chang L. “Irritable Bowel Syndrome”. In: Camilleri M, Podolsky D, editors. 
Yamada’s Textbook of Gastroenterology. 6 ed. Oxford, United Kingdom: Wiley-Blackwell; Copyright 2014, 
with permission from John Wiley & Sons, Ltd. 
Peripheral changes in IBS 
Changes in neuron density and receptor expression 
Some studies have shown increased nerve fibers in IBS patients compared with controls, in 
particular those expressing receptors for substance P and transient receptor potential vanilloid 
type 1 (TRPV-1),(56) but this has not been replicated in all studies.(57) Other studies have 
implicated cannabinoid receptors (58) and protease-activated receptors (PARs).(59)  
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Luminal and tissue mediators 
There is strong evidence for the presence of sensitizing mediators in the tissue or intestinal 
lumen of IBS patients.(60-64) Multiple studies have demonstrated that biopsy supernatants from 
IBS patients increase firing of afferent neurons in animal models (64,65) and submucosal 
enteric neurons in human biopsies.(66,67) In one study, a patient’s symptom severity was 
correlated with the degree to which their biopsy supernatant increased sensitivity in an animal 
model.(68) Protease activity is increased in IBS supernatants and may mediate the effect of 
these supernatants on neuronal sensitivity.(64) The increased visceral sensitivity following 
intracolonic administration of IBS biopsy supernatants in mice was decreased by protease 
inhibitors and was not present in mice lacking protease activated receptor 2 (PAR2).(64) 
Sensitivity of TRPV1 neurons was also increased by histamine, an effect mediated by the 
histamine 1 receptor.(69)  
Increased gut permeability 
Permeability has been linked to abdominal pain (70) and enhanced visceral perception (71) in 
patients with IBS. Gut permeability is frequently measured in experimental settings by ingestion 
of molecular probes which are excreted and can be measured in the urine.(72) Several studies 
have found increased small intestinal (71,73,74) and colonic permeability in IBS patients,(75) 
and increased paracellular permeability in colonic biopsies.(70) This has been corroborated by 
studies showing altered expression and cellular distribution of tight junction proteins in the colon 
(76) and jejunum of patients with IBS-D.(77) The association between increased permeability 
and IBS is strongest in PI-IBS (78) and IBS-D.(71,73,79)  
Altered immune reactivity 
Increased immune activation is hypothesized to play a role in the pathophysiology of IBS 
through effects on visceral sensitivity and gut epithelial function. The strongest evidence comes 
from studies in patients with PI-IBS,(27) which have shown increased numbers of T 
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lymphocytes in the lamina propria compared to controls,(32) and increased expression of the 
pro-inflammatory cytokine interleukin 1 beta (IL-1β).(80)  
Importantly, in one study, while sensitization of TRPV1 neurons persisted two years following 
infection, there were no longer differences in lymphocytes or tissue cytokine mRNA 
expression.(81) A potentially transient nature of immune alterations may help to explain why 
studies in unselected IBS patients have yielded less consistent results. The results of 22 studies 
measuring immune cells in intestinal biopsies (706 IBS patients, 401 controls) were summarized 
and pooled in a systematic review and meta-analysis published in 2018.(82) The results of this 
meta-analysis were increased mast cells in the rectosigmoid and descending colon (both in IBS-
C and IBS-D) and increased CD3+ T cells in the rectosigmoid and the descending colon, which 
was likely due to increased CD4+ cells as CD8+ cell numbers were similar.(82) 
Mast cells have been the most thoroughly studied immune cell population in IBS.(56,83,84) The 
putative role of mast cells in IBS is increased peripheral sensitization through release of 
histamine. In one study, the proximity of mast cells to sensory neurons was associated with 
increased severity and frequency of abdominal pain and discomfort.(83) In another study, mast 
cells were increased in IBS and were associated with increased colonic permeability and 
symptoms of diarrhea, but were not related to disease severity.(85) However, other studies 
have found similar numbers of mucosal immune cells in IBS and controls,(64,86-88) and one 
study found decreased mast cells, T cells and macrophages in IBS.(89)  
Studies have also shown alterations in cytokines in IBS patients, but there has been more 
evidence for blood levels than colonic mucosal levels.(90) The most frequent findings in studies 
of serum cytokines are increased tumor necrosis factor alpha (TNF-α) (91-94) and increased 
interleukin 6 (IL-6),(91,93,94) although these findings have not been replicated in all 
studies.(87,95,96) Secretion of TNF-α, and IL-6 was also increased following stimulation of 
peripheral blood mononuclear cells (PBMCs) from IBS patients in comparison to 
controls.(95,97) Tissue cytokine results are more variable, though several studies have shown 
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decreased interleukin 10 (IL-10).(87,98,99) In most studies, there was no association of 
cytokines or cell counts with symptoms.(87,91,94,95) 
Bile acid processing 
Bile acids are absorbed in the terminal ileum via active transport. Bile acids in the colon and 
rectum increase secretion, motility,(100) and visceral sensitivity in response to rectal 
distention.(101) Animal studies suggest that the visceral sensitivity induced by bile acids 
involves activation of the farnesoid X receptor (FXR) on mast cells leading to increased 
expression of nerve growth factor and subsequent increased TRPV1 expression on dorsal root 
ganglion neurons.(102) Bile acid diarrhea is present in around 25% of IBS-D patients.(103-105) 
Colonic bile acids correlate with stool weight,(106) even in patients without overt bile acid 
malabsorption.(107) Bile acids may also be relevant for a subset of patients with IBS-C who 
have reduced total bile acids and reduced fecal deoxycholic acid.(106,108) 
Serotonin 
The majority of serotonin (5-HT) is found within the gut. It is primarily stored in enterochromaffin 
(EC) cells, but is also contained in serotonergic neurons of the myenteric plexus of the 
ENS.(109) EC cells release 5-HT in response to a variety of stimuli such as mechanical 
distention. Serotonin is a neurotransmitter that binds to receptors on primary afferent neurons in 
the lamina propria in a paracrine fashion. These neurons may include extrinsic nerves and 
mucosal projections of intrinsic primary afferent neurons, which initiate gut reflexes affecting 
motility and secretion. Serotonin does not diffuse back into cells and it is not degraded 
enzymatically. The effects are mitigated by reuptake into cells via transporter proteins, such as 
the serotonin reuptake transporter, SERT. 
Evidence supports a role for serotonin processing and signaling in motility and transit alterations 
associated with IBS. Studies have shown increased postprandial concentrations of 5-HT in the 
platelet-depleted plasma of IBS patients compared to controls, particularly in IBS-D.(110,111) In 
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another study, colonic transit times correlated with the level of 5-HT in platelet-depleted plasma 
in IBS patients, with elevated levels predicting accelerated transit.(111) Studies also indicate 
changes in serotonin signaling in IBS. For example, while IBS-C patients had similar numbers of 
EC cells to controls, EC cells had increased serotonin content, which might suggest impaired 
release.(110) 
Gut microbiota 
There is evidence that the microbiota may play a role in IBS.(112) In a meta-analysis of 24 
studies, the microbiome of IBS patients in comparison to controls had increased abundance of 
family Enterobacteriaceae (phylum Proteobacteria), family Lactobacillaceae, and genus 
Bacteroides, and decreased abundance of uncultured Clostridiales I, genus Faecalibacterium 
(including Faecalibacterium prausnitzii), and genus Bifidobacterium.(113) A putative role for 
alterations in the microbiome on IBS symptoms is supported by studies of probiotics,(114) 
antibiotics,(115) and diets known to alter the microbiome (116) in the treatment of IBS, as well 
as the observation that IBS has been associated with antibiotic use.(117) Based on either 
animal or human models, probiotics have been shown to affect visceral sensitivity,(118) 
motility,(119) intestinal permeability,(120) and immune activity, although the mechanisms 
governing these responses are not known.(121,122) The microbiota has been linked to motility 
and transit in animal models. For example, germ-free rats have alterations in gastric emptying, 
intestinal transit and motility that resolve with introduction of normal gut flora.(123) It is 
hypothesized that these effects relate to neuroactive microbial metabolites, but direct evidence 
supporting this hypothesis is lacking.(124,125) Gut microbes have even been shown to regulate 
serotonin synthesis from enteroendocrine cells,(126) supporting a bacterial-neuropeptide 
dependent pathway in regulation of GI motility. 
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Alterations in the gut-brain axis contributing to sensitization 
Changes in the stress response system 
There is both preclinical and clinical evidence to support the link between chronic stress and 
IBS. Chronic stressful life events affect clinical outcomes in IBS,(127) and PI-IBS is predicted by 
psychological symptoms and stress.(32,128) Furthermore, experimental stress increases 
visceral sensitivity (129,130) and gut permeability.(131) In addition, patients with IBS have an 
exaggerated increase in motility in response to stress.(132) The effect of stress on gut function 
and sensation likely results from alterations in the brain-gut axis, or the bidirectional 
communication between the enteric, autonomic and central nervous systems.(41) The nature of 
this communication is likely complex and multidimensional. In addition to communication via 
neurons, communication occurs via humoral mediators of the HPA axis, ANS and immune 
system. The microbiota may also participate in brain-gut interactions. 
The HPA axis is the primary neuroendocrine system in the stress response. Activation of the 
HPA axis results in synthesis and release of corticotropin-releasing factor (CRF) in the 
paraventricular nucleus of the hypothalamus. CRF stimulates release of adrenocorticotropin 
hormone (ACTH) from the anterior pituitary, which leads to the release of cortisol from the 
adrenal glands. Cortisol in turn attenuates the response via negative feedback at the level of the 
hypothalamus and the pituitary. CRF is released into the circulation and has direct effects on 
many tissues. A large body of research in animal models has established an important role for 
central and peripheral effects of CRF on gut transit, motility and secretion, the local gut immune 
response, and changes in visceral sensitivity that occur in the context of tissue injury and 
inflammation.(133) 
Early adverse life events (EALs) 
Many chronic disorders are associated with EALs including chronic obstructive pulmonary 
disease, autoimmune disorders, obesity and mood disorders.(134,135) There is also a large 
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body of evidence linking early life stress to the development of anxiety behaviors and visceral 
hypersensitivity in animal models such that this paradigm is often used as an animal model of 
IBS.(136) Most studies use maternal separation (removal of pups from their mothers during the 
early post-natal period) as an animal model of EALs.(137-139) As adults, these rats show 
evidence of visceral hypersensitivity following water avoidance stress. Maternally separated 
animals also show alterations in the HPA axis and the microbiota,(140) as well as increased 
intestinal permeability.(141) The long-term effects of EALs may result from epigenetic 
programming. Epigenetics refers to mechanisms that affect gene expression (e.g. DNA 
methylation, histone modification) and may change phenotype without a change to the genetic 
sequence (genotype). These changes can be passed down meiotically and can permanently 
alter the expression of genes in somatic cells, an effect referred to as epigenetic 
programming.(142) Meaney and colleagues showed that methylation of the glucocorticoid 
receptor (GR) promoter in rodents was associated with perinatal stress, a phenomenon that 
they subsequently linked to a prolonged HPA axis response via decreased negative feedback in 
the adult animals.(143) Likewise, in humans, fetal exposure to cortisol resulted in reduced 
expression of the glucocorticoid receptor (GR) in the hippocampus, and a prolonged HPA axis 
response.(144) In addition, a study of human autopsy specimens revealed decreased 
hippocampal GR expression and increased methylation of the neuron-specific GR gene 
promoter in suicide victims with a history of childhood abuse when compared with suicide 
victims without abuse as well as controls without abuse who died from unrelated causes.(145) 
These findings have since been replicated in another study.(146) A role for epigenetics in 
animal models of IBS is supported by the finding that a histone deacetylase inhibitor prevented 
anxiety and visceral sensitivity in maternally separated animals.(147) 
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Gut-brain axis effects of peripheral changes 
Disciplines such as neuroimmunology and neuroendocrinology have emerged as a result of the 
growing body of knowledge describing the complex network in which the nervous system, 
immune system and endocrine system, particularly the HPA axis, interact in both health and 
disease. Many stress-induced changes in GI physiology are mediated by CRF and include: 
increased colonic motility in humans(148), increased motility and visceromotor response in 
animal models,(149) increased permeability and mast cell degranulation in human 
biopsies,(150) and stress-induced increased small intestinal permeability in humans.(131) The 
following paragraphs describe how peripheral factors discussed above relate to the gut-brain 
axis. 
Microbiota: Microbes contribute to the bidirectional communication that forms the brain-gut 
axis.(151) Both prenatal stress and postnatal stress in the form of maternal separation have 
been shown to affect gut microbiota in animal models.(140,152,153) Stress may affect the gut 
microbiota via changes in immune activation, permeability and autonomic nervous system-
mediated changes in mucus secretion.(154) Changes in the microbiota, in turn, have influence 
on the central nervous system. For example, prenatal stress resulted in HPA 
hyperresponsiveness in rats, a phenotype which was associated with the microbiota.(155) In 
another study, changes in the microbiota were associated with altered levels of expression of 
brain-derived neurotrophic factor (BDNF).(156) There is preliminary evidence that mood affects 
gut microbiota and vice versa in humans.(157) 
Immune activation: PI-IBS provides a good example of the interactions between stress and the 
immune system. PI-IBS is associated with increased gut lymphocytes and EC cells (78) and 
increased expression of IL-1β.(80) PI-IBS is also associated with increased gut 
permeability.(74,78) The most important predictors of PI-IBS are chronic life stress and anxiety 
and depression.(32,128) In a likely analogous manner, psychological symptoms are related to 
GI symptoms and disease activity in IBD.(158) In both PI-IBS and IBD, there is evidence that 
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the influence of stress on disease is mediated by the HPA axis via action of CRF in the 
gut.(159) 
Ibeakanma and colleagues studied the effect of stress on visceral sensitivity in mice following 
infection with C. rodentium, which produces a self-limited colitis.(160) Twenty-one days 
following the infection, a group of mice was subjected to 9 days of water avoidance stress. 
These mice had serum corticosterone and epinephrine levels that were 2- and 3- fold higher 
than mice exposed to infection alone without chronic stress. The mice exposed to stress also 
showed visceral hypersensitivity and increased visceromotor response to colorectal distention; 
patch-clamp studies revealed greater excitability of colonic primary afferent neurons and greater 
activity in response to balloon distention. While the levels of proteases were increased in post-
colitis mice regardless of exposure to stress, protease inhibition did not affect the changes in 
neuron excitability in the stressed mice. This suggests that protease signaling may play a role in 
increased sensitivity following infection, but not the further augmented response seen with 
chronic stress following infection. Additional studies showed that epinephrine and cortisol 
increased the excitability of DRG neurons from the gut.(160) Potentially more interesting was 
the fact that while a protease activated receptor (PAR)-activating peptide did not affect the 
excitability of neurons in control mice, it markedly increased excitability in neurons from mice 
exposed to chronic stress. These findings suggest that prior infection and chronic stress lead to 
alterations in the brain-gut axis characterized by increased sensitivity of peripheral neurons to 
mediators associated with both, stress and inflammation.(160) 
Permeability: Increased gut permeability may play a role in the interaction between stress, 
immune activation, dysbiosis and hypersensitivity in IBS. Permeability is increased by 
experimental stress in humans and animal models.(131,161) Stress-induced permeability is 
associated with changes in mucosal cellularity including increased mast cells counts and 
activation.(162) This process is also mediated by CRF,(163) particularly in maternally separated 
rat models of visceral hypersensitivity.(164)   
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Genetics 
As discussed earlier, genetic factors in IBS is supported by familial clustering and twin 
studies.(19,165) A small percentage (2-3%) of IBS patients have rare functional variants of the 
voltage-gated channel Nav1.5 (SCN5A) causing a channelopathy or the sucrose isomaltase (SI) 
gene causing carbohydrate malabsorption.(166,167)  
In 2014, Ek et al. published the first large genome-wide association study (GWAS) in IBS.(168) 
The cohort was a Swedish twin study. IBS cases (n = 534) were selected based on responses 
to a bowel symptom questionnaire that had a high concordance with Rome II criteria and 
exclusion of those with reported organic GI disease. Controls (n = 4,932) answered “no” to ‘ever 
had recurrent abdominal problems.’ There were no single nucleotide polymorphisms (SNPs) 
meeting the p value threshold for genome-wide association (p < 5 x 10-8). Of 42 genes with  
p < 10-4, fourteen were selected for validation in several population-based case-control cohorts 
(total n = 3,511). One locus (7p22.1) was significant in the replication. It includes the genes 
KDEL endoplasmic reticulum protein retention receptor 2 (KDELR2) and glutamate receptor, 
ionotropic, delta 2 (Grid2) interacting protein (GRID2IP).(168)   
The same group of investigators performed a larger GWAS published in 2018.(169) The study 
used a population-based cohort in the United Kingdom and included 9,576 cases with self-
reported IBS and 336,499 controls. The replication cohort included 2,045 IBS patients from 
multiple centers and 7,955 ancestry-matched healthy controls. There was high quality data for 
over 7 million SNPs in comparison to about 1 million in the 2014 study. There was one locus, 
rs10512344 on chromosome 9q31.2, which reached genome-wide significance. There were an 
additional fourteen loci with “suggestive” significance (p < 5x10-6). A gene set enrichment 
analysis showed that IBS risk genes were enriched for intracellular calcium activated chloride 
channel activity, ion gated channel activity, and anion channel activity, as well as for targets of 
the miR-15 family of microRNAs. The investigators noted the presence of another SNP at the 
chromosome 9 locus associated with age at menarche. A sex-specific analysis revealed the that 
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the IBS-risk SNP conferred no risk of IBS in men and the overall association was due to a 
strong association in women. Additional analyses conducted by the authors, suggest that 
association of rs10512344 with IBS is independent of allele associated with age at 
menarche.(169) 
Also in 2018, the same group of authors used meta-analysis techniques to determine IBS-
associated loci by pooling GWAS results from five independent European genotyped cohorts 
with Rome II compatible questionnaire data (total n: 1,335 IBS and 9,768 controls).(170) While 
no locus met genome-wide significance, seven regions (64 genes) met “suggestive” significance 
(p ≤ 5.0 x 10−6). Functional annotation highlighted regulation of ion channel activity.(170) 
The association of common variants with IBS has also been studied in a large number of case-
control studies, which are summarized in the review by Gazouli et al.(171) One of the best-
studied polymorphisms that has been linked to IBS is in a region of the serotonin transporter 
gene known as 5-HTTLPR. Overall, results have been inconclusive, with high quality studies 
and a meta-analysis that do not support the association of this gene with IBS,(172,173) but 
several subsequent studies which did find an association.(174,175) In one study, the 
polymorphism was shown to result in altered expression of SERT mRNA and protein, with 
higher expression in the colonic mucosa for the L/L genotype, which is more common in the 
IBS-C subtype.(174) Polymorphisms that have been associated with IBS have also been found 
in the genes for CRF receptor 1 (CRF-1R),(176,177) cannabinoid receptors,(178) catechol-O-
methyltransferase (COMT), interleukins and TNF-α.(165,179-182)  
In addition to genetic risk factors, researchers have identified alterations in a variety of 
epigenetic factors in IBS. These include alterations in gene methylation (183) and expression of 
non-coding microRNAs.(77,79,184,185) While overall, the results of these studies support the 
relevance of genetic and epigenetic factors, additional studies are needed for validation, and to 
determine the functional relevance of findings.   
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SUMMARY 
In summary, IBS is a common disorder with an incompletely understood pathophysiology. There 
is increasing evidence for molecular changes in colon tissue of IBS patients. Stress and its 
effect on gut function and sensation plays a key role in symptom generation. While central 
factors such as stress and hypervigilance are undoubtedly linked to IBS, central processes 
manifest in peripheral changes, such as changes in permeability as a result of stress in human 
and animal models. Furthermore, changes that may originate in the periphery (diet, microbiota, 
infection) may affect the CNS, which could account for their role in IBS pathophysiology. While 
our understanding of the pathogenesis of IBS has evolved over recent years, it is still far from 
complete. Understanding peripheral mechanisms in IBS may lead to the development of gut-
targeted therapies to treat symptoms in IBS. 
INTRODUCTION TO DISSERTATION RESEARCH 
The goal of my doctoral research was to investigate molecular changes in colon biopsies of IBS 
patients in comparison to healthy controls using a translational approach. The primary objective 
was to identify genes differentially expressed in IBS and study one of these genes in cellular 
models to understand how its dysregulation could be related to IBS symptoms or 
pathophysiology. Our group has previously found differences in IBS related to epigenetic 
regulation of gene expression (methylation, microRNA). In addition, researchers in the UCLA 
Center for Inflammatory Bowel Disease have implicated long non-coding RNAs (lncRNAs), 
another set of non-coding RNAs important in epigenetic regulation of gene expression, in IBD. 
The field of lncRNA biology is expanding rapidly and many lncRNAs play key roles in disease 
pathogenesis. Additionally, the lncRNA field is new, and based on important roles for these 
epigenetic regulators, it offers many opportunities to identify novel mechanisms. For these 
reasons, I set out to identify and study lncRNAs that may be involved in IBS pathogenesis. 
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The first phase of this research involved gene expression profiling of colonic mucosal biopsies 
from IBS patients and healthy controls using a microarray platform that identified protein-coding 
mRNAs as well as lncRNAs. Chapter 2 details the analysis of the mRNAs on the microarray and 
is a version of a manuscript published in The American Journal of Physiology-Gastrointestinal 
and Liver Physiology.(186) Chapter 3 describes analysis of the lncRNAs on the microarray and 
the process of selecting the lncRNA afadin divergent transcript (AFDN-DT) for further study in 
intestinal epithelial cell culture models. AFDN-DT was up-regulated in IBS and I hypothesized 
that dysregulation of AFDN-DT may affect epithelial permeability. In the second phase of this 
research, described in Chapter 4, I developed cell lines capable of inducible overexpression of 
AFDN-DT, and I tested the effect of AFDN-DT overexpression on transepithelial electrical 
resistance and transcellular permeability. I also used RNA sequencing to determine the 
downstream effectors of AFDN-DT.  
An additional aim of my doctoral training was to develop proficiency in the analysis of high-
throughput gene expression profiling data. I performed all analyses on the microarray data in 
Chapters 2 and 3 and the RNA sequencing data in Chapter 4. I also applied these techniques to 
publicly-available RNA sequencing data from brain and colon tissue of healthy deceased 
donors. I hypothesized that pathways important in the gut-brain axis could be identified through 
a systems biology approach to this data. These analyses are described in Chapter 5, a version 
of which will be submitted for publication. The code used for all analyses, which were performed 
using the R software,(187) is included in the Appendix. 
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Chapter 2: 
 
Sigmoid colon mucosal gene expression supports alterations 
of neuronal signaling in irritable bowel syndrome with constipation 
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ABSTRACT 
Objective: Peripheral factors likely play a role in at least a subset of irritable bowel syndrome 
(IBS) patients. Few studies have investigated mucosal gene expression using an unbiased 
approach. Here, we performed mucosal gene profiling in a sex-balanced sample to identify 
relevant signaling pathways and gene networks and compare to publicly available profiling data 
from additional cohorts. 
Design: 20 Rome III+ IBS patients (10 IBS with constipation (IBS-C), 10 IBS with diarrhea (IBS-
D) 5 men/women each) and 10 age/sex-matched healthy controls (HCs) underwent 
sigmoidoscopy with biopsy for gene microarray analysis, including differential expression, 
weighted gene co-expression network analysis (WGCNA), gene set enrichment analysis and 
comparison with publicly available data. Expression levels of 67 genes were validated in an 
expanded cohort, including the above samples and 18 additional participants (6 each IBS-C, 
IBS-D, HCs) using the NanoString nCounter technology. 
Results: There were 1270 differentially expressed genes (FDR<0.05) in IBS-C vs. HCs but 
none in IBS or IBS-D vs. HCs. WGNCA analysis identified activation of the cAMP/protein kinase 
A signaling pathway. Nine of 67 genes were validated by Nanostring nCounter technology 
(FDR<0.05) in the expanded sample. Comparison with publicly available microarray data from 
the Mayo Clinic and University of Nottingham supports the reproducibility of 17 genes from the 
microarray analysis and 3 of 9 genes validated by nCounter in IBS-C vs. HCs. 
Conclusion: This study supports the involvement of peripheral mechanisms in IBS-C, 
particularly pathways mediating neuronal signaling. 
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INTRODUCTION 
Irritable bowel syndrome (IBS) is prevalent and costly condition with limited therapies and poorly 
understood pathophysiology. Affecting around 11% of the general population in the U.S,(84) IBS 
is associated with a significant healthcare and economic burden, and a lack of treatment 
satisfaction.(25, 49) Improved understanding of the molecular basis for the dysregulated 
gastrointestinal function and sensation in IBS may lead to development of targeted therapies 
and improved quality of life.  
There is clear and growing evidence that peripheral mechanisms play a role in IBS 
pathophysiology, for at least a subset of IBS patients.(24) Peripheral mechanisms manifest in a 
range of phenotypes, including, but not limited to, alterations in intestinal permeability(41, 132), 
serotonin signaling(7, 36, 38, 45, 54, 63, 122), immune milieu, (2, 4, 12, 13, 20, 30, 39, 94) bile 
acids,(21) microbiota and neuronal sensitivity(9, 16-18, 27, 57, 95, 118, 124). It is not known 
whether these phenotypes result from universally deregulated molecular pathways or whether 
IBS represents a syndrome caused by heterogeneous pathophysiological mechanisms. In order 
to identify molecular pathways associated with IBS, we conducted a microarray analysis of 
sigmoid mucosal gene expression in a pilot study of Rome III+ IBS patients, and age and sex-
matched healthy controls (HCs) who were free of active psychiatric disease, and had limited use 
of medications. 
The National Institutes of Health recently launched an initiative to improve experimental 
reproducibility.(37) This has notoriously been a challenge in IBS. This likely results from the 
combination of heterogeneity in both population and study methodology, and pathophysiology 
resulting from subtle changes – a large sample is needed to detect small differences when 
standard deviations are large. Alternatively, IBS may not be caused by a universal 
pathophysiological mechanism. This difficulty with reproducibility may actually be 
underrepresented in the literature due to publication bias for positive results since very few 
studies used unbiased approaches (e.g. microarray or RNA-sequencing evaluation of mucosal 
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gene expression). In order to identify reproducible results within our own cohort, we compared 
our findings with publicly available data. Our comparison data comes from two microarray 
studies comparing well-phenotyped IBS patients with HCs. The first study, referred to as 
“Mayo”, evaluated gene expression in sigmoid biopsies from 36 Rome II+ IBS patients (15 IBS 
with constipation, IBS-C) and 25 HCs.(2) The second study, “Nottingham”, evaluated rectal 
biopsies in 56 Rome II+(115) IBS patients (19 IBS-C) and 25 HCs in addition to a group of post-
infection IBS patients.(112) The only currently published RNA-sequencing study in IBS,(22) as 
well as the comprehensive follow-up studies(19, 23) have focused on IBS-D. 
Here, we report on the 1) differential expression of transcripts found by microarray; 2) 
comparison with results from two prior microarray studies (Mayo and Nottingham); 3) weighted 
gene co-expression network analysis (WGCNA) and gene set enrichment analysis (GSEA) to 
identify pathways and networks relevant to IBS; and 4) validation of selected genes in a larger 
cohort. We have also created a website (http://uclacns.org/ibs-microarray-comparison/) which 
display tabular and graphical results of gene expression data from this study, Mayo and 
Nottingham for any gene present on the arrays.  
MATERIALS AND METHODS 
Participants and protocol 
Rome III+(80) IBS patients and HCs (men and women, aged 18-55) were recruited primarily by 
community advertisement. Bowel habit subtypes were based on Rome III criteria. The diagnosis 
was confirmed by a clinician with expertise in IBS. HCs had no personal or family history of IBS 
or other chronic pain conditions. Additional exclusion criteria for all subjects included: infectious 
or inflammatory disorders, active psychiatric illness over the past six months assessed by 
structured clinical interview for the DSM-IV (MINI),(105) use of corticosteroids in the past six 
months, use of narcotics, antidepressants or other medications that could affect neuroendocrine 
function in the past two months, or current tobacco or alcohol abuse. Participants were 
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compensated. The study was approved by the UCLA Institutional Review Board, and all 
subjects signed a written informed consent prior to starting the study. Overall IBS symptom, 
abdominal pain, and bloating severity over the prior week were each assessed with a numeric 
rating scale (0-20).(90) Current anxiety and depression symptoms were measured with the 
Hospital Anxiety and Depression (HAD) scale.(133) Sigmoid biopsies (30cm) were obtained by 
flexible sigmoidoscopy following tap water enemas. Specimens were flash frozen in liquid 
nitrogen and RNA was extracted with TRIzol reagent (ThermoFisher Scientific, Waltham, MA). 
Participants for the microarray study as well as the additional participants included in the 
nCounter validation were selected from the same biorepository at UCLA. The only criteria used 
to select participants for inclusion in both the microarray and validation cohorts was optimal 
matching of sex and age within each bowel habit subtype.  
Microarray 
Gene expression was measured using the Arraystar Human LncRNA Microarray V3.0 (Arraystar 
Inc, Rockville, MD), which profiles over 30,500 LncRNAs and 26,100 mRNAs. RNA quantity and 
quality were first measured using the NanoDrop ND-1000 (ThermoFisher Scientific) and RNA 
integrity was assessed by standard denaturing agarose gel electrophoresis. Sample labeling 
and array hybridization were performed according to the Agilent One-Color Microarray-Based 
Gene Expression Analysis protocol (Agilent Technologies, Santa Clara, CA) with minor 
modifications. Briefly, mRNA was purified from total RNA after removal of rRNA (mRNA-
ONLY™ Eukaryotic mRNA Isolation Kit, Epicentre, Madison, WI). Then, each sample was 
amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 
3’ bias utilizing a mixture of oligo(dT) and random priming method (Flash RNA Labeling Kit, 
Arraystar). The labeled cRNAs were purified using the RNeasy Mini Kit (Qiagen, Valencia, CA). 
The concentration and specific activity of the labeled cRNAs (pmol Cy3/μg cRNA) were 
measured with the NanoDrop ND-1000. 1 μg of each labeled cRNA was fragmented by adding 
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5 μl 10 × Blocking Agent and 1 μl of 25 × Fragmentation Buffer, heated to 60 °C for 30 min, and 
25 μl 2 × GE Hybridization buffer was added to dilute the labeled cRNA. 50 μl of hybridization 
solution was dispensed into the gasket slide and assembled to the LncRNA expression 
microarray slide. The slides were incubated for 17 hours at 65°C in an Agilent Hybridization 
Oven. The hybridized arrays were washed, fixed and scanned using the Agilent DNA Microarray 
Scanner (part number G2505C). Agilent Feature Extraction software (version 11.0.1.1) was 
used to analyze acquired array images. Quantile normalization and subsequent data processing 
were performed with using the GeneSpring GX v12.0 software package (Agilent Technologies). 
After quantile normalization of the raw data, LncRNAs and mRNAs that had flags in Present or 
Marginal (“All Targets Value”) in at least 10 out of 30 samples were chosen for further data 
analysis. Targets with mean raw signal intensity of <200 in both IBS or HCs were excluded. 
Data have been deposited in the ArrayExpress database at EMBL-EBI under accession number 
E-MTAB-5811 (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-5811.).  
Validation of selected targets 
RNA (100ng) from the 30 samples analyzed by microarray and 18 additional samples (identical 
recruitment and protocol) was analyzed using a custom nCounter panel including 67 targets and 
three reference genes (GAPDH, BACT, PPIA; NanoString Technologies, Seattle, WA). 
Statistical Analysis 
Code used for analyses in R is provided in the online Supplement. 
Sample Size 
Based on the proportion of differentially expressed transcripts (DETs) in the Mayo study,(2) 
(23/47,000) and an approximate standard deviation of 0.5, we estimated that 8 per group would 
provide 80% power to detect DETs with a fold change (FC) of ≥2.(78)  
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Microarray differential expression  
DETs were determined using the Linear Models for Microarray Analysis (limma)(107) package 
in R version 3.3.1(99) following log2 transformation. An adjusted-p value threshold (Benjamini-
Hochberg) of 0.05 determined statistical significance.  
Acquisition and analysis of external data  
External data (Mayo:E-TABM-176,(2) Nottingham:E-GEOD-36701(112)) were retrieved using 
the ArrayExpress package(61) and Affymetrix probe annotations were updated (annotate 
package(47)). Data were normalized using the robust multiarray average function (affy 
package(46)). The limma package was used to account for technical replicates 
(duplicateCorrelation function) and to determine DETs.(107)  
Determination of microarray probe transcript specificity 
The “ReAnnotator” pipeline(5) was used to obtain accurate alignments of Arraystar probe 
sequences from the current study to the exome. Updated annotations of Affymetrix probes 
(2015) were downloaded from ThermoFisher. Among non-specific probes in the current study, 
the probe with the maximum variance across samples was retained. Common results were 
defined as probes targeting the same transcript or gene and differentially expressed in the same 
direction (i.e. up- or down-regulated in both) with a threshold of p<0.05.  
WGCNA 
WGCNA (67) was performed in R on targets with mean raw signal intensity >200 using a soft-
thresholding power 14 and minimum module size 30. Highly-correlated modules (r>0.75) were 
merged.  
Functional annotation 
Gene Set Enrichment Analysis (GSEA)(111) was performed using the Java GSEA Desktop 
Application (v2.2.4) on all annotated mRNAs (log fold change and p value were entered) with 
mean signal intensity >200 in either group (n=14,775) using default parameters against the 
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following genes sets obtained from Molecular Signatures Database (v6.0)(89): Reactome,(43) 
KEGG,(60) and Gene Ontology (GO) Biological Process (BP).(6) Overrepresented GO terms for 
Mayo/Nottingham comparison and WGCNA were determined using the hypergeometric function 
in the GOstats(44) package in R. These overrepresented terms as well as those yielded from 
analysis in DAVID(55, 56) were used to select descriptive module names. Pathway analysis 
was performed using Ingenuity Pathway Analysis (Qiagen, Valencia, CA) using experimentally-
observed direct relationships in the Ingenuity Knowledge Base.  
NanoString nCounter expression and association with symptoms 
nCounter expression data was analyzed with the NanoStringNorm and limma packages in 
R.(107, 120) Counts were normalized to the geometric mean of all samples to adjust for 
technical variation between the four cartridges. Due to high variation of the housekeeping genes 
included in the code set (GAPDH, ACTB, PPIA), RNA quantity was normalized to the geometric 
mean of genes with the lowest coefficients of variation (GABBR1, RBM5, MUC4, IL17RE, 
RNF19A, ELMOD3, USP34, CDC42EP5, OPLAH, SGSM2) which was determined using 
NanoStringNorm (results were unchanged when MUC4, which was differentially expressed, was 
removed from the normalization set). Three outliers (mean count z-scores >3) were excluded 
from analysis (an additional with z-score 3.03 was retained) yielding 45 samples with nCounter 
data. Using the voom function(69) in the limma package, count data was prepared for analysis 
with linear models and DETs were determined with limma. An adjusted-p-value threshold of 
0.05 was used to determine statistical significance. Association with symptoms was determined 
using linear models. If sex, age or BMI was a predictor of the outcome variable, it was included 
in the model (sex for overall symptoms and all 3 for abdominal pain). 
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RESULTS 
Study Population 
Characteristics of the study participants are shown in Table 1. The total cohort with available 
NanoString nCounter gene expression data (excluding outliers, n=3) included 31 IBS patients 
and 14 HCs (51.6% and 42.9% women, respectively). These included a total of 15 IBS-C 
patients (10 women, 5 men), 16 IBS-D patients (6 women, 10 men) and 14 HCs (6 women, 8 
men).  
Only 24 participants (all IBS) reported any medication use and most used 
laxatives/antidiarrheals and ibuprofen only on an as-needed basis. All participants were 
instructed to hold aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) for 72 hours prior 
to the procedure. No participants in the microarray cohort reported use of 
antidepressants/neuromodulators. In the expanded cohort, one participant took sertraline (100 
mg/day) and bupropion (150 mg/day) and another took trazodone (50 mg/day). Participants 
were instructed not to take unnecessary medications 24-48 hours prior to the procedure.  
Identification of IBS gene signature by microarray profiling analysis 
Differentially expressed transcripts 
For IBS vs. HCs and IBS-D vs. HCs, there were no DETs meeting the threshold of FDR<0.05. 
However, there were 120 and 66 DETs using an unadjusted p value threshold of 0.001. For 
IBS-C, there were 1,270 DETs with FDR<0.05 (790 up-regulated and 480 down-regulated), 
mapping to 1,246 specific transcripts (retaining the probe with highest variance across samples 
among non-specific probes, Supplement 1). A heat map of the top 100 genes is shown in Figure 
1A. Since our sample was age- and sex-matched, our primary analysis did not include sex. 
There were 6 genes for which there was a significant effect of sex (FDR<0.05), and the effect of 
IBS-C vs. HC remained significant (FDR<0.05) in all six after controlling for sex.
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Table 2: External sample and study characteristics 
 
Comparison with external gene expression data 
Demographics of the samples and study protocols from Mayo Clinic and the University of 
Nottingham are shown in Table 2. Probes from the Arraystar (Agilent) array used in our study 
and the Affymetrix array used in Mayo and Nottingham were matched using the following 
algorithm. First, we identified transcripts or genes matched by only a single probe in each array. 
There were 452 probes uniquely matched to a specific transcript, and one probe uniquely 
matched to a specific gene. There were 90 Affymetrix probes that were non-specific and 
overlapped with more than one Arraystar probe (e.g. two Arraystar probes were transcript-
specific with multiple Affymetrix probes matching). In these cases, the affected Arraystar probes 
were reduced to retain the probe with the highest variance across samples (48 Arraystar probes 
excluded). This yielded a set of Affymetrix probes that each only matched a single Arraystar 
probe, though in many cases there were more than one Affymetrix probes matched with each 
Arraystar probe. The final matches were determined separately for Mayo and Nottingham by 
reducing the multiple matching Affymetrix probes to the one with the highest variance across 
samples. Among the 1,246 DETs (IBS-C vs. HCs) in the current study, 859 were matched with 
probes from the Mayo and Nottingham data. Among these, the number of DETs with the same 
direction of FC (p<0.05) in IBS-C and HC samples from Mayo and Nottingham were 57 and 
185, respectively with 17 matched in all three data sets. 
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Figure 1: Heatmaps of differentially expressed genes 
A. Top 100 differentially expressed genes in IBS-C vs. HC. B. Differentially expressed genes in IBS-C vs. 
HC that are replicated in both external cohorts (Mayo Clinic and University of Nottingham). Expression 
values are scaled. Descriptions are from gene ontology or KEGG pathways except where referenced. 
Genes and samples (within bowel habit subtypes) are clustered by Euclidean distance. Sample clustering 
is based on top 500 probes after ordering by variance across all 30 samples. 
IBS-C, IBS with constipation; IBS-D, IBS with diarrhea; HC, healthy control; cAMP/cGMP, cyclic 
adenosine/guansosine monophosphate; GTP, guanosine triphosphate; GTPase, enzymatic function 
catalyzing formation of GDP from GTP; BMP, bone-morphogenic protein; SNP, single nucleotide 
polymorphism; MHC, major histocompatibility complex; ATP, adenosine triphosphate; GPCR, G protein-
coupled receptor; PKA, protein kinase A. 
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Table 3: Genes differentially expressed in IBS-C vs. HC concordant in Mayo 
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To address a possible limitation of comparing rectal (Nottingham) expression with sigmoid, we 
focused further investigation on the 57 common genes between our study and the Mayo study 
(Figure 1B, Table 3). Up-regulated genes included reticulon 3 which is important in neurite 
outgrowth.(29) Down-regulated genes included corticotropin releasing factor receptor 1 
(CRHR1), SCO-Spondin (SSPO) which we previously found to be hyper-methylated in 
peripheral blood mononuclear cells from IBS vs. HCs,(82) and the glial cell line-derived 
neurotrophic factor receptor, GRFA4. 
Identification of IBS gene networks by performing WGCNA analysis 
WGCNA yielded 45 gene modules of which 26 significantly correlated with IBS status (p<0.05, 
Figure 2). None of the modules were significantly associated with sex. One module, 
subsequently named “cAMP-PKA”, was associated with IBS, IBS-C, overall symptom and 
bloating severity. Top GO terms associated with this module are shown in Table 4 and the other 
IBS-associated modules are described in Table 5. Results of the pathway analysis for the 
“cAMP-PKA” module are shown in Figure 3, which is displayed as a subset of two networks. 
The IPA analysis highlights up-regulation of cAMP/protein kinase A signaling. Interestingly, 
following review of the “hub” genes, those with the highest “module membership” (correlations 
with module “eigengene”), revealed a role for cAMP signaling in other modules that were 
associated with IBS, and the function of the gene products were consistent with increased 
cAMP (Figure 4, Table 6). For example, PDE9A, which hydrolyzes cAMP, is in a module that is 
down-regulated in IBS-C. IPA Pathway analysis settings, main results and references for the 
relationships in the network are provided as a supplementary file. 
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Figure 2: WGCNA modules associated with IBS 
Values are correlations between module eigengene and IBS status or overall symptom severity 
(0-20) with associated p value. Red and blue indicate positive and negative correlations, 
respectively 
 Ta
bl
e 
4:
 G
en
e 
on
to
lo
gy
 te
rm
s 
ov
er
re
pr
es
en
te
d 
am
on
g 
ge
ne
s 
in
 th
e 
cA
M
P/
PK
A
 m
od
ul
e 
 
54 
 
 55 
 
 
Figure 3: IPA pathway analysis network for the cAMP/PKA module 
Genes not in the cAMP/PKA module have shapes outlined in dashed lines. Fill is proportional to 
fold change from the microarray data (darker = greater fold change) and all are up-regulated 
except for P2RY14. Figure generated using IPA (Qiagen, Valencia, CA). 
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Table 5: Description of IBS-associated modules 
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Table 6: Correlation of cAMP-related genes with module eigengenes 
 
 
Figure 4: cAMP signaling roles for hub genes in IBS-associated modules 
Directionality of arrows indicates upstream/downstream of cAMP. Dotted lines indicate a 
negative correlation with the module eigengene. Note that CACNA1G in the GEF activity 
module is a different isoform than in the cAMP/PKA (Figure 3). The module memberships and p 
values are shown in Table 6.  
cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; GEF, guanine nucleotide 
exchange factor 
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Identification of IBS signaling pathways based on the gene expression data 
GSEA results are provided in a supplementary file. There were no gene sets enriched in IBS-C 
or HCs meeting a threshold of FDR<0.25 (recommended GSEA threshold). Most gene sets that 
were enriched among HCs with nominal (unadjusted) p<0.05 were thematically related to 
synaptic transmission or G-protein coupled receptor (GPCR) signaling. These included 
Reactome pathways “Activation of kainite receptors upon glutamate binding” (p=0.024), “G 
alpha(s) signaling” (p=0.026), “GPCR downstream signaling” (p=0.036), KEGG pathway 
“neuroactive ligand receptor interaction” (p=0.014), and GO:BP gene-sets “neuronal synaptic 
plasticity” (0.004), and “regulation of synaptic transmission glutaminergic” (p=0.021). Despite 
the absence of DETs in IBS vs. HCs, the Reactome pathway “signaling by FGFR1 mutants” was 
enriched in HCs vs. IBS (p/FDR 0.012/0.19). The 20 genes in this gene set include growth 
factors and downstream effectors (Jak/STAT pathway). The top enriched Reactome gene set 
was smooth muscle contraction (p/FDR 0.004/0.29); however, these genes (actins, myosin 
kinases) likely represent expression at cell-junctions rather than muscle. No gene sets were 
enriched at FDR<0.25 in IBS-D vs. HC, IBS-C vs. IBS-D or in men vs. women. Within IBS, the 
following KEGG gene sets were enriched in men vs. women (p/FDR): “allograft rejection” 
(0.002/0.12), “graft versus host disease” (0.006/.086), and “autoimmune thyroid disease” 
(0.002/0.139). These gene sets overlap and include (human leukocyte antigen) HLA complex 
proteins and tumor necrosis factor (TNF). 
Validation of selected targets 
Selection of genes to validate (n=67) was based on the following: a) visualization of dot plots to 
ensure consistent group difference, b) programmatic search (annotate package in R) of 
abstracts linked to each Entrez ID for the words “pain” or “gastrointestinal” and manual search 
of retrieved abstracts, c) comparison with external datasets, d) comparison with results of IBS 
GWA studies (HTR3A, CDC42EP5(125)), and e) results of other studies.  
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Differential Expression 
In the expanded cohort (15 IBS-C vs. 14 HC), differential expression of 9/67 DETs was 
validated with nCounter (FDR<0.05, same direction of FC as in microarray, Figure 5, Table 7). 
There were an additional six (ALDH3A1, ELMOD3, GH1, RAMP1, SSPO, TMEM80) with 
unadjusted p value<0.05 and five (ALDAH9A1, CLDN15, EZH2, RNF19A, YIF1B) with 
significant positive correlations (p<0.05) between microarray and nCounter values. Associations 
between gene expression and IBS symptoms were found though these did not retain 
significance after adjusting for multiple comparisons (n=67 genes). 
 
Figure 5: nCounter expression of 9 validated genes in IBS-C vs. HC 
Plotted results are mean (SD) for nCounter expression (n=45). Short description of genes not 
described in paper: ITPKB is expressed in cells with a brush border,(104) but is also important 
in immune cells(92) and neurons.(110) Its molecular function is related to intracellular calcium 
regulation.(113) SLC10A4 is a bile acid transporter, about which relatively little is known 
including whether it is able to transport bile acids or neurotransmitters.(1, 103, 109) Slc10a4 
knockout mice show altered dopamine homeostasis.(87, 128). MUC4 is a major component of 
intestinal mucus. Roles include barrier function and host-microbe interactions. Expression of 
MUC22, a susceptibility locus for panbronchiolitis and childhood asthma, is up-regulated in 
bronchial epithelial cells after exposure to a virus-like molecule or lipopolysaccharide.(31, 52) 
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Table 7: Results of nCounter validation 
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DISCUSSION 
The most important findings from this study are 1) sigmoid mucosal gene expression profiles 
differentiate IBS-C from HCs and 2) results of multiple analyses and in several cohorts support 
the relevance of neurally-mediated mechanisms in IBS overall and specifically in IBS-C.  
1) Defining a molecular signature for IBS-C 
Very few studies have reported DETs in IBS-C vs. HCs. A survey of the literature revealed ~90 
DETs in IBS (those included in our microarray are shown in Table 8). Recently, Peters et al. 
compared expression of tight junction proteins in sigmoid colonic mucosal biopsies from women 
with IBS-C vs. HC women and none were reported as differentially expressed.(97) As a 
demonstration of the heterogeneity in findings with different samples and methodology, some of 
the genes in this study were DETs in our study (FDR<0.05, Table 9). An important strength of 
our study is that our microarray sample included no individuals using SSRIs and there were only 
two with antidepressant use in the validation sample. Medication use was not reported in the 
Nottingham comparison study, but in the Mayo study, 42% of IBS participants took medications 
(SSRI, SNRI, TCA, or dopaminergic agent) vs. 1% of HCs. It is possible that this difference in 
medication use contributed to our findings. Divergent results by bowel habit subtype is 
supported by other studies,(28, 57) but notably, there is evidence for the absence of subtype-
specific effects as well.(38, 93) We caution the reader against over-interpretation of these 
findings. While gene networks may differ in IBS-C and IBS-D, one cannot conclude that these 
differences are causative and therefore represent different underlying pathophysiology. These 
differences also are not evidence of bowel habit differences at the phenotype level (i.e. nerve 
sensitivity). Furthermore, in accordance with our sample size calculation, one can only conclude 
that there are unlikely to be genes with greater than 2-fold difference between IBS-D and HC. 
We are underpowered to make a negative conclusion for smaller differences that could still be 
biologically relevant. 
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Table 8: Comparison of findings from current study for genes found to be differentially 
expressed in the literature 
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Table 9: Differentially expressed tight junction genes 
 
2) Evidence for neurally-mediated mechanisms in IBS 
cAMP-PKA signaling 
WGCNA and IPA analysis identified up-regulation of cAMP-PKA signaling in IBS and IBS-C 
biopsies compared to HCs. The down-regulation of phosphodiesterase 2A (PDE2A) (validated 
by nCounter), which hydrolyzes cAMP is also supportive. PKA signaling activates T-type 
calcium channels, and in our dataset, expression of the T-type calcium channel Cav3.1 
(CACNA1G) was increased in IBS (both IBS-C and IBS-D). The potential importance of this 
channel in IBS is supported by a study in rats, in which knockdown of Cav3.1 attenuated 
butyrate-induced visceral hypersensitivity.(83) In addition, Scanzi et al. found increased 
expression of an alternate isoform with similar properties(127) (Cav3.2, CACNA1H) in biopsies 
from IBS patients vs. HCs and in a mouse model of visceral pain.  
While cAMP-PKA signaling is important in nociceptive pain signaling,(11) this pathway regulates 
many aspects of cellular physiology including chloride secretion(15) and serotonin release by 
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enterochromaffin cells.(34) Furthermore, while evidence exists for altered neuronal sensitivity in 
IBS (9, 16-18, 27, 38, 95, 100, 118, 124) both desensitization(95) and sensitization(124) may 
occur. For these reasons as well as the increased relative abundance of mucosal projections of 
enteric neurons as compared to extrinsic afferents in the colonic mucosa, our findings are more 
likely to represent signaling mechanisms unrelated to pain. It is also possible that the 
differences in cAMP-PKA signaling may involve other cell types. Interestingly one of the hub 
genes in the cAMP-PKA module is an epithelial cell apical sodium channel (SCNN1D, 
correlation with module eigengene 0.91), which may influence fluid transport and contribute to 
the constipation phenotype.(62)  
Neurotransmitter and neuropeptide signaling 
CRHR1 was down-regulated (Mayo study and current study microarray and nCounter), perhaps 
involving a response to increased stress-induced release of CRH. In a previous study,(30) 
CRHR1 mRNA was not detectable in 81% of samples by quantitative real-time PCR, but 
microarray and nCounter are both more sensitive detection methods.  
The gamma-aminobutyric acid type A receptor gamma1 subunit (GABRG1) was also down-
regulated in IBS. In genome wide association study, a variant in this gene was associated with 
IBS within the discovery (but not replication) sample.(42) In the enteric nervous system, 
activation of GABA A receptors exerts an excitatory effect.(33) These receptors are also located 
on epithelial cells and agonists stimulate luminal chloride secretion.(73) Thus, potential 
relevance of GABA receptor down-regulation in IBS-C could be decreased peristalsis and/or 
secretion. An additional mechanism may be related to GABA receptor subunit stoichiometry. 
There are 19 GABA receptor subunit genes in the human genome and several dozen subunit 
combinations for the pentameric receptor have been described.(35) Differential composition of 
GABA receptors can affect membrane targeting and ligand sensitivity, which may be relevant in 
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IBS.(35, 65) It is also possible that the relevance to IBS is related to neuroimmune mechanisms 
as GABA receptors are present on immune cells.(8) 
Neurite outgrowth 
Several genes related to neurite outgrowth were dysregulated in IBS-C vs. HCs both in our 
cohort and Mayo (reticulon 3, SSPO, GRFA4). SSPO, which encodes the secreted glycoprotein 
SCO-spondin that may participate in neurite outgrowth and neuron/glial interaction (85) was 
previously found to be hyper-methylated in peripheral blood mononuclear cells in IBS.(82) 
Interestingly, changes in neuron density have been reported in full-thickness samples from 
animal models of IBS,(72, 116) and patients with slow-transit constipation.(123)  
Additional notable findings 
We also found that high mobility group box 1 (HMGB1) was up-regulated in IBS-C. HMGB1 is a 
chromatin-binding protein as well as a pro-inflammatory cytokine capable of increasing 
permeability of intestinal epithelial cell monolayers and ileal permeability and bacterial 
translocation in mice. While HMGB1 has well-defined roles in inflammation, it has recently 
emerged as a potential mediator of nociceptive pain signaling.(3, 40, 66) For example, in a 
mouse model of cyclophosphamide-induced cystitis it mediated mechanical bladder sensitivity 
induced by the protease activated receptor PAR4.(66) HMGB1 is a target of cyclin-dependent 
kinase 5 (CDK5),(117) which was also up-regulated and validated in our cohort. In a colon 
cancer derived cell line, CDK5 phosphorylated HMGB1 at serine-181, a post-translational 
modification that has been associated with increased secretion of HMGB1.(71) CDK5 activation 
is also pro-nociceptive through interactions with TRPV and purinergic receptors.(91, 126)  
We would also like to note the enrichment of a few gene sets that met the threshold of 
FDR<0.25. Specifically, enrichment of “signaling by FGFR1 mutants” in HCs vs. IBS overall may 
warrant further investigation into this pathway. In addition, enrichment of the gene sets “allograft 
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rejection”, “graft versus host disease” and “autoimmune thyroid disease” in men vs. women with 
IBS suggests that immune regulation may play a larger role in IBS among men.  
Table 10: Expression of neuronal and glial/astrocytic markers 
 
Limitations 
The most important limitation to consider in the interpretation of these results is that the results 
are not cell-type specific and furthermore, there may be group differences in cell-type 
composition of the biopsies with no reliable methods to measure or account for these 
differences. The up-regulated gene sets in HCs vs. IBS-C suggests that either there may be 
more neurons and/or increased transcriptional activity in neurons. However, decreased enteric 
neurons in the submucosal plexus has previously been associated with constipation.(10) We 
attempted to address this question by looking at expression of traditional neuronal and 
astrocyte/glial markers (Table 10), which did not reveal significant differences. Additionally, 
there are limitations to drawing conclusions on neuronal physiology based on findings from 
mucosal biopsies. While the mucosa is innervated by sensory nerve fibers, and biopsies 
frequently include some submucosa, an alternative explanation is that the expression changes 
may reflect alterations in transcriptional activity of glial cells or enteroendocrine cells.  
Another significant limitation is the small sample size of the microarray study. However, the 
composition (equal men and women, medication use) and rigor of phenotyping increases the 
probability that significant findings are not due to sampling bias. Despite the larger sample size 
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included in the IBS vs. HC comparison (n=20 vs. n=10 for IBS-C), we did not find DETs meeting 
a FDR<0.05 threshold. This may be due to bowel habit-specific differences in peripheral 
mechanisms as has been suggested by others.(57) Importantly, our study was only powered to 
detect larger changes (FC ≥ 2) at an FDR£0.05. Therefore, caution should be used in the 
interpretation of negative results (absence of changes).  
Reproducibility between IBS studies remains a challenge. There were 85 DETs in the literature 
which were present on our microarray, and we found the same direction of change (up or down 
in IBS vs. HCs) for 44 of these (Table 8). We did not find differences in SERT, which has been 
reported in several(36, 63, 122) but not all(20, 22) studies. While we have attempted to highlight 
findings that are reproducible though comparison with publicly available data, this approach has 
computational limitations as well as limitations due to differences in protocol (e.g. different bowel 
preparation) and patient populations. In particular, the current study used Rome III(80) criteria 
while Mayo and Nottingham used Rome II(115) which are less specific and may identify a less 
severe population. Given that inclusion of IBS patients in all three cohorts was supervised by 
experts in the field, the differences in diagnostic criteria are less likely to result in sample 
differences than for survey-based studies. We recommend pooling resources and increasing 
collaboration with the goal of larger samples that are uniformly phenotyped and processed in 
order to yield robust findings. 
CONCLUSIONS 
In conclusion, using a small but well-phenotyped and age- and sex-balanced sample, we have 
found additional support for peripheral mechanisms in IBS and demonstrate that these findings 
were more significant in IBS-C patients within our cohort, suggesting that pathophysiologic 
processes differ between IBS-C and IBS-D. Based on some of the observed changes, future 
investigations should focus on alterations in neuronal physiology. 
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Differential Expression of Long non-Coding RNAs 
in Irritable Bowel Syndrome  
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ABSTRACT 
Chapter 2 of this dissertation reported analysis and results of the mRNAs (protein-coding RNA 
transcripts) present on the microarray platform used for gene expression profiling in irritable 
bowel syndrome (IBS) vs. healthy controls (HCs). This microarray platform also included over 
30,000 long non-coding RNAs (lncRNAs). While lncRNAs do not encode protein, they can 
regulate gene expression and thus play an epigenetic role in phenotype expression. The goal of 
the experiments described in this chapter was to identify differentially expressed lncRNAs in 
IBS, and to select a lncRNA for further study in intestinal epithelial cell culture models. Based on 
microarray data, quantitative real-time PCR and in-situ hybridization, the lncRNA afadin 
divergent transcript (AFDN-DT) was selected for further study, and the subsequent cell culture 
experiments are the subject of Chapter 4. 
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INTRODUCTION 
The majority of genes do not encode proteins. Long non-coding RNAs (lncRNAs) are now 
known to be important regulators of gene expression and biological function,(1) and have been 
identified as important regulators of multiple diseases. They have diverse molecular functions. 
The best-known example is as allelic repressors. The lncRNA Xist, for example, regulates X-
inactivation by recruitment of silencing factors.(2) Examples of other lncRNAs with known 
functions are DACOR1 which up-regulates tumor suppressor genes and is down-regulated in 
colon cancer,(3) and Lethe and PACER, which bind subunits of nuclear factor kappa B (NF-κB) 
and prevent expression of pro-inflammatory genes.(4) Molecular mechanisms of lncRNAs are 
diverse and include recruitment of transcriptional machinery, transcriptional silencing through 
regulation of chromatin structure, stabilization of mRNA, and posttranscriptional gene regulation 
(protein synthesis, RNA transport).(5) Advances in the field of lncRNAs have led to novel 
therapeutics based on targeting lncRNAs with antisense oligonucleotides, and several 
compounds have advanced to clinical trials.(6)  
LncRNAs have been associated with multiple gastrointestinal (GI) diseases, such as colon 
cancer, inflammatory bowel disease, and celiac disease, but have not been extensively studied 
in irritable bowel syndrome (IBS).(7-9) The hypothesis that lncRNAs are dysregulated in IBS is 
based on several factors. Firstly, epigenetics is important in the response to stimuli and 
environment,(10) and onset or symptom exacerbation in IBS is stimulated by a variety of 
triggers, such as stress, history of early adverse life events, antibiotic use, infection and 
diet.(11,12) In addition, other epigenetic mechanisms such as methylation/histone modification 
and microRNAs have been associated with IBS.(13,14) 
Sigmoid mucosal expression of lncRNAs was determined by microarray in twenty Rome III+ IBS 
patients (ten IBS with constipation (IBS-C), ten IBS with diarrhea (IBS-D), five men/women 
each), and ten age- and sex-matched healthy controls (HCs). This chapter reports the results of 
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lncRNA profiling as well as the process and experiments used to select a differentially 
expressed lncRNA for further study in cellular models.  
Two approaches were used in the selection of a lncRNA for further study. The first was a data-
driven approach. In Chapter 2, a weighted gene co-expression network analysis (WGCNA (15)) 
was performed to identify clusters (modules) of highly correlated mRNAs, and determine 
module association with IBS.(16) Since lncRNAs can regulate expression of mRNAs, a lncRNA 
correlated with the module eigengene (first principal component) of an IBS-associated mRNA 
module may regulate and thus cause differential expression of these mRNAs, and would 
therefore be an promising target for further study. Correlation of a pre-filtered list of candidate 
lncRNAs (based on magnitude of fold change and other features described below) with IBS-
associated module eigengenes identified the lncRNA ghrelin opposite strand (GHRLOS) as a 
promising target; however, in-situ hybridization localized GHRLOS to the lamina propria, and 
thus it was ultimately not suitable for studies in an epithelial cell culture model. 
The second approach to selection of a lncRNA for further study was hypothesis-driven. IBS has 
been associated with increased intestinal permeability,(17-21) a phenotype linked to abdominal 
pain.(18,21-23) The lncRNA afadin divergent transcript (AFDN-DT) was selected due to 
differential expression in IBS-C vs. HCs and proximity to afadin (AFDN), also differentially 
expressed in IBS-C vs. HCs, which encodes an adherens junction protein. Since real time 
quantitative PCR supported microarray findings and in-situ hybridization revealed expression of 
AFDN-DT in epithelial cells, AFDN-DT was selected for further investigation in cellular models 
(described in Chapter 4). 
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METHODS 
Participants, protocol and microarray 
This chapter focuses on the lncRNAs in the ArrayStar (Rockville, MD) Human LncRNA 
Microarray V3.0 (includes 30,586 LncRNAs and 26,109 mRNAs). The microarray sample and 
methods are described in Chapter 2 (page 43).  
WGCNA 
WGCNA(15) was performed in R (24) on targets with mean raw signal intensity > 200 using a 
soft-thresholding power 14 and a minimum module size of 30. Highly-correlated modules  
(ρ > 0.75) were merged.  
Real-time Quantitative Polymerase Chain Reaction 
Total RNA (100 ng) was extracted from the 30 samples analyzed by microarray and eighteen 
additional samples (identical recruitment and protocol) with TRIzol Reagent (Thermo Fisher 
Scientific) or with the miRNeasy mini Kit plus on-column DNase treatment (Qiagen, 
Germantown, MD). RNA was quantified with the NanoDrop spectrophotometer (Thermo Fisher 
Scientific). Complementary DNA (cDNA) was synthesized from 250-500 ng RNA in a 10-μL 
reaction using the iScript™ gDNA Clear cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, 
CA) and was diluted 1:2 with nuclease free water. Real-time quantitative PCR (RT-PCR) was 
performed in 384-well plates using the CFX384 Touch Real-Time PCR Detection System (Bio-
Rad). Each 5-μL reaction contained 1μL diluted cDNA (concentration normalized across 
samples), 2.5 μL SYBR® Green Supermix (Bio-Rad), and 0.5 μL each of 10 μM forward and 
reverse primers (Integrated DNA Technologies, Coralville, IA). Primer sequences are shown in 
Table 1. Resulting data were calculated by using the 2-[delta][delta]Ct method. 
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Table 1: Primer sequences 
PPIA F - AGACAAGGTCCCAAAGAC 
R - ACCACCCTGACACATAAA 
18S F - AGAAACGGCTACCACATCCA 
R - CACCAGACTTGCCCTCCA 
GAPDH F - ATGTTCGTCATGGGTGTGAA 
R - GGTGCTAAGCAGTTGGTGGT 
B-Actin F - CCCAGCACAATGAAGATCAA 
R - ACATCTGCTGGAAGGTGGAC 
AFDN-DT F - TGAGAGATGCCACGTGATCG 
R - CACCGGGATGCTCACATAGT 
AFDN F - GAGCATGATGGAGGGTGTCA 
R - TCCGACTAAGGTCTCGGTCT 
ADD1 F - AACCCTTGCTGCAGTCTCTC 
R - TAGGGACAGCAGAGGTGGAA 
NECTIN F - TACAACCGGCAGCAGAAGAG 
R - CTCAGGCACAAGGGAGCTTT 
PVR F - AATGTTCCCGTGAGGTCCTT 
R - AGCTGAATAGGAGACATGCCC 
GHRLOS F - CTAACACCTGGCGCTGTG 
R - ATTCAGCCTCCCAGAGCTTT 
F, forward; R, reverse 
In-Situ Hybridization 
In-situ hybridization was performed on formalin-fixed paraffin-embedded colonic biopsies using 
the RNA Scope system (Advanced Cell Diagnostics, Newark, CA) with custom probes designed 
to target GHRLOS and AFDN-DT. 
Statistical Analysis 
All statistics were performed using the R software version 3.3.(24) 
Microarray differential expression  
Differentially expressed transcripts (DETs) were determined using the Linear Models for 
Microarray Analysis (limma)(25) package in R version 3.3.1(24) following log2 transformation. 
An adjusted p value threshold (Benjamini-Hochberg) of 0.05 determined statistical significance. 
Association of lncRNAs with IBS-associated gene modules was determined Pearson 
correlation.   
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RESULTS 
Clinical characteristics of the microarray sample are shown in Chapter 2, Table 1 (page 48). The 
numbers of differentially expressed transcripts (DETs, Total (up-regulated, down-regulated) are 
shown in Table 2. Similar to the mRNA analysis (Chapter 2), most differences were in IBS-C vs. 
HC.  
Table 2: Differentially expressed lncRNAs in IBS vs. HCs 
Group vs. 
HC 
All Fold Change > 1.5 Fold Change > 2 
FDR P FDR P FDR P 
IBS 4 (3,1) 
1236 
(482,754) 
4 
(3,1) 
252 
(103,149) 
2 
(1,1) 
70 
(14,56) 
IBS-D 0 1022 (718,304) 0 
391 
(312,79) 0 
113 
(86,27) 
IBS-C 896 (177,719) 
2460 
(681,1779) 
520 
(87,433) 
747 
(144,603) 
96 
(6,90) 
128 
(17,111) 
Total (up-regulated, down-regulated) lncRNAs for different fold change thresholds. IBS, irritable 
bowel syndrome; IBS-C, IBS with constipation; IBS-D, IBS with diarrhea 
Selection of candidate lncRNAs using a data-driven approach 
Stage I selection process 
Since very little is known about the function of most lncRNAs, an unbiased approach was used 
initially to select candidate DETs for further analysis. First, 224 DETs with a fold change > 2 and 
p < 0.05 in any comparison (IBS/IBS-D/IBS-C vs. HC) were identified. From these, we retained 
91 DETs that had been assigned an Entrez gene identification number by the National Center 
for Biotechnology Information (NCBI), as these were more likely to be valid transcripts. For all 
91, the following additional evaluation steps were performed: 1) visualize dot plots showing 
expression by group to determine whether differences were consistent in the groups (i.e. high 
expression of an up-regulated DET in most IBS samples rather than very high expression in a 
subset); 2) determine expression profile in colon and colon cancer cell lines through search of 
“Expression Atlas,” a resource of the European Bioinformatics Institute (EMBL-EBI) which 
shows expression across tissues and cell lines (26); and 3) literature search. Following this 
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process, the list of 91 was narrowed to seven candidates which are shown in Table 3. The 
pseudogene guanylate cyclase 1 soluble subunit beta 2 (GUCY1B2) was included in this list, 
because guanylate cyclase C agonists are effective therapies in IBS-C and chronic idiopathic 
constipation.(27) There were limited reports of functional pseudogenes at the time, which is why 
we did not investigate GUCY1B2 further; however, it should be noted that pseudogenes are 
now considered to be an important class of lncRNAs with regulatory functions.(28)  
Table 3: Fold change (p value) of candidate lncRNAs 
Group vs. HC IBS IBS-D IBS-C 
GUCY1B2 1.7 (0.046) 2.4 (0.0043) 
 
MTMR9LP 1.7 (0.044) 2.0 (0.0014) 
 
SACSAS1 2.0 (0.0058) 2.6 (0.0015) 
 
LINC01482 1.7 (0.024) 2.5 (0.0014) 
 
GHRLOS 
GHRLOS A 0.5 (0.0014) 0.61 (0.04) 0.41 (0.0004) 
GHRLOS B 0.54 (0.0039)  0.43 (0.001) 
BCAR4 -1.5 (0.034) 
 
-2.1 (0.0014) 
HYMAI -1.5 (0.003) 
 
-2.1 (<0.0005) 
P values are unadjusted. IBS-C comparisons are significant at FDR<0.05. IBS, irritable bowel 
syndrome; IBS-C, IBS with constipation; IBS-D, IBS with diarrhea 
Stage II selection 
Next, we selected a candidate lncRNA based on the potential role of lncRNAs in regulation of 
mRNA expression. As part of the analysis of microarray mRNA results (Chapter 2), WGCNA 
was performed to identify groups (“modules”) of highly correlated mRNAs and determine the 
association of modules with IBS status or symptoms. If a lncRNA regulated expression of 
mRNAs in these modules, its expression would likely correlate with that module’s eigengene 
(first principle component), which may predict an important regulatory role in IBS. The WGCNA 
analysis described in Chapter 2 identified 45 modules and seven of these were associated with 
IBS status (Chapter 2, Figure 2, page 53). Six of these IBS-associated module eigengenes were 
significantly correlated with one or more of six out of the seven candidate lncRNAs. A heatmap 
of these correlations is shown in Figure 1.  
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Figure 1: Correlation of candidate lncRNAs with IBS-associated mRNA modules 
 
GHRLOS and the “DNA repair” module 
Two probes of ghrelin opposite strand (GHRLOS) were down-regulated in IBS (Figure 2, Table 
3) and had a strong positive correlation with the “DNA repair” module, which was also down-
regulated in IBS (Figure 1).  Gene ontology terms overrepresented in the “DNA repair” module 
are shown in Table 4. Both microarray probes matched the same 5 transcript variants (Figure 
3). 
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Figure 2: GHRLOS is down-regulated in IBS 
Table 4: Top ten gene ontology terms associated with the “DNA repair” module 
Term p value 
Double-strand break repair via nonhomologous end joining 0.001 
MyD88-dependent toll-like receptor signaling pathway 0.005 
Interstrand cross-link repair 0.008 
Internal peptidyl-lysine acetylation 0.008 
Positive regulation of DNA repair 0.009 
Histone modification 0.009 
Ossification 0.009 
Muscle system process 0.010 
Modification-dependent protein catabolic process 0.010 
Regulation of canonical Wnt signaling pathway 0.010 
 
Figure 3: GHRLOS microarray probe and PCR primer alignments 
BLAT(29) alignment of microarray probes (Black arrows, GHRLOS A, GHRLOS B) and forward 
and reverse PCR primers(red arrow). Image created with the UCSC genome browser, 
http://genome.ucsc.edu (30) using the Human Dec. 2013 (GRCh38/hg38) assembly. 
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Table 5: “DNA repair” genes correlated with GHRLOS and IBS-C 
Symbol, Name GHRLOS Correlation 
Fold Change 
IBS-C vs. HC IBS vs. HC* 
APCDD1, APC down-regulated 1 0.72 (0.002) 0.69 (0.007) 0.81 (0.023) 
KCNMB3, potassium calcium-activated channel subfamily M 
regulatory beta subunit 3 0.94 (<0.005) 0.59 (0.010) 0.67 (0.001) 
TMCO6, Transmembrane and coiled-coil domains 6 -0.68 (0.010) 1.52 (0.010) 1.33 (0.005) 
MLN, motilin -0.64 (0.026) 1.49 (0.012) 1.38 (0.001) 
ROBO2, roundabout guidance receptor 2 0.71 (0.003) 0.66 (0.014) 0.74 (0.003) 
FAM153A, family with sequence similarity 153 member A 0.69 (0.006) 0.78 (0.016) 0.86 (0.022) 
ZNF45, zinc finger protein 45 0.97 (<0.005) 0.34 (0.018) 0.49 (0.011) 
TEK, TEK receptor tyrosine kinase 0.96 (<0.005) 0.30 (0.021) 0.43 (0.008) 
PDE7A, phosphodiesterase 7A 0.98 (<0.005) 0.36 (0.021) 0.50 (0.010) 
CALCA, calcitonin related polypeptide alpha 0.96 (<0.005) 0.27 (0.023) 0.40 (0.008) 
*unadjusted p value. P values for GHRLOS correlation and fold change in IBS-C vs. HCs are adjusted for 
multiple comparisons (Benjamini-Hochberg) 
Table 5 shows the top ten genes in the “DNA repair” module based on differential expression in 
IBS-C vs. HC as well as the correlation of those genes with GHRLOS. Interestingly, these 
genes included motilin (MLN), which was up-regulated in IBS-C (fold change = 1.49, p = 0.012) 
and negatively correlated with GHRLOS (Figure 4, r = -0.064, p = 0.026). Dysregulation of 
motilin in IBS is supported by other studies,(31-33) and motilin receptor agonists, such as 
erythromycin, accelerate GI transit. In addition to GO terms shown in Table 4, “positive 
regulation of ERK1 and ERK2 cascade” (GO:0070374, p=0.003) and “positive regulation of NF-
κB transcription factor activity” (GO:0051092, p=0.0016) were also enriched in the “DNA repair” 
module. Extracellular signal-regulated kinases (ERK1/ERK2) are downstream effectors of G 
protein-coupled receptors (GPCRs), such as the motilin receptor, and binding of the closely 
related hormone ghrelin to its receptor activates NF-κB.(34) 
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Figure 4: GHRLOS and MLN are negatively correlated 
 
PCR validation of GHRLOS 
Microarray findings were validated with RT-PCR. Primers (Table 1, Figure 3) were designed to 
amplify the region of GHRLOS targeted by both microarray probes (GHRLOS A, GHRLOS B). 
Characteristics of the PCR cohort are shown in Error! Not a valid bookmark self-reference.. 
Results of the PCR are shown in Figure 5. There was a trend for decreased expression in IBS-C 
vs. HC (p = 0.09). 
 
Table 6: GHRLOS PCR sample demographics 
 IBS HC 
N (% women) 38 (53%) 16 (44%) 
Cohort 
Microarray 15 (9 IBS-C, 6 IBS-D)  10 
Validation 23 (10 IBS-C, 9 IBS-D, 2 IBS-M, 1 IBS-U) 6 
Age 33.9 (12.5) 33.1 (9.2) 
BMI 25 (5) 25.5 (3.4) 
Hispanic 3 (7.9%) 4 (25%) 
Asian 8 (21.1%) 3 (18.8%) 
Black 4 (10.5%) 1 (6.2%) 
White 20 (52.6%) 8 (50%) 
Other 6 (15.8%) 3 (18.8%) 
BMI, body mass index; IBS-M, IBS with mixed bowel habit; IBS-U, IBS unsubtyped.  
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Figure 5: GHRLOS PCR 
RT-PCR of GHRLOS normalized to 18S and PPIA 
 
In-situ hybridization of GHRLOS 
In order to verify expression of GHRLOS in colonic mucosal biopsies, in-situ hybridization was 
performed on formalin-fixed paraffin embedded colonic biopsies using a custom probe designed 
to target GHRLOS. GHRLOS was predominantly expressed in the lamina propria (Figure 6). 
Because the goal of this project was to test a lncRNA in colonic epithelial cell culture models, no 
further investigation of GHRLOS was performed. 
 
Figure 6: GHRLOS gene expression by in-situ hybridization 
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Selection of candidate lncRNAs using a hypothesis-based approach 
Identification of GHRLOS as a candidate lncRNA for further study used an unbiased approach. 
Subsequently, a hypothesis-based approach was used, based on evidence indicating that 
impaired intestinal permeability is a consistent finding in IBS.(35) We therefore hypothesized 
that differential expression of lncRNAs may underlie alterations in intestinal permeability in IBS. 
Differential expression of adherens junction genes in IBS-C vs. HCs 
In Chapter 2 (16), differentially expressed mRNAs from this study were compared with publicly 
available microarray data from two additional cohorts (Mayo Clinic (36) and the University of 
Nottingham (37)). One of the mRNAs that was differentially expressed in our study as well as in 
the sigmoid biopsies from the Mayo Clinic was nectin cell adhesion molecule 1 (NECTIN1), 
which encodes an adherens junction protein. Formation of adherens junctions is an early step in 
the cellular adhesion process, and it is necessary for proper formation of tight junctions.(38) In 
addition to NECTIN1, genes encoding the adherens junction proteins poliovirus receptor (PVR), 
and afadin (AFDN) as well as the actin-capping protein adducin 1 (ADD1), were also 
differentially expressed in IBS-C vs. HCs (FDR<0.05,  
Table 7). The role of the adherens junction and these molecules specifically in the formation of 
cellular junctions is outlined in Figure 7.  
Microarray expression of NECTIN1, ADD1, PVR and AFDN is shown in Figure 8A-D. 
Expression measured by RT-PCR in a larger cohort (Table 8) is shown in Figure 8E-H. 
Microarray findings were not replicated overall, though the direction of fold change in IBS vs. 
HCs was maintained for PVR (down) and AFDN (up). Despite these results, based on findings 
in the literature, selection of a target involved in cell adhesion remained a primary focus. 
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Table 7: Differentially expressed adherens junction genes 
 IBS-C vs. HCs IBS-D vs. HCs IBS vs. HCs 
Symbol FC P Value Adj. P Value FC P Value Adj. P Value FC P Value Adj. P Value 
NECTIN1 0.63 0.0001 0.01 1.1 0.36 0.8 0.83 0.056 0.483 
ADD1 0.71 0.0001 0.009 1.11 0.18 0.68 0.89 0.087 0.54 
PVR 0.8 0.0028 0.04 1.03 0.63 0.9 0.91 0.122 0.581 
AFDN 1.51 0.0002 0.011 1.09 0.37 0.8 1.28 0.005 0.282 
FC, fold change; Adj., adjusted 
 
Figure 7: Cellular junction formation 
Modified from Current Opinion in Cell Biology, Vol. 19, Issue 5, Sakisaka et al, (39), The roles of 
nectins in cell adhesions: cooperation with other cell adhesion molecules and growth factor 
receptors, pages 593-602; Copyright 2007, with permission from Elsevier. 
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Figure 8: Expression of adherens junction genes by microarray and RT-PCR 
PCR expression is normalized to ACTB and GAPDH 
 
Table 8: Adherens junction genes PCR sample demographics 
 IBS HC 
N (% women) 30 (50%) 13 (46%) 
Cohort 
Microarray 18 (10 IBS-C, 8 IBS-D) 10 
Validation 12 (6 IBS-C, 10 IBS-D) 3 
Age 34.9 (12.2) 32.2 (7.8) 
BMI 25 (5.5) 25.5 (2.9) 
Hispanic 4 (13.3%) 2 (15.4%) 
Asian 6 (20.0%) 3 (23.1%) 
Black 4 (13.3%) 1 (7.7%) 
White 15 (50%) 6 (46.2%) 
Other 5 (16.7%) 3 (23.1%) 
BMI, body mass index 
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Afadin divergent transcript (AFDN-DT) is up-regulated in IBS-C vs. HCs 
A search of lncRNAs in close proximity to the cell adhesion genes in  
Table 7 identified AFDN divergent transcript (AFDN-DT). AFDN-DT (NCBI gene ID 653483) has 
two exons and encodes a 2,311-base-pair lncRNA (NR 027906). AFDN-DT is in a head-to-head 
relationship with AFDN, which means that there is overlap of the 5’ regions (Figure 9). In the 
microarray data, AFDN-DT was up-regulated in IBS-C vs. HCs with and FDR of 0.061 and in 
IBS overall vs. HCs with an unadjusted p value of 0.013 (Figure 10A). It was also positively 
correlated with AFDN (Figure 10B). 
 
 
Figure 9: Afadin divergent transcript (AFDN-DT) 
Image created with the UCSC genome browser, http://genome.ucsc.edu (30) using the Human 
Dec. 2013 (GRCh38/hg38) assembly. 
 
Validation of AFDN-DT by RT-PCR 
RT-PCR was performed in two larger overlapping cohorts (n=55, n=63). Sample demographics 
are shown in Table 9. PCR results are shown in Figure 11. Mean expression of AFDN-DT was 
greater in IBS-C vs. HCs but the difference was not statistically significant. There was a trend 
for increased expression in IBS overall vs. HCs (p = 0.08, p = 0.07 for PCR 1 and 2). There was 
a significant (p < 0.005) positive correlation between AFDN-DT and AFDN (Figure 12). 
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Table 9: AFDN-DT PCR cohort demographics 
 
PCR 1 (n=56) PCR 2 (n=65) 
IBS HC IBS HC 
N (% women) 39 (54%) 17 (47%) 45 (62%) 20 (45%) 
Cohort 
Microarray 15 (9 IBS-C, 6 IBS-D) 10 18 (10 IBS-C, 8 IBS-D) 10 
Validation 
23 
(11 IBS-C, 9 IBS-D, 
2 IBS-M, 1 IBS-U) 
7 
25 
(12 IBS-C, 10 IBS-D, 
2 IBS-M, 1 IBS-U) 
10 
Age 34.2 (12.5) 32.4 (9.3) 34.6 (12.3) 33.8 (10.4) 
BMI 25 (4.9) 25.7 (3.3) 25.1 (5.4) 25.7 (3.6) 
Hispanic 3 (7.7%) 4 (23.5%) 5 (11.1%) 4 (20%) 
Asian 8 (20.5%) 4 (23.5%) 10 (22.2%) 4 (20%) 
Black 5 (12.8%) 1 (5.9%) 8 (17.8%) 2 (10%) 
White 20 (51.3%) 8 (47.1%) 22 (48.9%) 10 (50%) 
Other 6 (15.4%) 3 (17.6%) 5 (11.1%) 3 (15%) 
BMI, body mass index; IBS-M, IBS with mixed bowel habit; IBS-U, IBS unsubtyped 
 
 
 
Figure 10: AFDN-DT microarray differential expression and correlation with AFDN 
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Figure 11: PCR validation of AFDN-DT 
 
Figure 12: PCR correlation of AFDN-DT and AFDN 
Results are from PCR 2 with normalization to 18S, PPIA and RPII. 
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Figure 13: AFDN-DT expression by in situ hybridization 
 
In-situ hybridization of AFDN-DT 
In order to verify the expression of AFDN-DT in colonic mucosal biopsies and to determine 
whether expression was present in epithelial cells, in-situ hybridization was performed on 
formalin-fixed paraffin embedded colonic biopsies using a custom probe designed to target 
AFDN-DT. AFDN-DT was expressed in epithelial cells (Figure 13A, arrows indciate positive 
signal).  
AFDN-DT selected for further study in cellular models 
In-situ hybridization confirmed expression of AFDN-DT in colonic epithelial cells. In Chapter 4, 
cell culture models are used to test the hypothesis that AFDN-DT overexpression affects the 
permeability of colonic epithelial monolayers. This specific hypothesis addresses the overall 
hypothesis that dysregulation of AFDN-DT may impact IBS symptoms and pathophysiology by 
affecting intestinal permeability. 
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DISCUSSION 
Dysregulation of lncRNAs in IBS 
Similar to the mRNA findings discussed in Chapter 2, differential expression of lncRNAs was 
primarily seen in IBS-C vs. HCs. As discussed in Chapter 2, the presence of positive findings in 
IBS-C vs. HCs may be due to careful age- and sex-matching of the samples and exclusion of 
those with medication use. Absence of significant differences in IBS overall and IBS-D vs. HCs 
should be interpreted with caution as the microarray study was only powered to make negative 
conclusions for genes with fold change > 2. Absence of smaller, but potentially biologically 
meaningful differences cannot be definitively concluded. 
GHRLOS 
GHRLOS was identified as a promising target for further study through a data-driven analytic 
approach to differentially expressed lncRNAs in IBS. Several transcripts of GHRLOS, the 
natural antisense transcript (NAT) of the ghrelin gene (GHRL), have been identified.(40) The 
first exon of the majority of transcripts overlaps 1.4 kb of the GHRL promoter and 106 
nucleotides of GHRL exon 4. Evidence that GHRLOS is a functional lncRNA includes 
polyadenylation, 5’ capping, extensive splicing and tissue-specific expression.(41) Expression is 
low in the stomach and highest in tissues known to have high expression of lncRNAs, such as 
the brain and thymus.(41) An association between decreased expression of GHRLOS and poor 
prognosis in colon cancer has been reported.(42) 
GHRLOS is down-regulated in IBS 
In this study, GHRLOS was down-regulated in sigmoid mucosal biopsies of twenty patients with 
IBS (ten with constipation, ten with diarrhea) in comparison to ten HCs (Figure 2). PCR 
validation was supportive (p = 0.09, Figure 5). A weighted gene correlation network analysis 
(WGCNA)(15) identified a strong positive association of GHRLOS with genes related to 
activation of NF-κB and ERK1/ERK2, which are both downstream targets of ghrelin signaling, 
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which parallels motilin signaling.(34,43) Expression of GHRLOS was also negatively associated 
with motilin (MLN), which was up-regulated in IBS (fold change 1.37, p = 0.0006). Dysregulation 
of motilin in IBS is supported in other studies,(31,33,44) and motilin receptor agonists, such as 
erythromycin accelerate GI transit.  
Ghrelin and motilin in gastrointestinal physiology 
Ghrelin and motilin are closely related hormones released from the GI tract. They are released 
by similar stimuli, such as fasting, but have different physiologic effects. Motilin is secreted in 
association with phase III of the migrating motor complex (MMC).(45) Motilin’s prokinetic effect 
is hypothesized to occur via facilitation of myenteric cholinergic activity at low concentrations 
and direct action on smooth muscle at high concentrations.(46) Motilin agonists are more potent 
prokinetics than 5HT4 agonists;(47) however, few of the agents studied in IBS clinical trials 
have succeeded in meeting clinical endpoints.(45,48) Additionally, despite observations that 
motilin increases contractility of human stomach or colon strips,(49,50) the non-peptide motilin 
receptor agonist erythromycin did not increase colonic motility or transit in the majority of studies 
in healthy individuals or those with chronic constipation.(51-53) Broad et al. proposed that this 
discrepancy is due to the longer duration of action with non-peptides, which prevents regulation 
of MMCs.(49) 
Co-regulation of GHRLOS and motilin may involve NF-κB activation  
The receptors for ghrelin and motilin are the growth hormone secretagogue receptor (GHSR) 
and the motilin receptor (MLNR) and they are both GPCRs. Ghrelin receptors are widely 
expressed outside the GI tract, and signaling can occur in autocrine or paracrine fashions, such 
as in adipocytes,(54) or activation of vagal afferents.(55) NF-κB is a known downstream target 
of GPCRs and ghrelin signaling,(56,57) and NF-κB activation was a GO term associated with 
the “DNA repair” module which contains motilin and was positively correlated with GHRLOS 
expression. Though data from the cell lines studied in the ENCODE project (58) may have 
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limited relevance to regulation of colonic gene expression, the presence of chromatin 
immunoprecipitation sequencing (ChIP-Seq) peaks in the GHRLOS promoter region for MAX 
and JUND, two transcription factors activation by ERK1/ERK2 signaling (downstream of 
GPCRs), provides support for the hypothesis that GHRLOS is regulated by GPCR-signaling. In 
addition, there is a NF-κB binding site in intron 2 of GHRLOS, and intronic NF-κB binding has 
been shown to induce gene expression.(59) Since signaling down-stream of GPCRs may 
increase GHRLOS expression, it can be hypothesized that GHRLOS could function as a 
feedback mechanism to regulate ligand expression and thereby influence autocrine signaling. 
This hypothetical mechanism is outlined in (Figure 14). While there was no significant 
correlation of GHRLOS and ghrelin (GHRL) RNA, correlations due to this type of mechanism 
might only be seen in single cell sequencing or cell culture experiments. 
 
Figure 14: Hypothesized role of GHRLOS 
If GHRLOS is regulated by signaling down-stream of GPCRs (NF-κB), perhaps it has a role in 
feedback regulation of ghrelin autocrine signaling 
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AFDN-DT 
AFDN-DT was selected for further investigation due to a putative role in epithelial permeability. 
It was up-regulated in IBS-C vs. HCs (Figure 10) and its expression in epithelial cells was 
confirmed by in-situ hybridization (Figure 13). Down-regulation of AFDN-DT (also known as 
MLLT4 antisense 1) is associated with poor prognosis in gastric cancer.(60) 
Mechanisms of antisense lncRNA regulation of mRNA 
Antisense transcripts play functional regulatory roles through a variety of mechanisms, which 
are outlined in Figure 15.(61,62) Some antisense transcripts result in epigenetic silencing of 
neighboring genes, such as KCNQ1 overlapping transcript 1 and the Air non-coding RNA, which 
both function through interactions with chromatin and histone methyltransferases.(63,64) 
Antisense transcripts can also act as positive regulators of neighboring genes. For example, 
TALAM1, positively regulates MALAT1 though stabilization by 3’ end processing.(65) 
 
Figure 15: Mechanisms of antisense transcripts 
Reprinted from Villegas VE and Zaphiropoulos PG, Neighboring gene regulation by antisense 
long non-coding RNAs. Int J Mol Sci, 2015. 16(2): 3251-66. Licensed under CC BY 4.0. 
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Impaired intestinal permeability in IBS 
Increased intestinal permeability is frequently seen in IBS,(17,20-23,66-72) and has been 
shown to correlate with abdominal pain.(21-23,71) The mechanism underlying this observation 
remains unknown; however, several groups have identified alterations in expression of tight 
junction proteins such as ZO-1 and occludin.(21,23,73) Decreased expression of the adherens 
junction protein E-cadherin has also been observed in IBS.(74) 
Notably, our findings were greatest in IBS-C vs. HCs. While many of the studies on permeability 
in IBS have been conducted in IBS-D patients, there are several studies which have shown 
increased permeability in IBS-C (21,23,66,75) and others have shown increased permeability in 
IBS vs. HCs overall (including IBS-C).(19,67) Increased permeability has also been associated 
with chronic constipation.(76) 
Adherens junctions in epithelial barrier formation 
The epithelial barrier is maintained by junctional complexes which include tight junctions and 
adherens junctions (Figure 7).(39) The gene encoding the adaptor protein AFDN, the sense 
counterpart to AFDN-DT, plays a crucial role in formation and maintenance of adherens 
junctions through interactions with nectins and cadherins.(77) Adherens junctions initiate 
signaling resulting in organization of the actin cytoskeleton and recruitment of tight junction 
proteins. Interestingly, the phenotype of mice lacking intestinal expression of afadin is 
reminiscent of IBS with a morphologically normal gut, but with increased permeability.(78)  
A potential role for AFDN-DT and AFDN in intestinal permeability 
Based on the differential expression of both AFDN-DT and AFDN in IBS as well as the positive 
correlation between AFDN-DT and AFDN, we hypothesize that AFDN-DT is a positive regulator 
of AFDN, and that AFDN-DT expression impacts epithelial permeability. While the direction of 
change (up-regulation) is opposite of what might be expected based on the animal model of 
intestinal afadin knockout (increased permeability with afadin knockout), mRNA and protein 
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expression may not be directly correlated. It is also possible that the change in expression is a 
response to impaired permeability, and increased expression of AFDN-DT and AFDN may be 
related to restoration of barrier function. In the next Chapter of this dissertation, the hypothesis 
that AFDN-DT can affect epithelial permeability is tested in a cell culture model using colonic 
epithelial cells with inducible overexpression of AFDN-DT. Barrier impairment following 
overexpression of AFDN-DT would support a role for AFDN-DT in IBS pathogenesis. The 
possibility that AFDN-DT contributes to the maintenance of barrier function will also be tested as 
though overexpression during treatment of monolayers with pro-inflammatory cytokines known 
to increase permeability. 
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Chapter 4 
 
The Role of the lncRNA AFDN-DT in epithelial permeability 
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ABSTRACT 
Chapter 3 of this dissertation describes the analysis of microarray data from sigmoid mucosal 
biopsies of patients with irritable bowel syndrome (IBS) and healthy controls (HCs) in order to 
determine differentially expressed long non-coding RNAs (lncRNAs). In addition, Chapter 3 
describes the process and experimentation which led to the decision to further study the lncRNA 
afadin divergent transcript (AFDN-DT). In the microarray data, AFDN-DT was up-regulated in 
IBS with constipation (IBS-C) vs. HCs and was positively correlated with its “head-to-head” 
sense counter-part, afadin (AFDN), which encodes for an actin-binding adherens junction 
protein. We hypothesized that AFDN-DT may play a role in IBS pathophysiology by affecting 
intestinal permeability. The cell culture experiments described in this chapter address two aims. 
The first aim was to test the hypothesis that AFDN-DT affects epithelial permeability. The 
second aim was to elucidate the role of AFDN-DT in colonic epithelial cells using a systems 
biology approach to gene expression profiling data. 
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INTRODUCTION 
In Chapter 3 of this dissertation, the long non-coding RNA (lncRNA) AFDN-DT was selected for 
further investigation due to dysregulation in irritable bowel syndrome (IBS) and confirmed gene 
expression in colonic epithelial cells by in-situ hybridization. We hypothesize that AFDN-DT 
affects epithelial permeability, possibly via regulation of afadin (AFDN), which encodes an 
adherens junction protein. The importance of adherens junctions in establishing the epithelial 
barrier as well as the association between IBS and intestinal permeability are discussed in 
Chapter 3. 
This chapter describes investigations in colonic epithelial cells, which were designed to address 
the following aims: 1) to test the hypothesis that up-regulation of AFDN-DT increased 
permeability of colonic epithelial cell monolayers; and 2) to determine downstream effectors of 
AFDN-DT.  
To perform these investigations, we generated colonic epithelial cells capable of inducible 
overexpression of AFDN-DT. The T84 cell line was used because it is an established model for 
the study of epithelial barrier function,(1) and one frequently used by our group.(2) Studies were 
repeated Caco2-BBE (Caco2) cells, another cell line commonly used for the study of epithelial 
barrier function.(3)  
Both T84 and Caco2 cells differentiate and form monolayers of polarized cells when seeded on 
permeable supports, which allow for separate apical and basolateral media compartments. The 
study of genetically modified differentiated cells presents a challenge. Differentiation can take 
one to two weeks and differentiated cells can be difficult to transfect. Therefore, the best 
approach is to create stably transfected cell lines. We chose to use an inducible expression 
system in order to control the timing of gene expression. In this way, we could study the effect of 
AFDN-DT after or during differentiation.  
Inducible expression of AFDN-DT was accomplished through use of the Tet-On Advanced 
System (Takara Bio) by sequential lentiviral transfection and antibiotic selection of cells 
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expressing the Tet repressor protein followed by AFDN-DT under control of the Tet Responsive 
Element. The Tet-On Advanced System is a modification of the mechanism for regulation of 
tetracycline-resistance genes in Escherichia coli. In E. coli, the Tet repressor protein (TetR) is 
constitutively bound to the tet operator but dissociates in the presence of tetracycline to allow 
transcription of resistance genes. The Tet-On Advanced System uses a mutated TetR (rTetR), 
which binds to tetO but activates transcription in the presence of tetracycline or its analog 
doxycycline.(4) The promoter controlling expression of AFDN-DT in the lentiviral vector (pLVX-
Tight-Puro) is a combination of a modified Tet-Responsive Element joined to a modified minimal 
cytomegalovirus (CMV) promoter which does not bind endogenous mammalian transcription 
factors, which improves the inducible characteristics of the system. Using this system, we tested 
the effect of AFDN-DT on a) differentiated cells; b) cells undergoing differentiation; and c) 
differentiated cells treated with pro-inflammatory cytokines known to increase epithelial 
permeability. 
In aim 2 of this chapter, we determined downstream effectors of AFDN-DT by investigating 
changes in gene expression in AFDN-DT-overexpressing cells. Differential gene expression and 
pathway analysis was performed using an approach similar to that described in Chapter 2 on 3’ 
RNA sequencing data, which yields gene level count data.  
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METHODS 
Generation of T84-TR-AFDN-DT and Caco2-TR-AFDN-DT cells 
Maintenance of T84 and Caco2-BBE cells 
T84 and Caco2-BBE cells, obtained from American Type Culture Collection (ATCC, Manassas, 
VA), were incubated at 37°C with 5% CO2 in Dulbecco's Modified Eagle's medium (DMEM, 
Corning, Fisher Scientific, Hanover Park, IL) supplemented with 10% (v/v) heat-inactivated fetal 
bovine serum (FBS, Thomas Scientific, Swedesboro, NJ), 10 U/mL penicillin, and 100 μg/mL 
streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA). Medium was changed every 2-3 
days and cells were passaged at 80% confluency. Cell lines were verified to be free of 
mycoplasma with the Mycoplasma Detection Kit (ATCC). 
Lentiviral particle generation 
Lentiviral vectors were generated by transient co-transfection of 293T cells with a three-plasmid 
packaging combination, as previously described, with minor modifications.(5) The construct 
pMD.G was used for the production of the VSV-G viral envelop in combination with the 
packaging constructs pMDLg/pRRE and pRSV–REV. Briefly, 100-mm dishes of 70-80% 
confluent 293T cells were co-transfected with 6.5 μg of pMDLg/pRRE, 3.5 μg of pMD.G, 2.5 μg 
of pRSV–REV and 10 μg of the lentiviral vector (pLVX-Tet-On Advanced, modified or empty 
pLVX-Tight-Puro) by the calcium phosphate-DNA coprecipitation method.(6,7) The next day, to 
obtain high-titer virus production,(8) cells were washed with phosphate-buffered saline (PBS), 
and fresh medium containing 10 mM sodium butyrate and 20 mM Hepes was added to the cells.  
After incubation for 6-8 h, cells were washed and incubated in fresh medium without the sodium 
butyrate. The virus-containing medium was harvested 16-18 h later and passed through 0.45-
μm filters.  Aliquots of the virus were stored at -80ºC until transductions were performed. Viral 
titer was determined by assessing viral p24 antigen concentration by ELISA (Coulter 
Immunetech, Miami, FL). 
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Lentiviral transfection 
For transfection, cells were seeded at 50% confluency in 6-well plates (Olympus Plastics, 
Genesee Scientific, San Diego, CA). After 24 hours, cells were incubated for 6 hours in lentiviral 
supernatant diluted with serum-free medium to calculated multiplicities of infection (MOIs) of 10, 
30-50, and 100 (not included for empty vector due to lower concentration). Lentivirus was 
replaced with complete medium which was exchanged for medium containing selection 
antibiotics after 12 hours. 
Generation of T84-TR cells 
T84-TR cells were generated by transfection with lentivirus carrying the pLVX-Tet-On Advanced 
vector (Takara Bio, Mountain View, CA). Following transfection, T84-TR cells were cultured in 
DMEM with 10% FBS and 0.5 mg/ml G418 (Fisher Scientific) for selection for 14 days.  
Generation of T84-TR-AFDN-DT cells 
T84-TR-AFDN-DT cells were generated by transfection with lentivirus containing the AFDN-DT 
transcript sequence under control of the Tet Responsive Element. The AFDN-DT transcript 
sequence (NR 027906) flanked by the Afl II and Asc I restriction enzyme sites (5’) and the  
EcoR I restriction enzyme site (3’) was synthesized and subcloned (GenScript, Piscataway, NJ) 
into the pcDNA3.1/Zeo (+) vector at Afl II and EcoR I to generate AFDN-DT-pcDNA3.1-Zeo(+) 
(Figure 1A). To create the lentiviral vector, the lncRNA sequence was released from the plasmid 
by digestion with AscI and EcoRI. The 2.3 kb DNA fragment was isolated from a 1% agarose 
gel and the DNA purified from the gel using a PCR clean up kit (Promega). The fragment was 
ligated into a lentiviral vector, pLVX-Tight-PGK-Puro (Takara Bio) that was digested with MluI 
and EcoRI. The resulting plasmids with the insert (Figure 1B) were sequenced to ensure that 
the sequence was correct. After transfection, T84-TR-AFDN-DT cells were cultured in DMEM 
with 10% FBS, 500 μg/ml G418 and 7.5 μg/ml puromycin (Enzo Life Sciences, Farmingdale, 
NY) for selection for 7 days. Following selection, T84-TR-AFDN-DT cells were maintained in 
 119 
DMEM with 10% FBS, 100 μg/ml G418 and 250 ng/ml puromycin. T84-TR-EV cells were also 
generated with the unmodified pLVX-Tight-Puro vector. T84-TR-GFP cells were generated to 
evaluate for expression in the absence of doxycycline (system leakiness). 
Generation of Caco2-TR-AFDN-DT cells 
The protocol for generation of Caco2-TR and Caco2-TR-AFDN-DT cells was identical to that of 
T84 except that a lower concentration of puromycin (2 μg/ml) was used. 
A 
 
B 
 
Figure 1: AFDN-DT vector maps 
Maps created with SnapGene software (from GSL Biotech; available at snapgene.com). 
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Permeability measurements 
Determination of the effect of AFDN-DT following or during differentiation 
For growth of differentiated monolayers, 105 cells were seeded on Transwell (Corning, Fisher 
Scientific) permeable supports (6.5-mm diameter, 0.4-μm pore size) in 24-well plates (Olympus 
Plastics, Genesee Scientific, San Diego, CA). Resistance (ohms, W) was measured using the 
Millicell ERS-2 Voltohmmeter (Millipore Sigma, Burlington, MA). TEER (W×cm2) was calculated 
by multiplying the difference between the resistance of the monolayer and the baseline 
resistance of the membrane without cells by the surface area of the membrane. TEER readings 
were performed in triplicate. Doxycycline (1 μg/ml) was added once stable TEER was 
established (4-8 days) or at seeding to determine the effect of AFDN-DT during differentiation. 
Interferon gamma and TNF alpha response 
Recombinant human interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) were 
from StemCell Technologies (Cambridge, MA). To ensure an effect on TEER, IFN-γ was used 
at a concentration of 10 ng/ml as previously described.(9) Medium was exchanged after 48 
hours without adding additional IFN-γ. For transcellular permeability measurements, the 
concentration of IFN-γ was increased to 100 ng/ml and medium was replaced daily with medium 
containing fresh IFN-γ. For transcellular permeability measurements in Caco2-TR-AFDN-DT, 
TNF-α (100 ng/ml) was added in combination with IFN-γ. IFN-γ and TNF-α were added to the 
basal compartment only, as the basal and not the apical region is responsive to IFN-γ.(10) 
Paracellular permeability 
Following equilibration in Hanks Balanced Salt Solution (HBSS, Corning, Fisher Scientific) with 
calcium and magnesium for 30 min at 37°C, 1 mg/ml conjugated-dextran in HBSS was added to 
the apical compartment and fresh HBSS was added to the basal compartment. For T84-TR-
AFDN-DT cells, 10-kDa Dextran AlexaFluor 555 (Fisher Scientific) was used, and for Caco2-
TR-AFDN-DT cells, 4-kDA dextran-FITC (Millipore Sigma, Burlington, MA) was used. At serial 
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time points, the HBSS in the basal compartment was removed and replaced with fresh HBSS. 
The fluorescence of the basal fluid was measured in clear-bottom 96-well plates (Life 
Technologies, Thermo Fisher Scientific, Waltham, MA) with a microplate reader (Molecular 
Devices, San Jose, CA) and the concentration of dextran was calculated with a standard curve. 
Real-time Quantitative Polymerase Chain Reaction 
Wells were washed twice with ice-cold PBS. Total RNA was extracted with TRIzol Reagent 
(Thermo Fisher Scientific) or with the miRNeasy mini Kit plus on-column DNase treatment 
(Qiagen, Germantown, MD). RNA was quantified with the NanoDrop spectrophotometer 
(Thermo Fisher Scientific). Complementary DNA (cDNA) was synthesized from 250-500 ng 
RNA in a 10-μL reaction using the iScript™ gDNA Clear cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, CA) and was diluted 1:2 with nuclease-free water. Real-time 
quantitative PCR (RT-PCR) was performed in 384-well plates using the CFX384 Touch Real-
Time PCR Detection System (Bio-Rad). Each 5-μL reaction contained 1 μL diluted cDNA 
(concentration normalized across samples), 2.5 μL SYBR® Green Supermix (Bio-Rad), and 0.5 
μL each of 10-μM forward and reverse primers (Integrated DNA Technologies, Coralville, IA). 
Primer sequences are shown in Table 1. Resulting data were calculated by using the 2-
[delta][delta]Ct method, and the level of RNA expression was normalized to HPRT1 which was 
constant across samples and conditions. 
Table 1: Primer sequences 
AFDN-DT F – TGAGAGATGCCACGTGATCG; R - CACCGGGATGCTCACATAGT 
HPRT1 F – GACCAGTCAACAGGGGACAT; R - GCTTGCGACCTTGACCATCT 
F, forward; R, reverse 
RNA sequencing 
Library preparation and sequencing 
RNA quantity was verified with the Quant-iT™ RiboGreen™ RNA Assay Kit (Fisher Scientific) 
and samples were normalized to a concentration of 25 ng/μL. RNA quality (RNA integrity 
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number > 9 for all samples) was confirmed by Agilent TapeStation capillary electrophoresis. 
RNA sequencing (RNA-seq) was performed in the UCLA Neuroscience Genomics Core 
Laboratory using Lexogen QuantSeq 3′ FWD cDNA library synthesis (11) and multiplex DNA 
sequencing on an Illumina HiSeq 4000 instrument with single-strand 65 nt sequence reads 
following standard manufacturer protocols.  
Generation of gene count data 
Samples yielded >3 million reads. De-multiplexed raw reads (FASTQs) were then subjected to 
the QuantSeq 3’ mRNA-Seq Integrated Data Analysis Pipeline on the Bluebee© Genomics 
platform (https://www.bluebee.com/lexogen/), which uses standard tools but with parameter 
settings optimized for processing QuantSeq data. This pipeline includes trimming of adapter and 
polyA sequences, as well as low quality nucleotides using BBDuk (http://jgi.doe.gov/data-and-
tools/bb-tools/), alignment of trimmed reads against the human genome (GRCh38) with 
STAR,(12) and determination of gene counts with HTseq.(13) 
Statistical analysis 
All statistics were performed using the R software version 3.5.2.(14) 
Permeability measurements 
Percent change in TEER was calculated as the percent of TEER at baseline (t = 0). If outliers 
were present (at least 1.5 times the interquartile range from the maximum/minimum of the 
interquartile range), values were replaced with the mean from the same group (cell line, 
treatment).  
Group differences 
Group differences (gene expression, mean or percent change TEER, flux) were determined with 
the Wilcoxon signed rank test. A p value threshold of 0.05 was used to determine statistical 
significance. 
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Meta-analysis 
Meta-analysis of permeability experiments was performed with the meta package for R using a 
random effects model.(15) 
RNA-sequencing 
Differential expression 
Differential expression was determined using the DESeq2 package in R.(16) The primary 
outcome was differential expression in T84-TR-AFDN-DT with vs. without doxycycline. 
Differential expression was also determined for overall effect of doxycycline and group (T84-TR-
AFDN-DT vs. T84-TR-EV) as well as for doxycycline within T84-TR-EV, and T84-TR-AFDN-DT 
vs. T84-TR-EV without doxycycline. These additional analyses were to assist in determining 
differences that were specific to doxycycline in T84-TR-AFDN-DT. A Benjamini-Hochberg 
adjusted p value of 0.1 was used to determine statistical significance. 
Weighted gene co-expression network analysis (WGCNA) 
WGCNA was performed using the WGCNA package in R.(17) First, according to the WGCNA 
developer’s recommendations, counts were prepared for linear modeling and quantile 
normalized. Preparation for linear modeling was performed with the variance stabilization 
function in the DESeq2 package.(16) Quantile normalization was performed using the linear 
models for microarray (limma) package.(18) WGCNA using “signed” networks was performed to 
generate both a single network and consensus networks in T84-TR-AFDN-DT and T84-TR-EV. 
The single network was performed using a soft-thresholding power of 18, a minimum module 
size of 30, and merging of modules with correlation of 0.75 or greater. The consensus network 
used the same parameter except a higher threshold for merging (correlation of 0.85 or greater).  
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Functional annotation 
Overrepresented gene ontology (GO) terms in WGCNA modules were determined using the 
hypergeometric function in the GOstats package in R.(19) For large modules, DAVID was used 
to assess for clusters of functional annotation terms.(20,21) Gene Set Enrichment Analysis 
(GSEA) (22) was performed using the Java GSEA Desktop Application (v2.2.4) on the 
expression data used for the WGCNA analysis (filtered and transformed for linear modeling) 
using default parameters against the KEGG (23) and GO (24) genes sets obtained from 
Molecular Signatures Database (v6.0).(25) 
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RESULTS 
Inducible expression of AFDN-DT in differentiated colonic intestinal epithelial cells (IECs) 
Expression of AFDN-DT in differentiated T84 cells was confirmed by RT-PCR. Expression was 
similar in differentiated and undifferentiated cells (p = 0.3). Because epithelial cell differentiation 
can take 1-2 weeks and transient transfection is not reliably effective in differentiated cells, we 
elected to use an inducible expression system. Inducible expression of AFDN-DT (T84-TR-
AFDN-DT) was accomplished through use of the Tet-On Advanced System (Takara Bio) by 
sequential lentiviral transfection and antibiotic selection of the Tet repressor protein followed by 
AFDN-DT under control of the Tet Responsive Element. The Tet-On Advanced System is 
described in the introduction (page 115). 
Verification of overexpression 
Overexpression was induced by supplementation of the medium with doxycycline (1 µg/ml, 
Enzo Life Sciences) and was verified by RT-PCR. Since some FBS contains trace tetracycline, 
T84-TR-GFP was generated and the absence of induced expression without doxycycline was 
confirmed by absence of fluorescent colonies after 48 h (fluorescent colonies were present 24 h 
following addition of doxycycline). 
Expression of AFDN-DT (normalized to HPRT1) was increased in differentiated T84-TR-AFDN-
DT, but not T84-TR-EV cells with vs. without doxycycline at baseline (Figure 2A). Medium 
with/without doxycycline was added at day six following seeding (n = 6 wells per group, 24 wells 
total). This was also seen in cells treated with IFN-γ (Figure 2B). For IFN-γ-treated cells, there 
were n = 7 wells with doxycycline and n = 4 wells without doxycycline for each cell line (22 wells 
total). Of the 7 wells with doxycycline, doxycycline was added at time of seeding to 3 of the 
wells and at day 7 to 4 wells. Expression was similar regardless of when doxycycline was added 
(p = 1). AFDN-DT expression was greater in T84-TR-AFDN-DT wells with vs. without 
doxycycline at 7 days (p = 0.029) and there was a trend for doxycycline at seeding (p = 0.057). 
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The higher p value in this group may be due to fewer wells. A similar trend was seen in 
undifferentiated T84-TR-AFDN-DT cells (Figure 2C), but this did not reach statistical 
significance likely due to small sample size.  
 
Figure 2: PCR verification of inducible AFDN-DT overexpression 
Expression of AFDN-DT (normalized to HPRT1) is increased in differentiated T84-TR-AFDN-DT cells with 
vs. without doxycycline at baseline (A) and following treatment with IFN-γ (B). Panel C shows expression 
in undifferentiated cells. IEC, intestinal epithelial cell; Dox, doxycycline 
Effect of AFDN-DT overexpression on permeability of IEC monolayers 
Effect of AFDN-DT overexpression on TEER 
To determine the effect of AFDN-DT overexpression on TEER of IEC monolayers, T84-TR-
AFDN-DT (n = 16 wells) and T84-TR-EV cells (n = 12 wells) were seeded on permeable 
supports in 24-well plates. When TEER was > 1000 ohms (day 4-8), medium was replaced with 
medium +/- 1 μg/ml doxycycline. Figure 3 shows percent change in TEER following addition of 
doxycycline for three separate experiments. There was no significant difference in TEER 
resulting from overexpression of AFDN-DT (p > 0.05). Results were similar across varying 
baseline TEER values, which ranged from 3,000-5,000 (Figure 3A) to 20,000 (Figure 3B).  
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Figure 3: Effect of AFDN-DT overexpression on TEER in differentiated cells 
Effect of AFDN-DT overexpression on TEER. A. T84-TR-AFDN-DT (n= 10 and 6 with and without 
doxycycline) and T84-TR-EV cells (n= 6 and 6 with and without doxycycline) following addition of 
doxycycline seven days after seeding on permeable supports (Time = 0). B and C show additional 
experiments with similar results for T84-TR-AFDN-DT (B: n=3 per group, doxycycline added day 6; C: 
n=4 per group, doxycycline added day 6). sd, standard deviation; AFDN-DT, T84-TR-AFDN-DT; EV, T84-
TR-EV 
 
Figure 4: Pooled results for TEER response to AFDN-DT overexpression 
Summary result shows the pooled result using random effects model. The data for Aug2017 1, Apr2018 1 
and Nov 2018 is shown in Figure 3B, C, and A. sd, standard deviation; Tot, total; Dox, doxycycline 
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There was a difference between T84-TR-AFDN-DT (n=16) and T84-TR-EV (n=16) with and 
without doxycycline at days 7 (p = 0.033) and 9 (p = 0.033). Meta-analysis of these experiments 
also revealed a similar TEER with vs. without overexpression of AFDN-DT (Figure 4). 
 
Figure 5: Effect of AFDN-DT overexpression during differentiation on TEER 
TEER was similar with or without overexpression of AFDN-DT during differentiation. A. T84-TR-AFDN-DT 
and T84-TR-EV (n= 4/8 with/without doxycycline). Doxycycline 1 μg/ml added at time of seeding (Time = 
0). B. Percent change in TEER from first recording on day 2 post seeding/doxycycline. C. Mean TEER 
(same data as in B). sd, standard deviation; AFDN-DT, T84-TR-AFDN-DT; EV, T84-TR-EV 
Effect of AFDN-DT overexpression during differentiation on TEER 
To determine whether overexpression of AFDN-DT during the process of differentiation may 
affect permeability of IEC monolayers, doxycycline was added at the time of seeding (Figure 5). 
Although TEER at day 2 was higher in T84-TR-EV than T84-TR-AFDN-DT (p < 0.005), there 
was no difference in either cell line with the addition of doxycycline (p = 0.68 and 1 for T84-TR-
AFDN-DT and T84-TR-EV). Subsequent TEER measurements expressed as percent of 
baseline (day 2) are show in (Figure 5B). Visualization of raw TEER (Figure 5C) demonstrates 
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that while differentiation lagged in T84-TR-AFDN-DT (with and without doxycycline), both lines 
reached similar TEER. 
Effect of AFDN-DT overexpression on TEER response to IFN-γ 
Since TEER did not change with overexpression of AFDN-DT, we next sought to determine 
whether an effect could be seen if the monolayers were treated with the pro-inflammatory 
cytokine IFN-γ, which results in a reduction in TEER in T84 cells.(9) T84-TR-AFDN-DT and T84-
TR-EV cells were treated with IFN-γ, which was added to the basal compartment at a final 
concentration of 10 ng/ml. Representative plots and meta-analytic results are shown in Figure 6 
and Figure 7. TEER response to IFN-γ was similar with or without overexpression of AFDN-DT. 
In one experiment (Figure 6A-C), there was a small but significant reduction in the response to 
IFN-γ for T84-TR-AFDN-DT with vs. without doxycycline at day 1 (p = 0.0061). Meta-analysis of 
the differences in percent baseline TEER showed a trend for a reduced response in T84-TR-
AFDN-DT with vs. without doxycycline at day 2 (p = 0.054, Figure 7A). There was no effect of 
doxycycline in T84-TR-EV (Figure 7B). The absolute differences were very small (5.4 % at day 
1 and 0.19 % at day 3). A difference between the cell lines (T84-TR-AFDN-DT vs. T84-TR-EV) 
was seen (p < 0.05) for days 1-3 (panels A-C) and days 2-3 in panel D. 
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Figure 6: Effect of AFDN-DT overexpression on TEER response to IFN-γ 
* p<0.05 for doxycycline vs. no doxycycline within cell line (T84-TR-AFDN-DT/EV). A. T84-TR-AFDN-DT 
and T84-TR-EV (n= 4/8 with/without doxycycline). Panels A-C show results of the same experiment which 
included wells with doxycycline along with IFN-γ (A, n= 4 each with/without doxycycline, n=16 total) and 
at time of seeding (B, n= 3 with and 4 without doxycycline, n=14 total). C shows the combination of all 
doxycycline/no doxycycline wells. Panel D shows a separate experiment (n= 4 each with and without 
doxycycline, n=16 total). AFDN-DT, T84-TR-AFDN-DT; EV, T84-TR-EV 
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Figure 7: Pooled results for the effect of AFDN-DT overexpression on the TEER response 
to IFN-γ 
Summary result shows the pooled difference in percent baseline TEER using a random effects 
model. The data for Apr2018 2 and Jul2018 is shown in C and D. * For Apr2018 2, doxycycline 
start was day 7 for 4 wells and day 0 for 3 wells. sd, standard deviation; Tot, total; Dox, 
doxycycline 
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Effect of AFDN-DT overexpression on paracellular permeability 
To determine the effect of AFDN-DT overexpression on paracellular permeability, the flux of 10-
kDa Dextran Alexa Fluor 555 (dextran-555) from apical to basolateral compartments was 
measured. Dextran-555 (1 mg/ml, 100μM) was added to the apical compartment of T84-TR-
AFDN-DT and T84-TR-EV cells with vs. without doxycycline which had been treated with IFN-γ 
(10 ng/ml) for three days or had not received IFN-γ (n=4 per group/treatment, n=32 total). 
Dextran in the basolateral compartment was measured at 1, 3 and 9 hours. TEER values for 
these samples are shown in Figure 6D. Baseline (day 3 in Figure 6D) TEER (sd) was 9,297 
(815) and 28,595 (1,949) for IFN-γ-treated and untreated cells. Cells treated with doxycycline 
had increased paracellular permeability (Figure 8). This was true for T84-TR-AFDN-DT with 
IFN-γ and for T84-TR-AFDN-DT and T84-TR-EV without IFN-γ. Although not statistically 
significant, the same pattern was seen in T84-TR-EV with IFN-γ. Multivariate regression 
revealed a significant overall effect of IFN-γ (p < 0.005) and for doxycycline (p < 0.005). There 
was no significant cell-line by doxycycline interaction effect (p = 0.87), which indicates that the 
effect of doxycycline was similar in T84-TR-AFDN-DT and T84-TR-EV. 
 
Figure 8: Effect of AFDN-DT overexpression on paracellular permeability 
Median flux of 10kDa Dextran Alexa Fluor 555 for T84-TR-AFDN-DT and T84-TR-EV (n = 4 wells per 
group/treatment/IFN-γ n=32 wells total). Flux of control well without cells = 4,735 nM/cm2/hr.  
* indicates p < 0.05 for doxycycline vs. no doxycycline 
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Replication in Caco2 cells 
In order to determine whether the results were specific to T84 cells, Caco2 cells capable of 
inducible expression of AFDN-DT were generated with the same lentivirus. Permeability 
experiments were repeated in these cells (Caco2-TR-AFDN-DT) and cells transfected with an 
empty vector (Caco2-TR-EV). 
Verification of AFDN-DT overexpression 
Caco2-TR-AFDN-DT cells treated with vs. without doxycycline had increased expression of 
AFDN-DT (normalized to HPRT1, Figure 9). The difference was not statistically significant likely 
due to sample size (p = 0.2). 
 
Figure 9: Inducible AFDN-DT overexpression in Caco2-TR-AFDN-DT 
Expression of AFDN-DT (normalized to HPRT1) in differentiated Caco2-TR-AFDN-DT cells with vs. 
without doxycycline. Doxycycline was added at day 12 following seeding and cells harvested 2 days 
following doxycycline treatment. p = 0.2 (Caco2-TR-AFDN-DT), 0.33 (Caco2-TR-EV). 
Effect of AFDN-DT overexpression on TEER of Caco2 monolayers 
TEER of Caco2-TR-AFDN-DT and Caco2-TR-EV in response to doxycycline vs. no doxycycline 
is shown in Figure 10. Baseline TEER (sd) was 6,058 (396) and 6,179 (468) for Caco2-TR-
AFDN-DT and Caco2-TR-EV. Doxycycline was added on day 12 following seeding on 
permeable supports. TEER was similar in Caco2-TR-AFDN-DT with vs. without doxycycline. 
There was a small (< 10%) but significant (p < 0.05) decrease in TEER with vs. without 
doxycycline in Caco2-TR-EV. 
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Figure 10: Effect of AFDN-DT overexpression on TEER of Caco2 monolayers 
Doxycycline was added day 12 after seeding to Caco2-TR-AFDN-DT and Caco2-TR-EV cells (n=11/8 
with/without doxycycline).  
* indicates p < 0.05 for doxycycline vs. no doxycycline. 
Effect of AFDN-DT overexpression on TEER response to IFN-γ and TNF-α in Caco2 
monolayers 
The TEER response of Caco2-TR-AFDN-DT and Caco2-TR-EV with vs. without doxycycline to 
IFN-γ followed by the combination of IFN-γ and TNF-α is shown in Figure 10. Twenty-one days 
after seeding (9 days after doxycycline treatment), basal compartment medium was exchanged 
for medium with or without 100 ng/ml IFN-γ (n = 4 per cell line/doxycycline/treatment for IFN-γ-
treated cells and n = 3 per cell line/doxycycline/treatment for IFN-γ/TNF-α-treated cells, n = 28 
total). Baseline TEER (sd) was 6,058 (396) and 6,179 (468) for Caco2-TR-AFDN-DT and 
Caco2-TR-EV. TEER response to IFN-γ was similar in Caco2-TR-AFDN-DT and Caco2-TR-EV 
cells with vs. without doxycycline. There was a small (<5%), but statistically significant (p < 0.05) 
increase in Caco2-TR-AFDN-DT without vs. with doxycycline at day 1 in cells without  
IFN-γ. Despite the increased concentration of IFN-γ (100 ng/ml vs. 10 ng/ml in T84 
experiments), the response to IFN-γ in Caco2 cells, which was a decrease of about 40%, was 
smaller in comparison to T84 cells (typically >50%). In an attempt to maximize transcellular 
permeability for subsequent experiments, untreated cells were treated on day 3 with IFN-γ and 
TNF-α (both 100 ng/ml). Cells treated with IFN-γ on day 0 continued to be treated with IFN-γ. In 
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all cases the medium was exchanged daily with medium containing fresh cytokines. The 
response to IFN-γ and TNF-α is shown by the red line in Figure 11. There was no effect of 
doxycycline on the response to IFN-γ/TNF-α (p > 0.05). 
 
Figure 11: Effect of AFDN-DT overexpression on TEER response to IFN-γ and TNF-α in 
Caco2 
IFN-γ (100 ng/ml) was added at day 21 after seeding (day 9 after doxycycline) to Caco2-TR-AFDN-DT 
and Caco2-TR-EV cells (n=4 per cell line/doxycycline/treatment, n=28 total). At day 3, untreated cells 
were exposed to IFN-γ and TNF-α (red line, n=3 per cell line/doxycycline/treatment).  
* indicates p < 0.05 for doxycycline vs. no doxycycline. 
Effect of AFDN-DT overexpression on paracellular permeability in Caco2 monolayers 
To determine the effect of AFDN-DT overexpression on paracellular permeability in Caco2 cells, 
the flux of 4-kDa Dextran FITC (dextran-FITC) from apical to basolateral compartments was 
measured. Dextran-FITC (1 mg/ml, 250 μM) was added to the apical compartment of Caco2-
TR-AFDN-DT and Caco2-TR-EV cells with/without doxycycline. IFN-γ-treated cells (n=4 per cell 
line/doxycycline, n=16 total) were treated with 100 ng/ml for 6 days. IFN-γ + TNF-α treated cells 
(n=3 per cell line/doxycycline, n=12 total) were treated with IFN-γ and TNF-α (both 100 ng/ml) 
for 3 days. Dextran in the basolateral compartment was measured at 8 and 24 hours. There was 
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no effect of doxycycline on flux in either cell line (Figure 12). TEER values for these samples are 
shown in Figure 11. Baseline (day 6 in Figure 11) TEER (sd) was 5,736 (154) and 5,368 (272) 
for IFN-γ and IFN-γ + TNF-α treated cells.  
 
Figure 12: Effect of AFDN-DT overexpression on paracellular permeability in Caco2  
Median flux of 4-kDa Dextran FITC for Caco2-TR-AFDN-DT and Caco2-TR-EV. IFN-γ-treated cells (n=4 
per cell line/doxycycline, n=16 total) were treated with 100 ng/ml for 6 days. IFN-γ + TNF-α treated cells 
(n=3 per cell line/doxycycline, n=12 total) were treated with IFN-γ and TNF-α (both 100 ng/ml) for 3 days. 
Flux of control well without cells = 4,381 nM/cm2/hr. 
Gene expression profiling of T84-TR-AFDN-DT and T84-TR-EV with and without 
doxycycline 
In order to determine downstream effectors of AFDN-DT, we performed RNA sequencing (RNA-
seq) on differentiated T84-TR-AFDN-DT and T84-TR-EV cells with and without doxycycline (n=4 
per group/doxycycline, n=16 total). The samples were selected from those shown in Figure 2A 
based on RNA quality and within group uniformity of AFDN-DT expression levels. RNA 
concentration was normalized to 25 ng/μl. Sequencing libraries were prepared with the 
QuantSeq 3’mRNA-Seq Library Prep Kit FWD for Illumina (Lexogen, Vienna, Austria).(11) For 
traditional mRNA Sequencing library preparation, mRNAs (with polyA tails) are isolated, 
fragmented, and then reversed transcribed into complementary DNA (cDNA) with random 
primers. Longer transcripts yield more fragments and thus higher counts, which can introduce a 
bias with longer transcripts more likely to be differentially expressed.(26) QuantSeq and other 3’ 
library preps use primers targeting the polyA tail. This results in one transcript per sequence. 
Furthermore, since the 3’ end is conserved between isoforms, fewer reads are needed for 
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confident read alignment. Because of the lower required sequencing depth, libraries can be 
multiplexed (with addition of primers containing index sequences to allow deconvolution of 
results) and sequenced in a single lane which reduces costs considerably. This method 
provides gene-level but not transcript-level counts. Mean RNA quality (RNA integrity number), 
reads yielded by sequencing, as well as TEER on day of harvest and AFDN-DT gene 
expression (RT-PCR) by group is shown in Table 2. There were no group differences in RNA 
quality, sequencing depth or TEER. Expression of AFDN-DT was increased in T84-TR-AFDN-
DT treated with doxycycline compared with each other group. One sample (T84-TR-AFDN-DT 
with doxycycline was excluded as it was determined to be an outlier following sample 
clustering). 
Table 2: RNA quality and reads 
Cell line T84-TR-AFDN-DT T84-TR-EV 
Treatment - Doxycycline - Doxycycline 
N wells 4 3 4 4 
RIN 9.9 (0.1) 9.8 (0.3) 9.9 (0.1) 9.8 (0.2) 
Reads x 106 3.6 (0.3) 3.2 (0.1) 3.5 (0.1) 3.3 (0.2) 
TEER x 103 34.3 (0.6) 32.6 (3.2) 34.5 (0.6) 34.2 (1.1) 
AFDT-DT expression 0.9 (0.1) 1.6 (0.4)* 0.8 (0) 0.9 (0.1) 
All values are mean (standard deviation). * indicates p<0.005 vs. all other groups. RIN, RNA integrity 
number 
Differential expression 
The numbers of differentially expressed genes (DEGs) for different comparisons and at different 
significance thresholds is shown in Table 3. There were more DEGs between the two cell lines, 
both overall and restricted to wells without doxycycline, than between cells within the same 
group (T84-TR-AFDN-DT/T84-TR-EV) with vs. without doxycycline. The principal components 
(PCA) plot shown in Figure 13 reveals that cells with vs. without doxycycline did not cluster 
separately, which is in concordance with the low number of DEGs. The sixteen DEGs in T84-
TR-AFDN-DT with vs. without doxycycline (FDR < 0.1) are shown in Table 4. There were four 
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genes for which there was also an effect of doxycycline in T84-TR-EV (p < 0.05) indicating that 
the effect may be due to doxycycline. On visualization of dot plots, two other genes also 
appeared to have the same pattern of change in T84-TR-EV. These six genes are in italics in 
Table 4. Expression of the remaining ten genes by group was visualized in dot plots (Figure 14).  
Table 3: Summary of differential expression 
Comparison 
n DEGs all (up/down) 
FDR < 0.05 FDR < 0.10 P < 0.05 
Dox. (All wells with vs. without Dox.) 3 (2/1) 5 (3/2) 506 (237/269) 
Group (All T84-TR-AFDN-DT vs. EV) 208 (117/91) 291 (157/134) 797 (424/373) 
Dox*Group interaction effect - - 575 (276/299) 
Dox. (T84-TR-AFDN-DT) 5 (3/2) 16 (7/9) 140 (45/95) 
Dox. (EV) - - 296 (145/151) 
T84-TR-AFDN-DT vs. EV in wells without Dox. 85 (60/25) 148 (91/57) 418 (233/185) 
DEGs, differentially expressed genes; Dox., doxycycline; EV, T84-TR-EV 
 
Figure 13: RNA-seq principal components plot 
The first two principal components are plotted. Each dot represents a well. Dot size is 
proportional to expression of AFDN-DT by RT-PCR. 
Dox., doxycycline 
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Table 4: Differential gene expression in T84-AFDN-DT with vs. without doxycycline 
Symbol, name Mean FC P Adj. P  
Up-regulated 
MT-ATP8, mitochondrially encoded ATP synthase membrane subunit 8 755 1.6 *** 0.001 
SFPQ, splicing factor proline and glutamine rich 326 1.5 *** 0.006 
MT-ND1, mitochondrially enc. NADH:ubiquinone oxidoreductase core subunit 1 1403 1.4 *** 0.022 
MT-CYB, mitochondrially encoded cytochrome b 4795 1.3 *** 0.059 
MTATP6P1, MT-ATP6 pseudogene 1 297 1.6 ** 0.079 
MT-CO2, mitochondrially encoded cytochrome c oxidase II 12965 1.2 ** 0.079 
MT-ND6, mitochondrially enc. NADH:ubiquinone oxidoreductase core subunit 6 707 1.5 * 0.096 
Down-regulated 
SNORA12, small nucleolar RNA, H/ACA box 12 5806 0.6 *** 0.002 
IER3, immediate early response 3 8002 0.7 *** 0.013 
MT-TV, mitochondrially encoded tRNA-Val (GUN) 394 0.7 *** 0.063 
ILRUN1, inflammation and lipid regulator with UBA-like and NBR1-like domains 284 0.7 *** 0.063 
RPL36A, ribosomal protein L36a 2250 0.7 ** 0.088 
NEDD8, neural precursor cell expressed, developmentally down-regulated 8 324 0.7 ** 0.088 
MRPL14, mitochondrial ribosomal protein L14 328 0.7 * 0.096 
DDIT4, DNA damage inducible transcript 4 4203 0.7 * 0.096 
SCARNA22, small Cajal body-specific RNA 22 377 0.6 * 0.096 
Italicized entries are likely to be doxycycline-related. *** p < 0.0005, ** p < 0.005, * p < 0.05; FC, fold 
change; Adj., adjusted (Benjamini-Hochberg); enc., encoded. 1ILRUN was renamed from C6orf106 in 
April 2019 
 
 
 
 
Figure 14: Plots of differentially expressed genes in T84-AFDN-DT with vs. without 
doxycycline 
AF, T84-TR-AFDN-DT; AF Dox, T84-TR-AFDN-DT + doxycycline; EV, T84-TR-EV; EV Dox, 
T84-TR-EV + doxycycline 
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WGCNA 
Initial network generation 
In order to gain more insight into the pathways and functions of DEGs, a weighted gene co-
expression network analysis was performed.(17) The initial WGCNA analysis was performed in 
all fifteen samples. There were nineteen modules (Figure 15A), though several were quite large. 
I was unable to find parameters that resulted in a network with a reasonable (<50) number of 
modules that did not contain several very large modules. For these modules, DAVID (20,21) 
was used to identify clusters within the modules, which was the case for the 
“Ribosome/Mitochondria” modules. The correlations of module eigengenes with cell line and 
treatment is shown in Figure 15B. The first two columns show correlations with cell line for all 
wells and for wells without doxycycline. Some of the modules were strongly associated with cell 
line, but in most cases, the association was similar even in wells without doxycycline, indicating 
that most differences were due to underlying differences in the cells and not overexpression of 
AFDN-DT.  
Consensus network analysis 
A single network was important in order to view module association with doxycycline for both 
T84-TR-AFDN-DT and T84-TR-EV. A trial of network generation by cell line revealed that the 
presence of the large modules in the single network was an effect of clustering by cell line (gene 
co-expression was strongly related to overall differences in cell lines). This can be seen in 
Figure 15B as the large modules are correlated with cell line. In order to construct modules 
more likely to reflect biological pathways rather than group differences between T84-TR-AFDN-
DT and T84-TR-EV, a consensus network WGCNA was performed. This analysis performs 
clustering in two related data sets (each cell line) and finds modules present in both sets. This 
allows visualization and comparison between the cell lines of T84-related modules, as well as 
correlation with doxycycline in each cell line. Consensus network intermodular connectivity and 
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correlations with treatment (doxycycline vs. no doxycycline) and AFDN-DT expression by PCR 
are shown in Figure 16. There were 24 consensus modules. The overall differences between 
T84-TR-AFDN-DT and T84-TR-EV can be seen by the different patterns of intermodular 
connectivity in Figure 16A. 
 
 
Figure 15: WGCNA, single network 
A) Intermodular connectivity. B) Correlations between module eigengenes (adjusted p values) with group 
(T84-TR-AFDN-DT vs. T84-TR-EV), treatment (doxycycline vs. no doxycycline), and AFDN-DT 
expression by PCR. Group/Dox (all) shows the correlation with cell line or treatment in all wells, whereas 
Dox (AFDN-DT) and Dox (EV) show the correlation with doxycycline for each cell line (T84-TR-AFDN-DT, 
T84-TR-EV). Group (no Dox) shows the correlation with cell line only in wells not treated with doxycycline. 
Dox., doxycycline 
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Figure 16: WGCNA, consensus networks 
A) Intermodular connectivity. B) Within group (T84-TR-AFDN-DT, T84-TR-EV) correlations for module 
eigengenes (p values) with treatment (doxycycline vs. no doxycycline) and AFDN-DT expression by PCR. 
AFDN-DT, T84-TR-AFDN-DT; EV, T84-TR-EV 
 
Modules correlated with doxycycline in T84-TR-AFDN-DT 
In the single network WGCNA (Figure 15B), there were six modules correlated with doxycycline 
in T84-TR-AFDN-DT. Three were positively correlated (“Fatty acid metabolism,” 
“Adhesion/Immune regulation,” and “Transcription regulation”), and three were negatively 
correlated (“Unfolded protein binding,” “Translation initiation,” and “Autophagy”). There was one 
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module (“Transcriptional repression”) in the consensus network (Figure 16B) that was 
negatively correlated with doxycycline in T84-TR-AFDN-DT. The top ten genes with the highest 
module membership (correlation with module eigengene, MM) in these modules are shown in 
Table 5. 
Module membership of DEGs 
Module membership was assessed for the ten DEGs specific to T84-TR-AFDN-DT for both 
networks. In the single network, only four had MM > 0.6 in any module: RPL36A and 
SCARNA22 were in the “Translation initiation” module, IER3 was in the “Adherens junction” 
module, and ILRUN was in the “Autophagy” module. The rest clustered (though with MM < 0.6) 
in “Adhesion/immune regulation” (SFPQ), “Translation initiation” (NEDD8, MRPL14, DDIT4), 
and “Autophagy” (MT-TV). The six doxycycline-related genes (MM) clustered into 
“Adhesion/immune regulation” (MT-ATP8 (0.3), MT-ND1 (0.3), MT-CYB (0.3), MTATP6P1 (0.8)) 
and “Ribosome/Mitochondria 2” (MTATP6P1 (0.8), MT-CO2 (0.35), MT-ND6 (0.28)). 
Seven of the ten T84-TR-AFDN-DT specific DEGs had module membership (MM) > 0.6 in the 
consensus network for T84-TR-AFDN-DT. These genes were in the following modules (module: 
gene (MM)): “Transcriptional repression”: SNORA12 (0.74), ILRUN (0.91); “Protein transport”: 
RPL36A (0.85); “Peptide biosynthesis”: NEDD8 (0.89); “DNA transcription”: DDIT4 (0.68); 
“rRNA processing”: SCARNA22 (0.88). SFPQ and MRPL14 were not in the consensus network 
indicating that they clustered differently in each cell line. MT-TV and IER3 clustered into 
“Peptide biosynthesis” and “Intermediate filament cytoskeleton” but with MMs < 0.6. 
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Table 5: Top genes in modules correlated with doxycycline in T84-TR-AFDN-DT 
A. Positive correlation 
Symbol Gene (MM) Consensus mod. (MM) 
Fatty acid metabolism 
LLGL2 LLGL scribble cell polarity complex component 2 (0.86) GF response (0.78) 
SCD stearoyl-CoA desaturase (0.86) TNF signaling (0.49) 
PDIA4 protein disulfide isomerase family A member 4 (0.84) GF response (0.35) 
CDT1 chromatin licensing and DNA replication factor 1 (0.83) Cell division (0.34) 
CCDC85C coiled-coil domain containing 85C (0.82) - 
STC2 stanniocalcin 2 (0.82) Cell division (0.37) 
SART1 spliceosome associated factor 1, recruiter of U4/U6.U5 tri-snRNP (0.82) NA 
PSAT1 phosphoserine aminotransferase 1 (0.81) GF response (0.47) 
ARG2 arginase 2 (0.8) Prot. targ. mem. (0.4) 
HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (0.79) GF response (0.72) 
Adhesion/immune regulation 
HES1 hes family bHLH transcription factor 1 (0.97) GF response (0.96) 
TMSB4X thymosin beta 4 X-linked (0.96) GF response (0.96) 
ELOB elongin B (0.96) GF response (0.96) 
COPS7A COP9 signalosome subunit 7A (0.95) TNF signaling (0.75) 
CYSTM1 cysteine rich transmembrane module containing 1 (0.95) GF response (0.89) 
DCAF5 DDB1 and CUL4 associated factor 5 (0.95) GF response (0.93) 
UBL5 ubiquitin like 5 (0.94) GF response (0.94) 
ID1 inhibitor of DNA binding 1, HLH protein (0.94) GF response (0.93) 
RPL41 ribosomal protein L41 (0.93) GF response (0.94) 
SLC44A1 solute carrier family 44 member 1 (0.93) GF response (0.97) 
Transcription regulation 
SRRM2 serine/arginine repetitive matrix 2 (0.91) Cell communication (0.74) 
CRIM1 cysteine rich transmembrane BMP regulator 1 (0.89) IF cytoskeleton (0.6) 
KIRREL1 kirre like nephrin family adhesion molecule 1 (0.87) Cell communication (0.54) 
SOX4 SRY-box 4 (0.85) TNF signaling (0.87) 
CDCP1 CUB domain containing protein 1 (0.84) IP signaling (0.88) 
CTNND1 catenin delta 1 (0.83) Cell communication (0.81) 
YLPM1 YLP motif containing 1 (0.82) IF cytoskeleton (0.9) 
SERINC5 serine incorporator 5 (0.81) IF cytoskeleton (0.8) 
EPB41L2 erythrocyte membrane protein band 4.1 like 2 (0.81) TNF signaling (0.87) 
P4HA2 prolyl 4-hydroxylase subunit alpha 2 (0.8) Cell communication (0.51) 
“-“ indicates that the gene did not cluster into a module. NA indicates that the gene was not in the analysis 
(was not expressed at levels to meet filtering in both cell lines) 
MM, module membership; mod., module; GF, growth factor; TNF, tumor necrosis factor; Prot. targ. mem., 
protein targeting to membrane; IF, intermediated filament; IP, inositol phosphate 
 
Table continued on next page. 
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B. Negative correlation 
Unfolded protein binding 
NACA nascent polypeptide associated complex subunit alpha (0.88) Resp. DNA damage (0.84) 
MTCH2 mitochondrial carrier 2 (0.86) Resp. DNA damage (0.72) 
HINT1 histidine triad nucleotide binding protein 1 (0.83) Cell division (0.69) 
FASTKD2 FAST kinase domains 2 (0.83) Protein transport (0.73) 
PIR pirin (0.83) Resp. DNA damage (0.69) 
KIAA1143 KIAA1143 (0.82) Resp. DNA damage (0.88) 
RCN1 reticulocalbin 1 (0.82) Cell division (0.61) 
H2AFZ H2A histone family member Z (0.82) Resp. DNA damage (0.84) 
ILVBL ilvB acetolactate synthase like (0.82) Resp. DNA damage (0.72) 
UFD1 ubiquitin recognition factor in ER associated degradation 1 (0.81) Ion transport (0.54) 
Translation initiation 
RPS10 ribosomal protein S10 (0.94) rRNA processing (0.84) 
SLC25A6 solute carrier family 25 member 6 (0.94) Peptide biosynthesis (0.89) 
MPDU1 mannose-P-dolichol utilization defect 1 (0.93) Protein transport (0.86) 
TOMM7 translocase of outer mitochondrial membrane 7 (0.91) rRNA processing (0.75) 
DDT D-dopachrome tautomerase (0.9) rRNA processing (0.91) 
EIF6 eukaryotic translation initiation factor 6 (0.89) Transcr. regulation (0.77) 
EMP2 epithelial membrane protein 2 (0.88) rRNA processing (0.34) 
NDUFAF8 NADH:ubiquinone oxidoreductase complex assembly factor 8 (0.87) Vesicle transport (0.67) 
TFCP2L1 transcription factor CP2 like 1 (0.87) Protein transport (0.58) 
S100A4 S100 calcium binding protein A4 (0.86) Transcr. repression (0.82) 
Autophagy 
UXS1 UDP-glucuronate decarboxylase 1 (0.92) Transcr. repression (0.89) 
ARRDC3 arrestin domain containing 3 (0.9) Protein transport (0.86) 
TRAPPC6A trafficking protein particle complex 6A (0.88) Transcr. repression (0.83) 
MRPL27 mitochondrial ribosomal protein L27 (0.88) Protein transport (0.88) 
PARP4 poly(ADP-ribose) polymerase family member 4 (0.88) Protein transport (0.94) 
PRKAG1 protein kinase AMP-activated non-catalytic subunit gamma 1 (0.87) Transcr. repression (0.96) 
GCC1 GRIP and coiled-coil domain containing 1 (0.86) Transcr. repression (0.8) 
TPX2 TPX2, microtubule nucleation factor (0.84) Protein transport (0.78) 
NDUFS2 NADH:ubiquinone oxidoreductase core subunit S2 (0.84) Transcr. repression (0.8) 
PCYOX1 prenylcysteine oxidase 1 (0.83) Protein transport (0.76) 
Transcriptional repression (consensus module) 
Symbol  Gene (consensus module MM) Single network mod (MM) 
CLIC1 chloride intracellular channel 1 (0.98) Endocytic vesicle (0.71) 
RNF24 ring finger protein 24 (0.97) Kinase regulation (0.65) 
PRKAG1 protein kinase AMP-activated non-catalytic subunit gamma 1 (0.96) Autophagy (0.87) 
HSF2 heat shock transcription factor 2 (0.96) Autophagy (0.78) 
TTF1 transcription termination factor 1 (0.95) Autophagy (0.74) 
C1orf74 chromosome 1 open reading frame 74 (0.94) Autophagy (0.66) 
DARS aspartyl-tRNA synthetase (0.93) Autophagy (0.5) 
SERBP1 SERPINE1 mRNA binding protein 1 (0.91) Autophagy (0.62) 
ILRUN inflammation and lipid regulator with UBA-like and NBR1-like domains(0.91) Autophagy (0.69) 
URM1 ubiquitin related modifier 1 (0.9) Autophagy (0.58) 
AP1S1 adaptor related protein complex 1 subunit sigma 1 (0.9) Autophagy (0.82) 
MM, module membership; mod., module; Resp., response; rRNA, ribosomal RNA; Transcr., 
transcriptional 
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Gene set enrichment analysis (GSEA) 
At the GSEA recommended statistical significance threshold of FDR q value < 0.25, the KEGG 
pathway “Fc gamma R-mediated phagocytosis” was enriched in T84-TR-AFDN-DT with vs. 
without doxycycline. This pathway involves formation of phagosomes following crosslinking of 
Fc gamma receptors. The top genes accounting for this enrichment were: protein kinase C, 
alpha (PRCKA), phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta, PIK3R2), vav 2 
oncogene (VAV2), phosphoinositide-3-kinase, catalytic, beta polypeptide (PIK3CB), and v-akt 
murine thymoma viral oncogene homolog 1 (AKT1). There were six gene sets enriched in T84-
TR-AFDN-DT vs. T84-TR-EV and 29 in T84-TR-EV vs. T84-TR-AFDN-DT (Table 6). 
Table 6: GSEA results for T84-TR-AFDN-DT vs. T84-TR-EV 
Gene Set ES FDR 
Enriched in T84-TR-AFDN-DT (n=6) 
DNA directed RNA polymerase III complex (GO) 0.60 0.21 
Pyrimidine containing compound catabolic process (GO) 0.60 0.14 
Pre-ribosome (GO) 0.52 0.14 
Pyrimidine metabolism (KEGG) 0.48 0.07 
ER associated ubiquitin dependent protein catabolic process (GO) 0.42 0.22 
Purine metabolism (KEGG) 0.39 0.14 
Enriched in T84-TR-EV (n=29*) 
Regulation of phosphatidylinositol 3 kinase activity (GO) -0.72 0.16 
Arrhythmogenic right ventricular cardiomyopathy ARVC (KEGG) -0.63 0.03 
Desmosome (GO) -0.60 0.13 
Dilated cardiomyopathy (KEGG) -0.60 0.07 
Neurological postsynaptic density (GO) -0.60 0.14 
Intercalated disc (GO) -0.56 0.10 
Cell-cell contact zone (GO) -0.54 0.07 
Extracellular matrix (GO) -0.50 0.14 
Fc gamma r mediated phagocytosis (KEGG) -0.50 0.07 
Extrinsic component of cytoplasmic side of plasma membrane (GO) -0.50 0.08 
*Only top 10 non-redundant gene sets shown. GSEA, gene set enrichment analysis; ES, enrichment 
score 
In order to better understand the patterns of enrichment in the four groups (each cell line with 
and without doxycycline), I compared gene sets enriched (nominal p value < 0.05) in cells with 
vs. without doxycycline for each cell line: T84-TR-AFDN-DT + doxycycline (AF+dox) vs. T84-
TR-AFDN-DT (AF) and T84-TR-EV + doxycycline (EV+dox) vs. T84-TR-EV (EV). Gene sets 
enriched in the doxycycline or no doxycycline group for both cell lines would likely be related to 
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doxycycline. I also compared gene sets enriched in T84-TR-AFDN-DT vs. T84-TR-EV for both 
treatment groups (AF+dox vs. EV+dox and AF vs. EV). Gene sets enriched in one cell line both 
with and without doxycycline would likely to be related differences in the cell lines.  
There were no gene sets that were enriched with or without doxycycline in both cell lines (i.e. 
AF+dox vs. AF and EV+dox vs. EV). There were five gene sets (all GO terms) that were 
enriched with doxycycline in T84-TR-AFDN-DT but were enriched without doxycycline in T84-
TR-EV: “embryonic heart tube development”, “chromosome condensation”, “positive regulation 
of cell cycle”, “neural tube formation”, and “eye development”. Three of the six gene sets 
enriched in AF vs. EV (FDR < 0.25) were also enriched in AF+dox vs. EV+dox (p < 0.05) and 
seventeen of the 29 gene sets enriched in EV vs. AF (FDR < 0.25) were also enriched in the 
EV+dox vs. AF+dox (p < 0.05). These are shown in Table 7, rows A and B and represent gene 
sets that reflect the underlying differences between T84-TR-AFDN-DT and T84-TR-EV. There 
were also gene sets that had divergent patterns of enrichment in the doxycycline-treated 
groups. These gene sets (Table 7, rows C and D) were enriched in one cell line without 
doxycycline, but the other cell line with doxycycline. The five gene sets listed above, which were 
enriched with doxycycline in T84-TR-AFDN-DT but without doxycycline in T84-TR-EV also 
represent divergent effects of doxycycline in the cell lines.  
Table 7: Comparison of cell line gene set enrichment by doxycycline treatment 
Enriched cell line by treatment category -dox +dox 
A Pre-ribosome, pyrimidine metabolism (KEGG), ER associated ubiquitin dependent 
protein catabolic process AF AF 
B Cell-cell contact zone, dilated cardiomyopathy (KEGG), intercalated disc, 
desmosome, cell leading edge, extracellular matrix, transcriptional repressor complex, 
regulation of phosphatidylinositol 3 kinase activity, side of membrane*, clathrin coated 
vesicle, ciliary membrane, vacuolar membrane, transporter complex* 
*also enriched in AF+dox vs. AF (p < 0.05) 
EV EV 
C Negative regulation of histone modification*, striated muscle cell differentiation*, Mll1 
2 complex 
*also enriched in EV+dox vs. EV (p < 0.05) 
EV AF 
D Transcription from RNA polymerase III promoter (also enriched in AF vs. AF+dox 
(p<0.05) AF EV 
Gene sets enriched in AF or EV (FDR < 0.25) that were also enriched in the same cell line with 
doxycycline are in rows A and B. Gene sets that in one cell line without doxycycline but in the other with 
doxycycline are in rows C and D. All gene sets are gene ontology terms except where noted. 
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DISCUSSION 
Summary of results 
The main results of the investigations in the chapter are the following: 
1. AFDN-DT was successfully overexpressed in differentiated epithelial cells. 
2. AFDN-DT overexpression did not affect TEER or paracellular permeability in T84 or 
Caco2 cells under the following conditions: 
a. Differentiated 
b. During differentiation 
c. Treated with pro-inflammatory cytokines that increase permeability 
RNA-seq revealed few genes differentially expressed with overexpression of AFDN-DT and 
pathway analyses supports that this differential expression is likely to be related to the 
increased transcriptional burden of AFDN-DT vs. an empty vector.  
Up-regulation of AFDN-DT is unlikely to affect epithelial barrier function 
There was no effect of AFDN-DT overexpression on TEER of differentiated T84 cells. This was 
confirmed in three experiments with a total of 34 wells (17 each with and with doxycycline, 
Figure 4), and was also true in Caco2 cells (Figure 10). Furthermore, AFDN-DT overexpression 
had no effect on TEER during differentiation (Figure 5) or on the increase in permeability 
following treatment with IFN-γ (Figure 6 and Figure 7) or IFN-γ + TNF-α for Caco2 cells (Figure 
11). While there was a significant effect at one time point in one experiment (Figure 6), the 
difference in TEER was small (5.4%) and there was no significant effect in pooled meta-analysis 
of multiple experiments (30 wells, 15 each with and without doxycycline, Figure 7). There was 
also no effect on paracellular permeability in T84 (Figure 8) and Caco2 cells (Figure 12), though 
doxycycline resulted in a small increase in flux in both cell lines for T84. If AFDN-DT affected 
epithelial permeability, differences are likely to have been seen in this experimental system as 
the expression of AFDN-DT was confirmed to be in colonic epithelial cells by in situ 
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hybridization (Chapter 3, Figure 13), overexpression in differentiated cells was confirmed by 
PCR (T84: Figure 2, Caco2: Figure 9), and T84 and Caco2 cells are both good models of 
epithelial barrier function.(3,9) This conclusion is supported by the RNA-seq results. A 
difference in TEER was seen between T84-TR-AFDN-DT and T84-TR-EV both with and without 
doxycycline, particularly in response to IFN-γ (Figure 6) where a greater decrease was seen in 
T84-TR-AFDN-DT. The top three differentially expressed genes (fold change, all with adjusted p 
value < 1 x 10-20) were membrane-associated: aquaporin 8 (AQP8, 6.6), lipocalin 15 (LCN15, 
2.7), and filamin A (FLNA, 0.49). AQP8 is a water channel expressed both intracellularly and on 
the apical surface of colonic epithelial cells.(27) It is increased in biopsies from IBS-D patients 
and could account for the observed permeability differences between the cell lines.(28) In 
addition, adhesion-related gene sets were enriched in T84-TR-EV vs. T84-TR-AFDN-DT (Table 
6). These differences in permeability and gene expression between the cell lines indicate that 
the experimental design was adequate to detect differences in permeability and associated 
gene expression. While it is possible that these underlying differences in T84-TR-AFDN-DT and 
T84-TR-EV could have changed the phenotype such that an effect of AFDN-DT on permeability 
was not seen, a functional effect of AFDN-DT (even if masked) is not supported by the RNA-seq 
results, which revealed little effect of AFDN-DT on gene expression.  
Differentially expressed pathways are likely to be non-specific effects of the 
overexpression model 
T84-TR-AFDN-DT and T84-TR-EV differ in cell adhesion and translational burden 
As discussed above, T84-TR-AFDN-DT and T84-TR-EV are different with regard to 
permeability, which is reflected in gene expression and gene set enrichment. This difference 
was also seen in the WGCNA analysis, in which the “Adherens junction,” and “Cell motility” 
(actin-binding proteins) modules were negatively correlated with T84-TR-AFDN-DT vs. T84-TR-
EV with and without doxycycline (Figure 15). The heatmap in Figure 15 also shows a group of 
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modules positively correlated with T84-TR-AFDN-DT vs. T84-TR-EV which include “Unfolded 
protein binding,” “Ribosome/Mitochondria 1,” “Ribonucleoprotein complex,” and “Translation 
initiation.”  
These findings suggest a difference in translational burden between the cell lines. Additional 
protein synthesis that is anticipated with this model includes expression of rTetR with associated 
G418 antibiotic resistance, and puromycin antibiotic resistance present on the vector with the 
Tet-Responsive Element. The same T84-TR cells were used to create T84-TR-AFDN-DT and 
T84-TR-EV, so similar expression of rTetR would be expected; however, all cell lines were 
polyclonal and it is possible that differential “drift” (29) in T84-TR-AFDN-DT vs. T84-TR-EV 
resulted in different levels of rTetR /G418-resistance translation. It is more likely that the 
puromycin resistance was transfected at different levels due to the variability in efficiency of 
lentiviral infection and insertion of viral DNA into the genome. The likelihood of variability in 
transfection of T84-TR cells with AFDN-DT/EV is further increased by the fact that we based our 
multiplicity of infection (MOI) calculations on an indirect lentiviral measure (p24 assay) rather 
than direct lentiviral titer. It has been observed that longer inserts decrease lentiviral titers,(29) 
which would predict increased efficiency and translational burden with T84-TR-EV, but this may 
not always be the case.  
Another source of variability is that the lentiviral genome is transcribed to dsDNA and inserted 
into the host genome randomly,(30) which can result in off-target effects and differences 
between cells lines. As mentioned, above, polyclonal populations were used, which mitigates 
these differences somewhat, but the population can become less diverse after repeated 
passages due to “drift”.(29) Gene set enrichment of “DNA directed RNA polymerase III complex” 
and gene sets related to nucleotide metabolism (Table 6) suggest an increase in RNA 
transcription even without doxycycline in T84-TR-AFDN-DT vs. T84-TR-EV. 
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Doxycycline increases transcriptional burden and cellular stress in T84-TR-AFDN-DT 
Differential gene expression in T84-TR-AFDN-DT cells with vs. without doxycycline may be 
related to the transcriptional burden associated with AFDN-DT (2,311 nucleotides), which can 
increase metabolic demand on the cell.(29) This is supported by positive correlation of 
doxycycline treatment in T84-TR-AFDN-DT with the WGCNA modules “Transcriptional 
regulation” (Figure 15) and negative correlation with “Transcriptional repression” (Figure 16).  
Review of the DEGs is also supportive. Five are directly related to gene expression: SCARNA22 
and SNORA12 are both small nucleolar RNAs (snoRNAs), which contribute to ribosomal 
biosynthesis; RPL36A encodes a component of the 60S subunit of cytosolic ribosomes (31); 
SFPQ is a DNA- binding protein involved in RNA splicing and transcriptional repression; and 
MT-TV is a transfer RNA for the amino acid valine.(32,33) The other five DEGs have some role 
in the response to DNA damage or cellular stress. NEDD8 is an ubiquitin-like protein. Ubiquitins 
and similar proteins are linked to other proteins to target them for degradation but also serve a 
variety of other cellular functions.(34) NEDD8 is involved in the response to DNA damage,(35) 
and has also been shown to modify the actin cytoskeleton.(36) DDIT4 is expressed in response 
to cellular stress and affects cellular growth and proliferation through negative regulation of the 
mTOR pathway.(37,38) IER3 is induced by cellular stress and can promote apoptosis.(39,40) 
ILRUN is a newly characterized antiviral protein that suppresses synthesis of interferon TNF-α 
in response to double-stranded RNA.(39-41) Of note, endoplasmic reticulum (ER) stress can 
induce autocrine pro-apoptotic TNF-α signaling,(42) which can result in increased reactive 
oxygen species and mitochondrial damage.(43)  
Increased cellular stress in T84-TR-AFDN-DT cells with doxycycline may also account for 
divergent effect of doxycycline on the enrichment of certain gene sets. These were gene sets 
enriched in either T84-TR-AFDN-DT or T84-TR-EV in untreated cells, but enriched in the 
opposite cell line in doxycycline-treated cells (Table 7, rows C and D). For example, while 
without doxycycline, “Transcription from RNA polymerase III promoter” was enriched in T84-TR-
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AFDN-DT, treatment with doxycycline may have led to compensatory down-regulation of this 
gene set resulting in enrichment in T84-TR-EV. 
Effects of doxycycline are evident in gene expression profiling data 
Several of the DEGs in T84-TR-AFDN-DT with vs. without doxycycline were transcripts of 
mitochondrial origin (mitochondrially encoded ATP synthase 8, mitochondrially encoded 
cytochrome c oxidase II, mitochondrially encoded NADH dehydrogenase 1 and 6, and 
mitochondrially encoded cytochrome b). These were also differentially expressed in T84-TR-EV 
with vs. without doxycycline (although at p < 0.05) or had the same trend of expression when 
plotted. Impairment of mitochondrial function and increased cellular stress is a well-documented 
effect of tetracyclines.(44-46) These changes are even seen for the doses commonly used in 
doxycycline-induced expression systems, such as 1 μg/ml, which was used in this 
experiment.(46) While some of the genes were up-regulated with doxycycline, which does not fit 
with the observed dysfunction of mitochondria, directionality of change for mitochondrial genes 
should be interpreted with caution when using polyA-based library generation, as polyA-
shortening is an important mechanism for transcript degradation in mitochondria.(47,48) 
Limitations 
Challenges of LncRNA expression models 
The most important limitation to the experimental design is that the exogenous expression of 
AFDN-DT may not replicate the function of the lncRNA in its genomic context. For some 
lncRNAs, the effect of their transcription is entirely based on their proximity to other genes. For 
example, transcription may change the chromatin structure exposing nearby genes for 
transcription, or lncRNAs may bind and thereby recruit enhancers or other gene regulatory 
proteins.(49) The fact that AFDN expression was unaffected by AFDN-DT overexpression (fold 
change 0.9) could be due to this out-of-context transcription. This is a considerable limitation to 
 153 
our design; however, there are limitations to most experimental methods of manipulating 
lncRNA gene expression, including CRISPR/Cas9 methods.(50) 
Selection of controls 
The empty vector control was both a strength and a limitation in this study. Since the differential 
transcriptional burden of the 2,311 nucleotide AFDN-DT vs. the vector with no insert was 
evident in gene expression profiling, a better control may have been a scrambled nucleotide 
sequence of the same length as AFDN-DT; however, it would be difficult to confidently conclude 
that there were no functional effects of the random sequence that occurred by chance. The 
choice of an inducible expression system was also a strength as the internal control was not 
associated with differences in cell populations arising from non-specific or off-target effects of 
lentiviral transfection. These differences between T84-TR-AFDN-DT and T84-TR-EV turned out 
to be quite significant and incidentally provide some evidence that up-regulation of AQP8 may 
increase epithelial permeability. This chance finding demonstrates the effectiveness of 
approaches that use random mutagenesis and phenotype screening to determine gene 
function. 
Conclusions 
In conclusion, exogenous expression of AFDN-DT did not affect permeability of colon epithelial 
cell monolayers. The possibly that AFDN-DT could affect other aspects of cellular physiology is 
unlikely in the absence of gene expression changes associated with AFDN-DT expression.  
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Chapter 5: 
 
Gene Expression Profiling of the Gut-Brain Axis in Healthy Deceased Donors 
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ABSTRACT 
While the preceding chapters of this dissertation have focused on changes in the colonic 
mucosa in irritable bowel syndrome (IBS), alterations in the gut-brain axis is another key 
concept in IBS pathophysiology. This chapter of my dissertation describes a proof-of-concept 
analysis in which I have used a systems biology approach in the analysis of gene expression 
profiling data from the gut and the brain. This approach can be used to explore changes in the 
gut-brain axis in animal models of IBS. It also identified significant correlations between gene 
modules (groups of highly correlated genes) in the gut and the brain. The genes in these 
modules could be important in the gut-brain axis. Interestingly, while we found most differential 
gene expression in IBS with constipation vs. healthy controls, genes that were in these gut-brain 
modules were more likely to be differentially expressed in IBS with diarrhea vs. healthy controls. 
A version of this chapter will be submitted for publication. 
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INTRODUCTION 
The "gut-brain axis" describes the bidirectional communication between the enteric, autonomic 
and central nervous systems (Figure 1). A unifying theory in the pathogenesis of irritable bowel 
syndrome (IBS) is that there is a dysregulation in the gut-brain axis that results in altered 
sensation and motility.(1) 
 
Figure 1: The gut-brain axis 
HPA, hypothalamic pituitary adrenal. Modified from Neuroscience & Biobehavioral Reviews, Vol 
36, Issue 1, Kennedy P, et. al.(2), Gut memories: Towards a cognitive neurobiology of irritable 
bowel syndrome, pages 310-340, Copyright 2012 with permission from Elsevier. 
Dysregulation of the gut-brain axis results in enhanced visceral perception (decreased pressure 
thresholds to pain and other sensations, and/or increased sensory ratings and viscerosomatic 
referral areas to barostat distension), which is a reproducible finding in a subset of patients with 
IBS.(3) Enhanced perception of visceral stimuli can occur in IBS patients either as a result of 
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greater sensitivity of visceral afferent pathways or as central amplification of visceral afferent 
input.(4) Gut-brain axis dysregulation may be due to dysfunction in any of the components 
involved in gut sensation, such as signal transmission from the gut, signal transmission to the 
central nervous system (CNS), and modulation/processing of sensation by the CNS.(5)  
One of the better understood mechanisms for alterations in the gut-brain axis relates to the 
effect of psychological stress on the gut. There is strong support for a link between chronic 
stress and IBS.(6-8) Studies in IBS patients have shown that experimental stress increases 
visceral sensitivity,(9,10) and preclinical studies support stress-induced changes at the mucosal 
level.(11,12) Additional triggers that can affect the gut-brain axis include infection (post-infection 
IBS),(13,14) diet and changes in the microbiome.(15) The cellular and molecular mechanisms 
involved in modulation of the gut-brain axis in health and disease, including IBS, are poorly 
understood. 
I hypothesized that a systems biology approach to the gut-brain axis would yield insight into the 
integrated biology of the two organs. Furthermore, diseases of the gut-brain axis, such as IBS, 
could be better understood by comparing the gut-brain axis at the molecular level between 
disease and control, an approach that would be feasible in animal models.  
The goal of the project described in this chapter was to perform this analysis using publicly 
available data as a proof of concept. While there are multiple publicly available gene expression 
profiling data-sets from the brain and the colon, these cannot be easily used for cross-tissue 
comparisons as observed differences are likely to result from experimental and batch effects. 
Brain and colon tissues should be collected using the same protocol and should not be 
processed or sequenced in separate batches. Ideally, the tissues should be from the same 
organisms (each organism contributes both brain and colon). One data-set that meets these 
requirements is the data from the genotype-tissue expression (GTEx) project.(16) Designed to 
study the relationship between genetic variation and gene expression across tissues, this 
project has resulted in a large and publicly available repository of RNA-sequencing (RNA-seq) 
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samples from healthy deceased donors. The advantage of this data is that it was designed for 
comparison across tissues. Samples were distributed by tissue and donor to prevent batch 
effects. 
Using data from the GTEx project, I performed several weighted gene co-expression network 
analyses (WGCNA) using donors with both sigmoid colon (SC) and cerebral cortex (CC) gene 
expression data. The analyses and the aims addressed by each analysis are outlined in Table 1 
and Figure 2. 
Table 1: Analyses and aims 
Analysis Description Aims 
Tissue-specific WGCNA of SC and CC To identify correlations between SC and CC modules 
Consensus Consensus network of SC/CC To identify modules present in both SC and CC 
Unified 
Single WGCNA 
using merged SC 
and CC data 
To identify modules containing both SC and CC genes 
and to explore relationships between SC-predominant 
and CC-predominant modules. 
SC, sigmoid colon; CC, cerebral cortex 
 
Figure 2: Outline of network analyses 
SC, sigmoid colon; CC, cerebral cortex 
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METHODS 
All analysis was performed in R version 3.4 for Mac.(17) 
Data acquisition 
GTEx data in the form of gene-level counts was obtained from the recount2 database.(18) 
Donors with data for both SC and CC were included. CC was used because it resulted in a good 
sample size and is readily available (in contrast to smaller brain regions). Retrieved counts were 
scaled with the recount package for R.(18-20) Data were filtered to include genes with counts of 
10 or more in at least 30% of samples. 
Weighted gene co-expression network analysis (WGCNA) 
WGCNA was performed using the WGCNA package in R.(21) First, according to the WGCNA 
developer’s recommendations, counts were prepared for linear modeling and quantile 
normalized. Preparation for linear modeling was performed with the variance stabilization 
function in the DESeq2 package.(22) Quantile normalization was performed using the linear 
models for microarray (limma) package.(23) Genes on the X and Y chromosomes were 
excluded. Sample clustering was performed with the WGCNA package and outliers were 
excluded. Parallel analyses were performed with data from lung and CC for comparison. 
WGCNA using a “signed” network was performed with a soft-thresholding power of 18 and a 
minimum module size of 80. Highly correlated (ρ > 0.85) modules were merged. For the unified 
analysis, the top 10,000 genes after sorting by variance were combined into one matrix  
(n = 20,000 genes). Prior to combination, probe names were appended with “c” or “b” so that 
the tissue of origin could be determined. A soft-thresholding power of 12 was used for the 
unified analysis.  
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Functional enrichment and visualization 
Overrepresented gene ontology (GO) terms were identified with the GOstats package.(24) 
Visualization was performed using Cytoscape version 3.5.(25) Edge weights were derived from 
the Topology Overlap Matrix used in the WGCNA. 
Statistical analysis 
Association between module eigengenes in the tissue-specific networks was determined with 
Pearson correlations. P values were adjusted using the Benjamini-Hochberg method and an 
adjusted-p value threshold of 0.05 was used to determine statistical significance. 
Comparison with colonic mucosal biopsy data from IBS and controls 
Genes in the CC-correlated SC modules (gut-brain-axis genes) were compared with differential 
gene expression results from our microarray study (Chapter 2 (26), Chapter 3) and the sigmoid 
colon biopsy microarray data from the Mayo Clinic, which was used for external comparison in 
Chapter 2.(26,27) Statistical significance was determined by adjustment of p values (Benjamini-
Hochberg) for the gut-brain-axis genes present in the microarray data. 
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RESULTS 
Donor characteristics 
There were 34 donors with data from SC and CC. After excluding outliers in either tissue, 29 
donors (17 men, 12 women) were included. Distribution of age range and death classifications 
are shown in Figure 3. Most donors were ages 50-69 with deaths classified as “Fast and 
natural,” which corresponds to a terminal phase of less than one hour, such as death due to 
myocardial infarction. RNA quality was good with a median RNA integrity number of 6.4. 
 
Figure 3: Donor characteristics 
Tissue-specific networks 
WGCNA uses unsupervised clustering to identify modules of highly correlated genes.(21) Each 
module can be represented by its first principal component which is referred to as the module 
eigengene. Genes that are highly correlated with the module eigengene are referred to as hub 
genes. Clustering of hub genes in the SC and CC networks are shown in Figure 4A and B. 
Different colors represent different modules and module names are derived from 
overrepresented GO terms. Hub genes cluster in modules but related modules also cluster, 
such as the immune related modules (“Response to cytokines”, “NF-kappaB signaling” and 
“Immune Response”) in the SC network (Figure 4A). There is more intermodular connectivity in 
the brain likely due to increased homogeneity of cell type. In  Figure 4C, the dots represent 
module eigengenes from the SC (green) and CC (pink) networks. The lines are correlations that 
are significant (p < 0.05) after adjusting for multiple comparisons. Yellow highlighting shows 
positive correlations between SC and CC module eigengenes.  
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Figure 4: Tissue-specific networks 
A and B show clustering of hub genes in sigmoid colon and cerebral cortex. Different modules 
are in different colors and annotations are overrepresented GO terms. Panel C shows 
significant (Benjamini-Hochberg adjusted p value <0.05) correlations between module 
eigengenes in the SC (green) and CC (pink) organ-specific networks. 
Prot., protein; Resp., response; sig., signaling; catab., catabolism; ext., external; stim., stimulus; 
Mitochond., mitochondrial; org., organization; med., mediated; transd., transduction 
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Consensus Networks 
There were fifteen SC-CC consensus modules (present in both tissues). Heatmaps showing 
correlations between modules (intermodular connectivity) are shown in Figure 5A. Similar to the 
tissue-specific analysis, there is increased intermodular connectivity in the CC with two main 
clusters of positively-correlated modules. While the connectivity in the SC is quite different than 
in the CC, there are modules with similar relationships in both tissues (highlighted by dashed 
outline). Figure 5B shows consensus modules for lung and CC (n = 19). Comparison of these 
analyses reveals that consensus modules are specific to tissue pairs. There are more 
consensus modules in the lung-CC analysis. The reason for this is unclear but perhaps relates 
to conserved microtubule-related biology in axons and ciliated cells.  
 
Figure 5: Consensus networks 
Intermodular connectivity of SC and CC (A) and lung and CC (B). 
SC, sigmoid colon; CC, cerebral cortex; dev. development; sig., signaling; reg., regulation; 
metab., metabolism; resp., response; org., organization 
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Unified network 
The SC-CC unified network (generated from merged SC and CC data) contained 16 modules of 
which 5 were comprised predominantly of genes expressed in SC (≥ 98%). Intermodular 
connectivity is shown in Figure 6A. There was a positive correlation between SC and CC 
modules with neuro-glial and inflammation-related themes. The lung-CC analysis (n = 19) did 
not reveal the same level of cross-tissue integration in related pathways (Figure 6B). The 
strongest cross-tissue correlations were between inflammation-related modules. Connectivity of 
hub genes in these modules in shown in Figure 7. CC expression of the interleukin 4 receptor 
(IL4R) in the CC inflammatory response module (yellow) was highly correlated with genes in the 
SC inflammatory response module (purple). 
 
Figure 6: Unified network 
SC/lung modules are in red. Module size and % SC or lung (size, %) refer to the number of 
genes with at least 0.6 correlation with module eigengene. Module names are overrepresented 
GO terms or KEGG pathways. SC, sigmoid colon; CC, cerebral cortex 
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Figure 7: Inflammation hub genes 
Networks of hub genes in inflammation-related modules in the unified SC-CC network (Figure 
6). Each node represents a single gene. Node colors correspond to modules. Functional 
annotation, identified by node border colors, was performed using the StringApp in 
Cytoscape.(28) Larger nodes have higher correlations with the module eigengene. The tissue 
origin of each node is identified by the colon or brain graphic. Purple edges highlight gut-brain 
(SC-CC) connectivity. SC-SC and CC-CC edges are blue and grey, respectively. Thicker edges 
have stronger weight. 
SC, sigmoid colon; CC, cerebral cortex 
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Differential expression of gut-brain-axis genes in IBS 
As dysregulation of the gut-brain axis is hypothesized to be central to IBS pathophysiology, 
differentially expressed genes in IBS present in CC-correlated SC modules would be potential 
targets for further study. I focused on the inflammation-related modules, as correlation of 
inflammation-related genes was consistent across analyses. Genes with module membership 
(correlation with module eigengene) > 0.6 in the SC inflammation-related modules (tissue-
specific analysis, Figure 4, “NF-kappaB signaling,” “Response to interferon gamma,” “Response 
to cytokine,” and “Pro-inflammatory”) were classified as immune gut-brain-axis (GBA) genes. 
Differential expression was determined for immune GBA genes that were present in our 
microarray study (Chapter 2 (26), Chapter 3) and/or the sigmoid colon biopsy microarray data 
from the Mayo Clinic, which was used for external comparison in Chapter 2.(26,27) P values 
were adjusted for the number of immune GBA genes. Only one immune GBA gene was 
differentially expressed in our microarray data. The zinc transporter, solute carrier family 39 
member 1 (SLC39A1) was up-regulated in IBS with diarrhea (IBS-D) vs. healthy controls (fold 
change = 2.9, adjusted p value = 0.024). In the Mayo clinic data, there were fifteen differentially 
expressed immune GBA genes. Fourteen were down-regulated in IBS-D vs. healthy controls 
(Table 2). One gene, heparan sulfate-glucosamine 3-sulfotransferase 2 (HS3ST2) was up-
regulated in IBS vs. healthy controls (fold change = 1.3, adjusted p value = 0.02). The IBS-D 
genes (Table 2) were all in three of the four modules (“Response to interferon gamma,” 
“Response to cytokine,” “Pro-inflammatory”). 
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Table 2: Immune gut-brain-axis genes differentially expressed in IBS-D (Mayo Clinic 
cohort) 
Symbol Name FC (p value) MM 
Response to cytokine 
ADGRE2 adhesion G protein-coupled receptor E2 0.72 (0.02) 0.61 
CDK2 cyclin dependent kinase 2 0.87 (0.03) 0.83 
HAT1 histone acetyltransferase 1 0.86 (0.04) 0.73 
RPL22L1 ribosomal protein L22 like 1 0.83 (<0.005) 0.71 
SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 0.7 (0.02) 0.84 
ZNF367 zinc finger protein 367 0.76 (0.02) 0.63 
Response to IFN-γ 
CARD16* caspase recruitment domain family member 16 0.77 (<0.005) 0.64 
CASP1 caspase 1 0.71 (<0.005) 0.80 
PSMB8-AS1 PSMB8 antisense RNA 1 (head to head) 0.78 (0.03) 0.83 
WARS tryptophanyl-tRNA synthetase 0.8 (0.03) 0.91 
Pro-inflammatory 
C1orf162 chromosome 1 open reading frame 162 0.79 (0.04) 0.80 
GGCT gamma-glutamylcyclotransferase 0.89 (0.02) 0.76 
RFC2* replication factor C subunit 2 0.81 (<0.005) 0.79 
RPN1 ribophorin I 0.91 (0.03) 0.64 
*indicates also differentially expressed in IBS vs. healthy controls. P values are adjusted.  
FC, fold change; MM, module membership 
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DISCUSSION 
Inflammation-related genes are correlated in the gut and brain 
My hypothesis was that a systems biology approach to gene expression profiling data from the 
gut and the brain could yield insight into the gut-brain axis. In order to test this hypothesis, I 
used three approaches for analysis of sigmoid colon (SC) and cerebral cortex (CC) gene 
expression profiling data to address the following aims (Table 1): 1) To identify correlations 
between SC and CC modules in tissue-specific networks; 2) To identify modules present in both 
SC and CC using a consensus network; and 3) To identify modules containing both SC and CC 
genes, and to explore relationships between SC-predominant and CC-predominant modules in 
a unified network of genes from both tissues. Both the tissue-specific (Aim 1) and unified (Aim 
3) analyses highlighted positive correlations between inflammation-related genes in SC and CC. 
Association between systemic (29) and colonic (30-32,33) inflammation and central nervous 
system (CNS) neuroinflammation has been well-documented in animal models (described 
further below). Thus, the identification of positive correlation in inflammation-related genes in the 
current analyses supports the validity of the analytic approach and confirms the hypothesis that 
a systems biology approach to gut-brain gene expression data can be used to study the gut-
brain axis. 
Central effects of peripheral inflammation 
There is strong evidence in animal models for the effect of systemic and peripheral inflammation 
on brain neuroinflammation. In one study, both intra-peritoneal injection of endotoxin as well as 
skin inflammation induced by Imiquimod resulted in increased transcription of interferon-
stimulated genes in the brain.(29) There have also been several studies on CNS effects of 
intestinal inflammation. Experimental colitis in rodent models resulted in microglial activation 
and increased cytokine production in the brain.(30-32,33) This was seen in both of the 
established chemically-induced experimental colitis models: trinitrobenzene sulfonic acid 
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(TNBS) (30,31) and dextran sodium sulfate (DSS).(32,33) The presence of intestinal 
inflammation following traumatic brain injury in animal models demonstrates the bidirectionality 
of this communication.(34)  
The effect of peripheral inflammation on the CNS is supported by data in humans. For example, 
progression of multiple sclerosis can be triggered by infection,(35) and interferon alpha 
treatment causes symptoms of depression,(36) which has been linked to microglial activation in 
animal models.(37) In addition, the phenomenon of “sickness behavior,” which describes the 
psychological correlates of systemic illness, including insomnia, impaired cognition, fatigue, 
anhedonia and anorexia, is mediated by circulating cytokines, predominantly tumor necrosis 
factor alpha (TNF-α) and interleukin 1 beta (IL-1β), and to a lesser extent interleukin 6 (IL-
6).(38) 
There are three main routes whereby peripheral immune events are communicated to the CNS: 
neural, humoral and cell-mediated.(39) The neural route is mediated by vagal afferents, which 
can respond to local cytokines (“vago-vagal inflammatory reflex”).(40) In the humoral route, 
circulating cytokines signal to the brain via receptors on cerebral endothelial cells or access the 
brain via regions without a blood brain barrier, such as the circumventricular organs and choroid 
plexus.(39,41) Cell-mediated communication is triggered by adhesion of circulating monocytes 
to cerebral endothelial cells, which leads to proinflammatory signaling as well as migration of 
monocytes to the brain.(39) Interestingly, natalizumab which targets monocyte adhesion by 
blocking alpha 4 integrin, reduced fatigue in multiple sclerosis (42) and improved health-related 
quality of life in Crohn’s Disease.(43) Gut microbes also contribute to the gut-brain axis in the 
setting of inflammation. Increased epithelial permeability facilitates gut-brain signaling via 
circulating microbial metabolites.(44) There is also evidence that the effect of microbes on the 
CNS is mediated by the vagus nerve.(45)  
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Interleukin 4 signaling 
CC expression of the interleukin 4 receptor (IL4R) was highly correlated with SC genes in the 
inflammatory response module. Interleukin-4 (IL-4) is a cytokine produced by Th2 subtype T 
helper cells, as well as by basophils and mast cells.(46) Th2 cells are a subset of CD4 
lymphocytes that mediate the humoral immune response directed against extracellular 
pathogens.(47) Th2 cells produce cytokines associated with allergic (IL-4, IL-5, IL-13) and anti-
inflammatory (IL-10) responses, and which counteract Th1 T helper cells (phagocytic 
response).(47) 
IL-4 plays an important role in mediating the allergic response by inducing B cells to produce 
IgE immunoglobulins (class-switching).(48) Secreted by Th2 cells, IL-4 propagates the Th2 
response by promoting differentiation of lymphocytes into Th2-like cells (48) and up-regulating 
IL4R, which encodes the alpha subunit of the IL-4 receptor (IL-4Rα).(49)  IL-4 also promotes 
recruitment of T cells and eosinophils through up-regulation of vascular cell adhesion molecule -
1,(48) and down-regulation of E-selectin, which is mediated by competitive binding of signal 
transducer and activator of transcription 6 (STAT6) to NF-κB sites in the E-selectin 
promoter.(50) In the intestine, IL-4 is central to allergic response and defense against 
helminths.(51) It has also been shown to impair epithelial barrier function.(52-54) 
IL-4/IL-13 signaling is important in inflammatory bowel disease 
IL-13 has been implicated in the barrier dysfunction associated with ulcerative colitis (UC). (55) 
Both IL-13R and IL-4R are expressed on colonic epithelial cells,(55) and have shared biology 
due to the use of a common receptor, the IL-13 receptor alpha 1 chain (IL-13Rα1), which 
heterodimerizes with IL-4Rα and forms a complex that can bind both IL-4 or IL-13.(56) IL-4 can 
also signal through heterodimerization IL-4Rα with a gamma chain, which is a component of the 
IL-2 receptor.(48) Downstream signaling is predominantly via STAT6, but also can involve PI3 
kinase.(48) Lamina propria mononuclear cells from UC patients vs. controls and patients with 
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Crohn’s Disease produce increased IL-13.(55) IL-13 producing cells in UC are positive for 
CD161, a marker of natural killer (NK) T cells.(57) In cell culture models, IL-13 decreased 
transepithelial resistance and increased paracellular permeability, an effect that involved 
apoptosis of epithelial cells and dysregulation of tight junctions characterized by increased 
mRNA and protein expression of claudin-2.(55) This effect was only minimally reduced by 
addition of an antibody neutralizing IL-4R, however the effect was not induced by IL-4.(55) 
Tralokinumab, a human monoclonal antibody targeting IL-13, did not provide improve clinical 
response rates over placebo in UC (though clinical remission and Mayo score were 
improved),(58) but improved atopic dermatitis symptoms in a Phase 2 trial,(59) and Phase 3 
trials are ongoing (NCT03131648, NCT03160885, NCT03363854). Likewise, anrukinzumab, a 
humanized IgG1 antibody targeting the binding of IL-13 to IL-4Rα, was not effective over 
placebo in UC.(60) While there is not an establish role for epithelial IL-4 signaling in Crohn’s 
disease, one study found IL-4 to be increased in the muscularis externa of Crohn’s disease 
samples, and showed that IL-4 and IL-13 increased intestinal smooth muscle cell contractility 
via STAT6.(61) 
IL-4 is immunoregulatory in CNS and may contribute to CNS effects of peripheral inflammation 
In the CNS, both microglial cells and astrocytes produce IL-4 and express IL-4Rα.(62) Microglial 
cells expressing IL-4Rα have an M2 (immune-regulatory) phenotype and were found to regulate 
autoimmune inflammation in an animal model of multiple sclerosis.(63) IL-4 signaling is 
neuroprotective in CNS injury and ischemia through IL-4Rα expressed on neurons,(64) and 
through neuronal production of IL-4.(65) Conversely, increased expression of IL-4Rα has also 
been associated with neurodegeneration due to increased oxidative stress.(62) 
There are several studies in animal models that suggest a role for IL-4 signaling in the CNS 
response to peripheral inflammation. Peripheral lipopolysaccharide increased microglial 
expression of IL-4Rα,(66) and depressive behavior in mice treated with interferon alpha was 
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associated with down-regulation of IL-4Rα.(67) In addition, while IL-4 knockout mice, have 
increased depressive behavior, it is not further modified by interferon alpha.(67) 
Additional genes in the SC inflammatory response are linked to IL-4 signaling 
Several of the genes in the SC inflammatory response module (bolded text below) are related to 
IL-4 signaling, which provides additional support for the presence of integrated gut-brain 
inflammatory signaling. Expression of B-cell CLL/lymphoma 6 (BCL6) is induced by IL-4 via 
STAT6.(68) BCL6, in turn, can repress transcription of IL-4/STAT6 induced genes.(69) Signal 
transducer and activator of transcription 3 (STAT3) also increases BCL6 expression and is 
involved in T cell repression of IL-4 expression by BCL6.(70) Strawberry notch homolog 2 
(SBNO2) is a transcriptional corepressor of NF-κB in macrophages, and its expression is 
induced by the Th2 cytokine IL-10 via STAT3.(71) Finally, Chitinase 3 like 1 (CHI3L1), which is 
increased in the circulation in asthma, is secreted by respiratory epithelial cells and 
macrophages in response to IL-13.(72)  
Comparison of WGCNA methods 
Both the tissue-specific and unified networks identified the correlation between inflammation-
related genes in SC and CC. In the unified network, the modules were almost entirely tissue-
specific (modules consisted of either SC or CC genes), so the results of these analyses were 
quite similar. The advantage of the unified network is that it calculated connectivity between SC 
and CC genes and allowed the visualization in Figure 7. The consensus network is important 
because it confirmed that consensus modules were present. This analysis would be particularly 
useful in the comparison of disease and control groups in gut-brain axis disorders as it would 
highlight the conserved biology in the gut and brain and allow for comparison of consensus 
networks in disease and controls.  
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Dysregulation of immune gut-brain-axis genes in IBS-D 
Differential expression of immune gut-brain-axis (GBA) genes was primarily seen in IBS-D vs. 
healthy controls. Overall, our IBS-D microarray samples were more similar to controls than in 
other cohorts, which explains why there was only one immune GBA gene differentially 
expressed in our data while there were fifteen in the Mayo Clinic data. The dysregulation of 
immune GBA genes in IBS-D, could lead one to hypothesize that gut-brain communication of 
immune-related phenomena is altered in IBS-D, which could potentially be linked to the 
increased intestinal permeability commonly seen in this subtype.(73) 
Interestingly, two dysregulated immune GBA genes (CASP1, CARD16) are related to protease 
activity which is a potential factor in visceral sensitivity.(74) Although not dysregulated in the 
microarray data, two other genes involved in this pathway, histamine receptor H1 and F2R like 
thrombin or trypsin receptor 3 (encodes protease activated receptor 4), were among the colon 
genes closely linked to brain IL4R in the unified network. 
Conclusions 
A systems biology approach to the analysis of gene expression profiling of the gut and brain is 
feasible. The ability to do this relies upon careful experimental design that avoids batch effects, 
such as is the case with data from the GTEx project, which was specifically designed to 
compare expression across tissues. In this proof of concept analysis in healthy deceased 
donors, the known connection between peripheral and CNS inflammatory signaling was 
illustrated. Comparison with gene expression profiling data in IBS, revealed dysregulation of 
gut-brain axis immune-related genes, specifically in IBS-D. Furthermore, IL-4 signaling was 
identified as potential target for further investigation of the mechanisms of gut-brain immune-
related communication. Interestingly, there is already some experimental support for IL-4 
signaling as a mediator of the CNS response to peripheral inflammation.(37,66,67)  
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Chapter 6: 
 
Summary and Future Directions 
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Summary 
The overall goal of my doctoral research was to investigate molecular changes in colon biopsies 
of IBS patients in comparison to healthy controls using a translational approach. This was 
accomplished through analysis of gene expression profiling data by microarray, selection of a 
target gene differentially expressed in IBS and further study of that gene in cellular models. 
I began analysis of the microarray data by determining differentially expressed genes and 
pathways among the protein-coding genes on the array. This analysis (Chapter 2) yielded the 
most significant findings of my doctoral research, which were published in The American 
Journal of Physiology-Gastrointestinal and Liver Physiology.(1) We found that most differences 
were in IBS with constipation (IBS-C) vs. healthy controls and that these changes were 
supportive of alterations in neuronal signaling. 
Following the analysis of the mRNAs, I used both data-driven and hypothesis-based 
approaches to select a lncRNA for further study in cellular models (Chapter 3). The decision to 
study a lncRNA was based on the presence of epigenetic changes in IBS and our group's 
experience in studying non-coding RNA. Initial analysis identified ghrelin opposite strand 
(GHRLOS) as a promising target; however, it was not expressed in epithelial cells, and would 
therefore not serve to provide me with experience in epithelial cell culture models. Another 
lncRNA, afadin divergent transcript (AFDN-DT) was up-regulated in IBS and expressed in 
colonic epithelial cells and was therefore selected for further study.  
Due to the proximity of AFDN-DT to afadin, which encodes an adherens junction protein, and 
was also up-regulated in IBS, we hypothesized that AFDN-DT might regulate cell junctions and 
affect epithelial permeability, which is consistently altered in IBS. Chapter 4 describes the study 
of AFDN-DT in colonic epithelial cells. I developed cell lines capable of inducible overexpression 
of AFDN-DT, and I tested the effect of AFDN-DT overexpression on transepithelial electrical 
resistance and transcellular permeability. I also used RNA sequencing to determine the 
downstream effectors of AFDN-DT. 
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Despite successful overexpression of AFDN-DT in differentiated epithelial cells, there was no 
effect on permeability or gene expression. This may have been due to a principal challenge 
inherent in genetic manipulation of lncRNAs, which is that the genomic context of transcription is 
not fully replicated in the model system. It is also possible, that AFDN-DT is a transcriptional by-
product without an independent function or that the effects are only evident in a tissue setting 
where different cell types are present. 
Even though we were not able to identify a functional role for AFDN-DT in epithelial cells, my 
primary educational objective to complete a translational project were met. Specifically, I 
identified a molecular target in clinical samples and studied it in cell culture models. The fact 
that AFDN-DT did not have the anticipated effect actually increased the educational value of this 
project as it unmasked changes in cellular physiology due to off-target effects of common cell 
culture methodologies, such as lentiviral transfection and antibiotic treatment. It also highlighted 
the challenges in using transgenic approaches to model dysregulation of lncRNAs. One of the 
most valuable aspects of this project was the opportunity to become proficient in the analysis of 
high-throughput gene expression profiling data. 
Following my doctoral studies, I intend to continue to study disorders of the gut-brain axis. In 
particular, I am interested in studying the gut-brain axis at the molecular level. In Chapter 5, I 
analyzed publicly-available RNA-sequencing data from brain and colon tissue of healthy 
deceased donors, which highlighted the correlation of inflammation-related genes in the gut and 
the brain. These findings will support future independent research into the role of colonic 
inflammation in Parkinson’s Disease.  
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Chapter 2 
Microarray Differential Expression 
Data set-up 
Expression data 
Download: https://www.ebi.ac.uk/arrayexpress/files/E-MTAB-5811/E-MTAB-5811.processed.3.zip 
Expression data is pre-processed by Agilent feature extraction.  
dat01<-read.delim("Normalized_unfiltered_mRNAonly.txt",row.names = 1) 
Sample data 
Download: https://www.ebi.ac.uk/arrayexpress/files/E-MTAB-5811/E-MTAB-5811.sdrf.txt 
pheno<-read.delim("E-MTAB-5811.sdrf.txt",row.names = 1) 
reorder/reformat 
pheno<-pheno[names(dat01),] 
pheno$Sex<-ifelse(pheno$Characteristics.sex.=="male","M","F") 
pheno$IBS<-ifelse(pheno$Characteristics.disease.=="irritable bowel syndrome","IBS","HC") 
pheno$Group[pheno$Characteristics.clinical.history.=="healthy control"]<-"HC" 
pheno$Group[pheno$Characteristics.clinical.history.=="constipation"]<-"C" 
pheno$Group[pheno$Characteristics.clinical.history.=="diarrhea"]<-"D" 
pheno<-pheno[,c("IBS","Group","Sex")] 
Array Data 
Download: https://www.ebi.ac.uk/arrayexpress/files/A-MTAB-619/A-MTAB-619.adf.txt 
remove lines above column names 
datArray<-read.delim("A-MTAB-619.adf.txt",row.names = 1) 
names(datArray)<-c("Seq","EntrezID") 
match expression data, add symbol and gene name 
datArray<-datArray[rownames(dat01),] 
 
library(annotate) 
library(org.Hs.eg.db) 
 
datArray$Symbol<-NA;datArray$Name<-NA 
datArray2<-datArray[!is.na(datArray$EntrezID),] 
datArray2$Symbol <- getSYMBOL(as.character(datArray2$EntrezID),"org.Hs.eg.db") 
datArray2$Name <- as.character(lookUp(as.character(datArray2$EntrezID),  
                                      "org.Hs.eg.db", "GENENAME")) 
 
datArray3<-rbind(datArray[!rownames(datArray)%in%rownames(datArray2),],datArray2) 
 
# match expression data 
datArray3<-datArray3[rownames(dat01),c("Symbol","Name","EntrezID")] 
compile expression set 
library(Biobase) 
phenoData<-new("AnnotatedDataFrame", data=pheno) 
UCmRNAeset<- new("ExpressionSet", exprs=as.matrix(dat01), phenoData=phenoData) 
fData(UCmRNAeset)<-datArray3 
Differential expression 
library(limma) 
convenience function to edit topTable (limma output) 
# adds means, direction, FC, variable that is direction + Entrez ID 
top.revision<-function(toptable,eset,Group1,Group2){ 
    dat1<-toptable 
    dat1$Direction[dat1$logFC>0]<-"Up"; dat1$Direction[dat1$logFC<0]<-"Down" 
    dat1$FC <- 2^(dat1$logFC); dat1$DirID<-paste(dat1$Direction,dat1$EntrezID) 
    eset1<-eset[rownames(dat1),eset$Group%in%Group1] 
    eset2<-eset[rownames(dat1),eset$Group%in%Group2] 
    dat1$mean1 <- rowMeans(exprs(eset1));dat1$mean2 <- rowMeans(exprs(eset2)) 
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    return(dat1) 
} 
Run limma 
f<-as.factor(UCmRNAeset$Group) 
design <- model.matrix(~ 0 + f) #factorial design  
colnames(design)<-levels(f) 
contrasts <- makeContrasts((D+C)/2-HC, D-HC, C-HC, levels=design) 
fitUC<-lmFit(UCmRNAeset,design) 
fitUC <- contrasts.fit(fitUC, contrasts)  
fitUC <- eBayes(fitUC) #empirical Bayes moderated t-statistics test 
coefficients<-colnames(fitUC$coefficients) 
IBS vs HC 
Group1<-c("D","C");Group2<-c("HC") 
Cont<-coefficients[1] 
UC.IBSvHCall <- topTable(fitUC, coef=Cont, adjust.method="BH", number=Inf) 
UC.IBSvHCall<-top.revision(UC.IBSvHCall,UCmRNAeset,Group1,Group2) 
#filter by raw mean > 200 in either group 
filter<-UC.IBSvHCall$mean1>=log2(200)|UC.IBSvHCall$mean2>=log2(200) 
UC.IBSvHC.200<-UC.IBSvHCall[filter,] 
repeated for IBS-D vs HC, IBS-C vs HC 
Where there are redundant matches, retain by probe with highest variance 
ReAnnotate was used to align probes to exome ranges Process output from reAnnotate 
options(stringsAsFactors = F) 
reAnnoAgil<-read.delim("probesAgil_exome_readAnnotation.txt",stringsAsFactors = FALSE) 
hits.agil<-strsplit(reAnnoAgil$HIT,"\\;") 
names(hits.agil)<-reAnnoAgil$X.PROBE_ID 
for (Probe in names(hits.agil)) {hits.agil[[Probe]]$AgilProbe<-Probe} 
hit.agilTable<-do.call(rbind,hits.agil) 
review of alignments revealed that most probes were specific to one or more transcript 
hit.conflicts<-read.csv("hitAgilTableConflicts.csv",row.names = 1) 
 
ConflictProbes<-as.character(na.omit( 
    hit.conflicts$AgilProbe[hit.conflicts$NonSpecific==1])) #43 
 
AgilMatched<-data.frame(row.names = hit.conflicts$AgilProbe, 
                        RefSeq_ReAnno=hit.conflicts$RefSeq2, 
                        Symb_ReAnno=hit.conflicts$Symb2) 
for (Probe in names(hits.agil[!names(hits.agil)%in%rownames(AgilMatched)])) { 
    df.probe<-hits.agil[[Probe]] 
    AgilMatched[Probe,"RefSeq_ReAnno"]<-paste(unique(df.probe$RefSeq),collapse = "/") 
    AgilMatched[Probe,"Symb_ReAnno"]<-paste(unique(df.probe$Symb),collapse = "/") 
} 
Retain by highest variance among nonspecific probes 
library(WGCNA) 
options(stringsAsFactors = FALSE) 
 
# subset expression data 
datExpr<-exprs(UCmRNAeset)[rownames(exprs(UCmRNAeset))%in%ConflictProbes,] 
 
# collapse rows by max variance---- 
ProbeKey<-read.csv("Nonspecific.csv") 
datExpr2<-collapseRows(datExpr,rowGroup = ProbeKey$Symb, 
                       rowID = ProbeKey$AgilProbe, method ="maxRowVariance") 
ExcludeProbes<-names(datExpr2$selectedRow[datExpr2$selectedRow==F]) 
# load("UC_CvHCtoptables.rda") 
UCfilt<-UC.CvHCall$adj.P.Val<=0.05 &  
        (UC.CvHCall$mean1>=log2(200)|UC.CvHCall$mean2>=log2(200)) 
UC<-UC.CvHCall[UCfilt,] #1270 
UC.maxVar<-UC[!rownames(UC)%in%ExcludeProbes,] #1248 
 
for (Probe in rownames(UC.maxVar)) { 
    if(Probe%in%rownames(AgilMatched)){ 
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        UC.maxVar[Probe,"RefSeq_ReAnno"]<-AgilMatched[Probe,"RefSeq_ReAnno"] 
        UC.maxVar[Probe,"Symb_ReAnno"]<-AgilMatched[Probe,"Symb_ReAnno"] 
        } 
} 
 
# 2 of top 100 only mapped to non-coding sequences 
UC.filteredVar_noNC<-UC.filteredVar[ 
        !UC.filteredVar$RefSeq_ReAnno%in%c("NR_046338","NR_147125"),] 
Heatmap 
library(gplots) 
load("Top100Desc.rda") #contains gene descriptions for row labels 
 
esetTop100<-UCmRNAeset[rownames(Top100Desc),] 
dim(esetTop100) #100 x 30 
 
# re-order subjects by clustering within group 
ReorderSubjects<-function(eset){ 
    hc<-eset$Group=="HC"; d<-eset$Group=="D";c<-eset$Group=="C" 
    eset.hc<-eset[,hc]; eset.d<-eset[,d]; eset.c<-eset[,c]  
    getInd<-function(eset.group){ 
        data1<-t(exprs(eset.group)) 
        dend<-as.dendrogram(hclust(dist(data1))) 
        dend <- reorder(dend, rowMeans(data1)) 
        Ind<-rev(order.dendrogram(dend)) 
        return(Ind) 
    } 
    subs.c<-rownames(pData(eset.c[,getInd(eset.c)])) 
    subs.d<-rownames(pData(eset.d[,getInd(eset.d)])) 
    subs.hc<-rownames(pData(eset.hc[,getInd(eset.hc)])) 
    subs<-c(subs.c,subs.d,subs.hc) 
    eset2<-eset[,subs] 
} 
 
UC.grouped<-ReorderSubjects(esetTop100) 
colors<-pData(UC.grouped) 
colors$color[colors$Group=="HC"]<-"black" 
colors$color[colors$Group=="C"]<-"red" 
colors$color[colors$Group=="D"]<-"green" 
patientcolorsUC_grouped<-as.character(colors$color) 
 
exprs.dat<-exprs(UC.grouped) 
 
pdf("Top100.pdf", width = 3.5, height = 7.7) 
heatmap.2(exprs.dat, scale = "row", Colv = NA, dendrogram = "none", 
          ColSideColors=patientcolorsUC_grouped,  
          trace="none", col = topo.colors(50), 
          lmat=rbind(c(0,4),c(0,1),c(3,2),c(0,5)),  
          lwid = c(0.01,.5), lhei = c(0.01,.03, 2,.08), 
          labRow = paste(Top100Desc$Symbol,Top100Desc$Description,sep = ", ") , 
          labCol = FALSE, cexRow =  .7 ,  
          margins = c(0,17), key.title = NA, density.info = "none", 
          offsetRow = 0, keysize = 0.25, key.par = list(mar=c(3.2,0,0.5,37.5),cex=0.3), 
          key.xtickfun = function() { 
              breaks = pretty(parent.frame()$breaks) 
              breaks = seq(breaks[1],breaks[length(breaks)],2) 
              list(at = parent.frame()$scale01(breaks), 
                   labels = breaks) 
          } 
) 
dev.off() 
Sensitivity analysis for sex 
xy<-fData(UCmRNAeset) 
xy<-xy[!is.na(xy$EntrezID),] 
xy$chr<-as.character(lookUp(as.character(xy$EntrezID), "org.Hs.eg.db", "CHR")) 
xy<-xy[xy$chr%in%c("X","Y"),] 
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noxy<-setdiff(rownames(exprs(UCmRNAeset)),rownames(xy)) 
eset21<-UCmRNAeset[noxy,] 
Repeat fit exlcuding x and y 
f<-as.factor(eset21$Group) 
design <- model.matrix(~ 0 + f)  
colnames(design)<-levels(f) 
contrasts <- makeContrasts((D+C)/2-HC, D-HC, C-HC, levels=design) 
fitUC2<-lmFit(eset21,design) 
fitUC2 <- contrasts.fit(fitUC2, contrasts) 
fitUC2 <- eBayes(fitUC2) 
coefficients<-colnames(fitUC2$coefficients) 
Group1<-c("C");Group2<-c("HC") 
Cont<-coefficients[3] 
UC.CvHCall2 <- topTable(fitUC2, coef=Cont, adjust.method="BH", number=Inf) 
UC.CvHCall2<-top.revision(UC.CvHCall2,eset21,Group1,Group2) 
#filter by raw mean > 200 in either group 
filter<-UC.CvHCall2$mean1>=log2(200)|UC.CvHCall2$mean2>=log2(200) 
UC.CvHC.200.2<-UC.CvHCall2[filter,] 
UC.CvHC.filtered2<-UC.CvHC.200.2[UC.CvHC.200.2$adj.P.Val<=0.05,] #1146 rows 
Collapse by max variance 
datExpr<-exprs(UCmRNAeset)[rownames(exprs(UCmRNAeset))%in%ConflictProbes,] 
# collapse rows by max variance---- 
ProbeKey<-read.csv("Nonspecific.csv") 
datExpr2<-collapseRows(datExpr,rowGroup = ProbeKey$Symb,  
                       rowID = ProbeKey$AgilProbe, method ="maxRowVariance") 
ExcludeProbes<-names(datExpr2$selectedRow[datExpr2$selectedRow==F]) 
UC.maxVar2<-UC.CvHC.filtered2[!rownames(UC.CvHC.filtered2)%in%ExcludeProbes,] #1204 
Make expression set just of these 1204 DETs and control for sex within these DEGs 
esetsig<-eset21[rownames(UC.maxVar2),] 
BH<-factor(esetsig$Group,levels = c("HC","C","D")) 
Sex<-factor(esetsig$Sex,levels = c("M","F")) 
design <- model.matrix(~Sex*BH) # Sex+BH+Sex*BH 
colnames(design)[2:4]<-c("SexF","C","D") 
fit_BH.sex<-lmFit(esetsig,design) 
fit_BH.sex <- eBayes(fit_BH.sex) 
5 with significant sex effect 
SigSex <- topTable(fit_BH.sex, coef="SexF", adjust.method="BH",p.value = 0.05) # 5 rows  
2 with signifcant interaction effect (these overlap with the 5 with significant sex effect) 
SigInt <- topTable(fit_BH.sex, coef="SexF:BHC", adjust.method="BH",p.value = 0.05) # 2 
For two with significant Sex and interaction efffects, C Vs HC effect remains significant controlling for Sex interaction 
SigC<-topTable(fit_BH.sex, coef="C", adjust.method="BH",number = Inf) 
SigC[rownames(SigInt),] 
Exclude interaction effect for remainder (was not sigficicant in other 3) 
design <- model.matrix(~Sex+BH) 
colnames(design)[2:4]<-c("SexF","C","D") 
fit_BH.sex<-lmFit(esetsig,design) 
fit_BH.sex <- eBayes(fit_BH.sex) 
For all 5 with significant sex effect, effect of CvHC remains sigificant after controlling for sex 
SigC2 <- topTable(fit_BH.sex, coef="C", adjust.method="BH",number = Inf) 
SigC2[rownames(SigSex),] 
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WGCNA 
Download processed data: https://www.ebi.ac.uk/arrayexpress/files/E-MTAB-5811/E-MTAB-5811.processed.2.zip 
Set-up 
dat01<-read.delim("Normalized_SignalFiltered_noXY.txt",row.names = 1) 
mean.filter<-rowMeans(dat01)>=log2(200) 
dat01<-dat01[mean.filter,] 
datExpr<-as.data.frame(t(dat01)) 
Create modules 
Choose soft thresholding power 
see: https://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA 
library(WGCNA) 
options(stringsAsFactors = FALSE) 
allowWGCNAThreads() #if computer allows multi-threading 
adjacency = adjacency(datExpr, power = 14) 
TOM = TOMsimilarity(adjacency) #takes very long (30-60 min depending on RAM) 
dissTOM = 1-TOM 
geneTree = hclust(as.dist(dissTOM), method = "average"); 
rm(adjacency) 
Plot clustering tree (dendrogram) 
plot(geneTree, xlab="", sub="",  
 main = "Gene clustering on TOM-based dissimilarity", labels = FALSE, hang = 0.04) 
Identify modules using dynamic tree cut: 
minModuleSize = 30; 
dynamicMods = cutreeDynamic(dendro = geneTree,  
                            distM = dissTOM, deepSplit = 2,  
                            pamRespectsDendro = FALSE,  
                            minClusterSize = minModuleSize) 
Convert numeric labels to colors 
dynamicColors = labels2colors(dynamicMods) 
Plot the dendrogram and colors 
plotDendroAndColors(geneTree, dynamicColors, 
                    "Dynamic Tree Cut", dendroLabels = FALSE, hang = 0.03, 
                    addGuide = TRUE, guideHang = 0.05, 
                    main = "Gene dendrogram and module colors") 
Merging similar modules 
MEList = moduleEigengenes(datExpr, colors = dynamicColors) 
MEs = MEList$eigengenes 
Calculate dissimilarity of module eigengenes 
MEDiss = 1-cor(MEs) 
Cluster module eigengenes 
METree = hclust(as.dist(MEDiss), method = "average"); 
Plot the result 
plot(METree, main = "Clustering of module eigengenes", xlab = "", sub = "") 
height cut of 0.25, corresponding to correlation of 0.75: 
MEDissThres = 0.25 
plot(METree, main = "Clustering of module eigengenes",xlab = "", sub = "")+ 
abline(h=MEDissThres, col = "red") 
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Merge correlated modules 
merge = mergeCloseModules(datExpr, dynamicColors, cutHeight = MEDissThres, verbose = 3) 
mergedColors = merge$colors; mergedMEs = merge$newMEs 
 
plotDendroAndColors(geneTree, cbind(dynamicColors, mergedColors), 
                    c("Dynamic Tree Cut", "Merged dynamic"), dendroLabels = FALSE, 
                    hang = 0.03, addGuide = TRUE, guideHang = 0.05) 
Rename to moduleColors 
moduleColors = mergedColors 
Create numerical labels for colors 
colorOrder = c("grey", standardColors(50)); 
moduleLabels = match(moduleColors, colorOrder)-1; 
MEs = mergedMEs 
Relate modules to clinical traits 
load("UCmRNAeset.rda") 
datTraits<-pData(UCmRNAeset) 
datTraits$IBS<-ifelse(datTraits$IBS=="IBS",1,0) 
datTraits$Sex<-ifelse(datTraits$Sex=="F",1,0) 
datTraits$C[datTraits$Group=="HC"]<-0; datTraits$C[datTraits$Group=="C"]<-1 
datTraits$D[datTraits$Group=="HC"]<-0; datTraits$D[datTraits$Group=="D"]<-1 
datTraits<-datTraits[,c("IBS","C","D","Sex")] 
nGenes = ncol(datExpr); nSamples = nrow(datExpr) 
MEs0 = moduleEigengenes(datExpr, moduleColors)$eigengenes 
MEs = orderMEs(MEs0) 
moduleTraitCor = cor(MEs, datTraits, use = "p") 
moduleTraitPvalue = corPvalueStudent(moduleTraitCor, nSamples) 
textMatrix =  paste(signif(moduleTraitCor, 2),  
 "\n(", signif(moduleTraitPvalue, 1), ")", sep = "") 
dim(textMatrix) = dim(moduleTraitCor) 
 
pdf(file = "wgcnaplot.pdf", height = 16) 
par(mar = c(6, 8.5, 3, 3)); 
labeledHeatmap(Matrix = moduleTraitCor, textMatrix = textMatrix, 
               xLabels = names(datTraits), yLabels = names(MEs), 
               ySymbols = names(MEs), colorLabels = FALSE, 
               colors = blueWhiteRed(50), setStdMargins = FALSE, 
               cex.text = 0.5, zlim = c(-1,1),  
               main = paste("Module-trait relationships")) 
dev.off() 
Comparison with external data 
Data Acquisition: Mayo 
ten samples are in triplicate with one done 3 months later. Per reference, these were well correlated (no change in 
expression over 3 months). I will use all available, because there is no annotation as to which were the ones done 
later 
library(ArrayExpress) 
library(affy) 
library(hgu133plus2.db) 
Mayo <- ArrayExpress("E-TABM-176") 
Sample data 
phMayo <- pData(Mayo)  
 
# remove extra columns 
phMayo <- phMayo[,c(3,5:6)]  
 
# rename (IBS is IBS/HC, Group is C/D/HC) 
colnames(phMayo)<-c("ID","IBS", "Group")  
 
# rename 
phMayo$IBS[phMayo$IBS=="irritable bowel syndrome"] <- "IBS" 
 195 
phMayo$IBS[phMayo$IBS=="normal"] <- "HC" 
phMayo$Group[phMayo$Group=="diarrhea-predominant"] <- "D" 
phMayo$Group[phMayo$Group=="constipation-predominant"] <- "C" 
phMayo$Group[phMayo$Group=="not applicable"] <- "HC" 
Mayo@phenoData@data <- phMayo  # add back new pheno table 
 
# shorten row and column names 
rownames(pData(Mayo))<- gsub(".Hybridization","", 
 gsub("jaerssen.prdbe.jnj.com.Tab2MAGE.","", 
 rownames(pData(Mayo)))) 
 
colnames(exprs(Mayo))<- gsub(".Hybridization","", 
 gsub("jaerssen.prdbe.jnj.com.Tab2MAGE.","", 
 colnames(exprs(Mayo)))) 
Data are not preprocessed 
dim(Mayo) 
# Features  Samples  
#  1354896      131  
Process, normalize, log transform with RMA 
MayoNorm <- rma(Mayo) 
dim(MayoNorm) 
# Features  Samples  
#    54675      131 
genes<-data.frame(row.names = rownames(exprs(MayoNorm))) 
library(annotate) 
genes$Symbol <- getSYMBOL(as.character(rownames(genes)),"hgu133plus2.db") 
genes$Name <- as.character(lookUp(as.character(rownames(genes)), 
                                  "hgu133plus2.db", "GENENAME")) 
genes$EntrezID <- as.character(lookUp(as.character(rownames(genes)),  
 "hgu133plus2.db", "ENTREZID")) 
fData(MayoNorm)<-genes 
Data Acquisition: Nottingham 
Nott <- ArrayExpress("E-GEOD-36701") 
phNott <- Nott@phenoData@data  
phNott <- phNott[,33:36] 
colnames(phNott) <- c("Batch", "Group", "Sex", "ID") 
phNott$Group[phNott$Group=="HV"]<-"HC" 
phNott$Group[phNott$Group=="IBS-D"]<-"D" 
phNott$Group[phNott$Group=="IBS-C"]<-"C" 
phNott$Group[phNott$Group=="PIBD"]<-"PIBSCamp" 
 
# The data are not pre-processed 
dim(Nott) 
#Features  Samples  
#1354896      221  
Process, normalize, log transform with RMA 
NottNorm <- rma(Nott) 
dim(NottNorm) 
#Features  Samples  
#54675      221  
The experiment is described as two batches. Compare mean expression from the batches to see if experimental 
groups across batches can be compared. (Code not included but I also did without combining batches and not much 
different) 
dataAll<-exprs(NottNorm) 
rowmeans <- rowMeans(t(dataAll)) 
ph1 <- cbind(phNott,rowmeans) 
library(ggplot2) 
ggplot(ph1,aes(Batch,rowmeans))+geom_bar(stat = "summary", fun.y = "mean") 
# Means are similar 
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Make expression set 
# there is a punctuation mark difference in the sample names between expression data 
# and pheno data (they are the same but this makes them identical) 
colnames(dataAll)<-rownames(phNott) 
genes<-data.frame(row.names = rownames(dataAll)) 
genes$Symbol <- getSYMBOL(as.character(rownames(genes)),"hgu133plus2.db") 
genes$Name <- as.character(lookUp(as.character(rownames(genes)), 
                                  "hgu133plus2.db", "GENENAME")) 
genes$EntrezID <- as.character(lookUp(as.character(rownames(genes)), 
                                      "hgu133plus2.db", "ENTREZID")) 
pData(NottNorm)<-phNott; fData(NottNorm)<-genes 
Differential expression: Mayo 
this uses the duplicateCorrelation function to average replicates. I also used means with similar results. note that 
duplicateCorrelation can take ~30 min 
f <- as.factor(MayoNorm$Group) 
design <- model.matrix(~ 0 + f)  
colnames(design)=levels(f) 
subID<-MayoNorm$ID 
cor <- duplicateCorrelation(MayoNorm, design, block = subID) 
fitMayo <- lmFit(MayoNorm, design, block = subID, correlation = cor$consensus.correlation) 
contrasts <- makeContrasts((D+C)/2-HC, D-HC, C-HC, levels=design) 
fitMayo <- contrasts.fit(fitMayo, contrasts) 
fitMayo <- eBayes(fitMayo) 
coefficients<-colnames(fitMayo$coefficients) 
 
Group1<-c("C");Group2<-c("HC");Cont<-coefficients[3] 
MayoCvHCdupCorAll<- topTable(fitMayo, coef=Cont, adjust.method="BH", number=Inf) 
MayoCvHCdupCorAll<-top.revision(MayoCvHCdupCorAll,MayoNorm,Group1,Group2) 
Differential Expression: Nottingham 
this averages healthy controls over two batches. also did using only batch 1 which compared IBS-C, IBS-D and HC 
and similar results 
f <- as.factor(NottNorm$Group) 
design <- model.matrix(~ 0 + f)  
colnames(design)=levels(f) 
subID<-NottNorm$ID 
cor <- duplicateCorrelation(NottNorm, design, block = subID) 
fitNott <- lmFit(NottNorm, design, block = subID, 
                 correlation = cor$consensus.correlation) 
contrasts <- makeContrasts((D+C+PIBS+PIBSCamp)/4-HC, (D+C)/2-HC,D-HC,C-HC,levels=design) 
fitNott <- contrasts.fit(fitNott, contrasts) 
fitNott <- eBayes(fitNott) 
coefficients<-colnames(fitNott$coefficients) 
 
Group1<-"C";Group2<-"HC";Cont<-coefficients[4] 
NottCvHCdupCorAll <- topTable(fitNott, coef=Cont, adjust.method="BH", number=Inf) 
NottCvHCdupCorAll<-top.revision(NottCvHCdupCorAll,NottNorm,Group1,Group2) 
Find common genes 
ReAnnotate was used to align UC probes to exome ranges. Affymetrix annotation (2016) downloaded from 
Thermofisher 
options(stringsAsFactors = F) 
 
affy<-read.csv("HG-U133_Plus_2.na36.annot copy.csv") 
affy<-affy[!affy$RefSeq.Transcript.ID=="---",] 
hits.affy0<-strsplit(affy$RefSeq.Transcript.ID," /// ") 
names(hits.affy0)<-affy$Probe.Set.ID 
hits.affy<-list() 
for (Probe in names(hits.affy0)){ 
    x<-hits.affy0[[Probe]] 
    Remove<-c(x[grep("XM",x)],x[grep("XR",x)],x[grep("NR",x)]) 
    x<-x[!x%in%Remove] 
    if(length(x)>0){hits.affy[[Probe]]<-x} 
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} 
 
affyUniqueTx<-data.frame(AffyProbe=character(0),RefSeq=character(0)) 
affyMultiTx<-list() 
 
for (Probe in names(hits.affy)) { 
    x<-hits.affy[[Probe]] 
    if(length(x)==1){ 
        affyUniqueTx<-rbind(affyUniqueTx,c(Probe,x)) 
    }else{affyMultiTx[[Probe]]<-x}} 
names(affyUniqueTx)<-c("AffyProbe","RefSeq") 
Find affy probes matching by common RefSeqIDs 
agil.RefSeqs0<-lapply(hits.agil, function(x){x[,"RefSeq"]}) 
agil.RefSeqs<-list() 
for (Probe in names(agil.RefSeqs0)) { 
        x<-agil.RefSeqs0[[Probe]] 
        Remove<-x[grep("NR",x)] 
        x<-x[!x%in%Remove] 
        if(length(x)>0){agil.RefSeqs[[Probe]]<-x} 
} 
 
AgilUniqueTx<-data.frame(AgilProbe=character(0),RefSeq=character(0)) 
AgilMultiTx<-list() 
 
for (Probe in names(agil.RefSeqs)) { 
        x<-agil.RefSeqs[[Probe]] 
        if(length(x)==1){ 
                AgilUniqueTx<-rbind(AgilUniqueTx,c(Probe,x)) 
        }else{AgilMultiTx[[Probe]]<-x} 
} 
names(AgilUniqueTx)<-c("AgilProbe","RefSeq") 
 
CommonUniqueTx<-intersect(affyUniqueTx$RefSeq,AgilUniqueTx) #0 
 
agil.matches<-lapply(agil.RefSeqs, function(x){ 
        y<-list() 
        for (affyProbe in names(hits.affy)) { 
                if(length(intersect(x,hits.affy[[affyProbe]]))>0){ 
                        y[[affyProbe]]<-intersect(x,hits.affy[[affyProbe]]) 
                } 
        } 
        return(y) 
}) 
Subset by match status 
noMatch<-list(); SingleMatch<-list(); MultiMatch<-list() 
for (Probe in names(agil.matches)) { 
        if(length(agil.matches[[Probe]])==0){ 
                noMatch[[Probe]]<-agil.matches[[Probe]] 
        }else if(length(agil.matches[[Probe]])==1){ 
                SingleMatch[[Probe]]<-agil.matches[[Probe]] 
        }else {MultiMatch[[Probe]]<-agil.matches[[Probe]]} 
} 
length(noMatch); length(SingleMatch); length(MultiMatch) 
NoMatch 331 SingleMatch 452 MultiMatch 472 
Start Matched table 
AffyProbes<-unlist(lapply(SingleMatch, function(x){names(x)})) 
RefSeqs<-unlist(lapply(SingleMatch, function(x){paste(unlist(x),collapse = "/")})) 
Matched<-data.frame(AgilProbe=names(SingleMatch), 
                    AffyProbe=AffyProbes, 
                    Match=RefSeqs) 
Remove matched from multimatch—no difference 
MultiMatch2<-lapply(MultiMatch, function(x){ 
        x<-x[!names(x)%in%AffyProbes]}) 
 198 
Tabulate matches 
MultiMatch2<-lapply(MultiMatch2, function(x){ 
        x<-lapply(x, function(y){y<-paste(y,collapse = "/")}) 
}) 
 
for (Probe in names(MultiMatch2)) { 
        df<-data.frame(AgilProbe=Probe, 
                       AffyProbe=names(MultiMatch2[[Probe]]), 
                       Match=unlist(MultiMatch2[[Probe]])) 
        MultiMatch2[[Probe]]<-df 
} 
 
MultiMatchTable<-do.call(rbind,MultiMatch2) 
Unmatched by RefSeq - see if match by gene 
UsedAffy<-c(MultiMatchTable$AffyProbe,Matched$AffyProbe) 
UnusedAffyHits<-hits.affy[!names(hits.affy)%in%UsedAffy] 
NoMatchAgil<-names(noMatch) 
NoMatchAgilHits<-hits.agil[names(hits.agil)%in%NoMatchAgil] 
 
agil.Genes<-lapply(NoMatchAgilHits, function(x){x[,"Symb"]}) 
 
genehits.affy0<-strsplit(affy$Gene.Symbol," /// ") 
names(genehits.affy0)<-affy$Probe.Set.ID 
genehits.affy<-genehits.affy0[names(genehits.affy0)%in%names(UnusedAffyHits)] 
 
agil.matches.gene<-lapply(agil.Genes, function(x){ 
        y<-list() 
        for (affyProbe in names(genehits.affy)) { 
                if(length(intersect(x,genehits.affy[[affyProbe]]))>0){ 
                        y[[affyProbe]]<-intersect(x,genehits.affy[[affyProbe]]) 
                } 
        } 
        return(y) 
}) 
 
noMatchGene<-list() 
SingleMatchGene<-list() 
MultiMatchGene<-list() 
 
for (Probe in names(agil.matches.gene)) { 
        if(length(agil.matches.gene[[Probe]])==0){ 
                noMatchGene[[Probe]]<-agil.matches.gene[[Probe]] 
        }else if(length(agil.matches.gene[[Probe]])==1){ 
                SingleMatchGene[[Probe]]<-agil.matches.gene[[Probe]] 
        }else {MultiMatchGene[[Probe]]<-agil.matches.gene[[Probe]]} 
} 
length(noMatchGene);length(SingleMatchGene);length(MultiMatchGene) 
 
AffyProbesGeneMatch<-unlist(lapply(SingleMatchGene, function(x){names(x)})) 
Genes<-unlist(lapply(SingleMatchGene, function(x){paste(unlist(x),collapse = "/")})) 
MatchedGene<-data.frame(AgilProbe=names(SingleMatchGene), 
                    AffyProbe=AffyProbesGeneMatch, 
                    Match=Genes) 
No match 330 Single 1 Multi 0 
Combined Key 
MatchKey<-rbind(Matched,MultiMatchTable,MatchedGene) 
rownames(MatchKey)<-NULL 
matches.unique<-unique(MatchKey[,c("AgilProbe","AffyProbe")]) 
MatchKey<-MatchKey[rownames(matches.unique),] 
 
# remove the UC probes excluded by max variance filter 
MatchKey<-MatchKey[MatchKey$AgilProbe%in%rownames(UC.filteredVar_noNC),] 
 
NonUniqueMatches<-MatchKey[MatchKey$AffyProbe%in% 
                                   MatchKey[duplicated(MatchKey$AffyProbe),"AffyProbe"],] 
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#add full list of matched RefSeqs and reannotated UC probes with isoform specificity 
 
for (i in 1:nrow(NonUniqueMatches)) { 
        AgilProbe<-NonUniqueMatches$AgilProbe[i] 
        AffyProbe<-NonUniqueMatches$AffyProbe[i] 
        probeRS<-hits.affy[[AffyProbe]] 
        probeSymb<-genehits.affy0[[AffyProbe]] 
        NonUniqueMatches$Symb[i]<-paste(unique(probeSymb),collapse = "/") 
        NonUniqueMatches$RefSeqAll[i]<-paste(unique(probeRS),collapse = "/") 
        NonUniqueMatches[NonUniqueMatches$AgilProbe==AgilProbe,"AgilSymb"]<- 
                UC.maxMean_noNC[AgilProbe,"Symb_ReAnno"] 
        NonUniqueMatches[NonUniqueMatches$AgilProbe==AgilProbe,"AgilRS"]<- 
                UC.maxMean_noNC[AgilProbe,"RefSeq_ReAnno"] 
} 
 
length(unique(NonUniqueMatches$AffyProbe)) 
#These resulted from 90 non-specific affy probes matching to two agil probes. 
# In order to choose the correct match, collapse agil probes by max mean in UC data. 
ConfToCollapse<-read.csv("NonUniqueMatchesResolved.csv") 
 
# subset expression data 
datExpr<-exprs(UCmRNAeset)[rownames(exprs(UCmRNAeset))%in%ConfToCollapse$AgilProbe,] 
datExpr2<-collapseRows(datExpr,rowGroup = ConfToCollapse$Symb,  
                       rowID = ConfToCollapse$AgilProbe, method = "maxRowVariance") 
ExcludeProbes<-names(datExpr2$selectedRow[datExpr2$selectedRow==F]) 
 
UCtoMatch<-UC.filteredVar_noNC[!rownames(UC.filteredVar_noNC)%in%ExcludeProbes,] 
 
MatchKey2<-MatchKey[!MatchKey$AgilProbe%in%ExcludeProbes,] 
Collapse External data by highest variance per matched probe among probes with multiple matches 
# Mayo 
datExpr<-exprs(MayoNorm) 
MatchTab<-MayoCvHCdupCorAll 
MatchName<-"M" 
datExpr2<-datExpr[rownames(datExpr)%in%MatchKey2$AffyProbe,] 
datExpr2<-collapseRows(datExpr,rowGroup = MatchKey2$AgilProbe,  
                       rowID = MatchKey2$AffyProbe, method = "maxRowVariance") 
datExpr3<-datExpr2$datETcollapsed 
rownames(datExpr3)<-names(datExpr2$selectedRow[datExpr2$selectedRow==T]) 
matchResult<-MatchKey2[MatchKey2$AffyProbe%in% 
                               names(datExpr2$selectedRow[datExpr2$selectedRow==T]),] 
 
for (i in 1:nrow(matchResult)) { 
    AgilProbe<-matchResult$AgilProbe[i] 
    AffyProbe<-matchResult$AffyProbe[i] 
    matchResult[i,"Symb"]<-UCtoMatch[AgilProbe,"Symb_ReAnno"] 
    matchResult[i,"logFC_UC"]<-UCtoMatch[AgilProbe,"logFC"] 
    matchResult[i,"FC_UC"]<-UCtoMatch[AgilProbe,"FC"] 
    matchResult[i,"p_UC"]<-UCtoMatch[AgilProbe,"P.Value"] 
    matchResult[i,"FDR_UC"]<-UCtoMatch[AgilProbe,"adj.P.Val"] 
    matchResult[i,"AveExpr_UC"]<-UCtoMatch[AgilProbe,"AveExpr"] 
    matchResult[i,"mean1_UC"]<-UCtoMatch[AgilProbe,"mean1"] 
    matchResult[i,"mean2_UC"]<-UCtoMatch[AgilProbe,"mean2"] 
    matchResult[i,"Dir_UC"]<-UCtoMatch[AgilProbe,"Direction"] 
    matchResult[i,paste("logFC",MatchName,sep = "_")]<-MatchTab[AffyProbe,"logFC"] 
    matchResult[i,paste("FC",MatchName,sep = "_")]<-MatchTab[AffyProbe,"FC"] 
    matchResult[i,paste("p",MatchName,sep = "_")]<-MatchTab[AffyProbe,"P.Value"] 
    matchResult[i,paste("FDR",MatchName,sep = "_")]<-MatchTab[AffyProbe,"adj.P.Val"] 
    matchResult[i,paste("AveExpr",MatchName,sep = "_")]<-MatchTab[AffyProbe,"AveExpr"] 
    matchResult[i,paste("mean1",MatchName,sep = "_")]<-MatchTab[AffyProbe,"mean1"] 
    matchResult[i,paste("mean2",MatchName,sep = "_")]<-MatchTab[AffyProbe,"mean2"] 
    matchResult[i,paste("Dir",MatchName,sep = "_")]<-MatchTab[AffyProbe,"Direction"] 
    matchResult[i,"Name"]<-UCtoMatch[AgilProbe,"Name"] 
} 
rownames(matchResult)<-matchResult$AgilProbe 
dir.filter<-matchResult[,"Dir_UC"]==matchResult[,paste("Dir",MatchName,sep = "_")] 
matchedDir<-matchResult[dir.filter,] 
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matchedDirSig<-matchedDir[matchedDir[,paste("p",MatchName,sep = "_")]<0.05,] 
 
M.datExpr.matched<-datExpr3 
M.CvHC.matchedDir<-matchedDir 
M.CvHC.matchedDirSig<-matchedDirSig 
 
# Repeat for Nottingham 
N.datExpr.matched<-datExpr3 
N.CvHC.matchedDir<-matchedDir 
N.CvHC.matchedDirSig<-matchedDirSig 
 
# All 3 
commonSymb<-intersect(M.CvHC.matchedDirSig$Symb,N.CvHC.matchedDirSig$Symb) 
commonTable<-M.CvHC.matchedDirSig[M.CvHC.matchedDirSig$Symb%in%commonSymb,] 
nottCommon<-N.CvHC.matchedDirSig[rownames(commonTable),] 
notCols<-names(nottCommon)[grep("_N",names(nottCommon))] 
commonTable<-cbind(commonTable,nottCommon[,names(nottCommon)%in%notCols]) 
GO enrichment 
library(GOstats) 
library(hgu95av2.db) 
view.GOstats<-function(toptable,universe,dir){ 
        if(dir=="up"){toptable<-toptable[toptable$logFC>0,]} 
        else{toptable<-toptable[toptable$logFC<0,]} 
        selectedEntrezIds<-as.character(toptable$EntrezID) 
        params <- new("GOHyperGParams", geneIds = selectedEntrezIds, 
  universeGeneIds = universe, annotation = "hgu95av2.db",  
  ontology = "BP", pvalueCutoff = 0.05, conditional = FALSE,  
  testDirection = "over") 
        hgOver <- hyperGTest(params) 
        table <- summary(hgOver) 
        return(table) 
} 
Common genes 
commonTable<-UCtoMatch[rownames(UCtoMatch)%in%rownames(M.CvHC.matchedDirSig),] 
universeUC<-as.character(fitUC$genes$EntrezID) 
universeMayo<-as.character(fitMayo$genes$EntrezID) 
universeCommon<-union(universeUC,universeMayo) #same chip/same universe for Roch and Nott 
common.up<-view.GOstats(commonTable,universeCommon,"up") 
common.down<-view.GOstats(commonTable,universeCommon,"down") 
WGCNA modules done in same way, universe was EntrezIDs in WGCNA analysis. 
Nanostring nCounter validation 
quality control initially identified 4 outliers. The fourth is only z score 3.03 so will retain this one 
library(NanoStringNorm) 
Load data (outliers removed) 
load("NSraw0717NoOutliers.rda") 
load("NSpheno0717NoOutliers.rda") 
Normalization 
See NanoStringNorm paper:  https://doi.org/10.1093/bioinformatics/bts188 
Code-count normalization: accounts for lane-by-lane variation of the nCounter platform. Normalization occurs by 
summarizing (i.e. mean, median, sum or geometric mean) the positive control counts and adjusting samples by a 
factor relative to other samples. 
Background correction: negative controls 
Sample content normalization: normalization genes summarized (e.g. geometric mean, etc.) and a sample 
adjustment factor is calculated. 
convenience function for normalization 
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myNSnorm<- function(raw,method,logged){ 
        library(NanoStringNorm) 
        norm <- NanoStringNorm( 
            x = raw, CodeCount = method[1], 
            Background = method[2], SampleContent = method[3],  
            OtherNorm = method[4], round.values = TRUE, 
            take.log = logged, return.matrix.of.endogenous.probes = TRUE) 
    return(norm) 
} 
convenience function to save counts 
savecounts<-function(countmatrix,namestart){ 
    date <- gsub("-","",gsub("2016-","",Sys.Date())) 
    methName <- gsub("geomean","gm",  
                     gsub("\\.","",  
                          gsub("none","na", 
                               gsub("housekeeping","hk", paste(method,collapse = "_"))))) 
    filename <- paste(namestart,"_",methName,date,".csv",sep = "")  
    write.csv(countmatrix, file = filename) 
    print(paste("Filename:",filename)) 
    method.sum<<-methName 
} 
negative controls were extremely low and the NanoString rep advised against using a background control factor. for 
content norm, used low.cv.geo.mean which chooses good reference genes (low variation) since pre-selected 
reference genes (GAPDH, beta actin, PPIA had higher CV) 
Since will use voom, do not log transform 
method <- c("geo.mean","none", "low.cv.geo.mean", "none") 
NSnormNolog<-myNSnorm(raw = NSraw0717NoOutliers, method = method,logged = FALSE) 
savecounts(countmatrix = NSnormNolog, namestart = "NSnolog45") 
#there were 6 in the set that were not part of this analysis 
load("NSvalidationMAprobes.rda") #maps symbols to microarray probes 
NSnormNolog<-NSnormNolog[as.character(NSvalidationMAprobes$GeneSymbol),] 
dim(NSnormNolog) #[1] 67 45 
Differential Expression 
Use voom to transform for linear modeling 
library(limma) 
f <- as.factor(NSpheno0717NoOutliers$Group) 
design <- model.matrix(~ 0 + f)  
levels(f) 
## [1] "C"  "D"  "HC" 
colnames(design)=levels(f) 
v1<-voom(NSnormNolog,design) 
Linear modeling 
fit <- lmFit(v1, design) 
contrasts <- makeContrasts((D+C)/2-HC, D-HC, C-HC, levels=design) 
fitcon <- contrasts.fit(fit, contrasts) 
eb1 <- eBayes(fitcon) 
coefficients<-colnames(eb1$coefficients) 
Function to save results 
mytop<-function(object,names){ 
    # returns list, saves csv of top tables 
    # object: eg eb 
    # names vector of names of top tables 
    toplist<-list() 
    top1<-topTable(object, coef = coefficients[1], adjust.method = "BH", number = Inf) 
    top2<-topTable(object, coef = coefficients[2], adjust.method = "BH", number = Inf) 
    top3<-topTable(object, coef = coefficients[3], adjust.method = "BH", number = Inf)  
    write.csv(top1,file = paste(names[1],"csv",sep = ".")) 
    write.csv(top2,file = paste(names[2],"csv",sep = ".")) 
    write.csv(top3,file = paste(names[3],"csv",sep = ".")) 
    toplist[["IBSvHC"]] <-top1 
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    toplist[["DvHC"]] <-top2 
    toplist[["CvHC"]] <-top3 
    return(toplist) 
} 
tops_all<-mytop(eb1,names = c("IBSvHCall","DvHCall","CvHCall")) 
Determine results in microarray cohort and validation cohort as above 
Determine validation 
load("UC_CvHCtoptables.rda") 
MA.C<-UC.CvHCall 
MA.C<-MA.C[rownames(NSvalidationMAprobes),] 
names(MA.C)<-paste(names(MA.C),"MA",sep = "_") 
rownames(MA.C)<-MA.C$Symbol_MA 
 
NS.C.all<-tops_all$CvHC 
NS.C.MA<-NStopsMA$CvHC #nanostring results in microarray cohort 
NS.C.val<-NStopsVal$CvHC #nanostring results in validation cohort 
 
names(NS.C.all)<-paste(names(NS.C.all),"NS",sep = "_") 
names(NS.C.MA)<-paste(names(NS.C.MA),"NS",sep = "_") 
names(NS.C.val)<-paste(names(NS.C.val),"NS",sep = "_") 
 
length(setdiff(rownames(MA.C),rownames(NS.C.all))) #0 
 
MA.C<-MA.C[order(rownames(MA.C)),] 
NS.C.all<-NS.C.all[order(rownames(NS.C.all)),] 
NS.C.MA<-NS.C.MA[order(rownames(NS.C.MA)),] 
NS.C.val<-NS.C.val[order(rownames(NS.C.val)),] 
 
NSMA.C.all<-cbind.data.frame(NS.C.all,MA.C) 
NSMA.C.MA<-cbind.data.frame(NS.C.MA,MA.C) 
NSMA.C.val<-cbind.data.frame(NS.C.val,MA.C) 
 
matchDirection<-function(data){ 
    data<-data[data$P.Value_NS<=0.05,] 
    same<-(data$logFC_MA>0&data$logFC_NS>0)|(data$logFC_MA<0&data$logFC_NS<0) 
    data<-data[same==TRUE,] 
} 
 
NS.C.validated.all<-matchDirection(NSMA.C.all) 
NS.C.validated.ma<-matchDirection(NSMA.C.MA) 
NS.C.validated.val<-matchDirection(NSMA.C.val) 
 
NS.C.validated.all.FDR<-NS.C.validated.all[NS.C.validated.all$adj.P.Val_NS<0.051,] 
NS.C.validated.ma.FDR<-NS.C.validated.ma[NS.C.validated.ma$adj.P.Val_NS<0.051,] 
NS.C.validated.val.FDR<-NS.C.validated.val[NS.C.validated.val$adj.P.Val_NS<0.051,] 
 
NSMAvalC<-list() 
NSMAvalC$allP<-NS.C.validated.all 
NSMAvalC$maP<-NS.C.validated.ma 
NSMAvalC$valP<-NS.C.validated.val 
NSMAvalC$allFDR<-NS.C.validated.all.FDR 
NSMAvalC$maFDR<-NS.C.validated.ma.FDR 
 
for(df in names(NSMAvalC)){ 
    f<-paste("NSMAvalC",df,".csv",sep = "") 
    write.csv(NSMAvalC[[df]],f) 
} 
Association with symptoms 
load("NStraits.rda") #loads pheno data 
load("NSnormNolog67x45.rda") 
NSvoom<-voom(NSnormNolog) 
traits<-traits[traits$IBS=="IBS",] 
NS.norm.values<-as.data.frame(t(NSvoom$E)) 
geneData<-NS.norm.values[rownames(traits),] 
genes<-names(geneData) 
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Overall symptoms 
OverallSx<-data.frame( 
        row.names = genes, F.pvalue=numeric(length(genes)), 
        B=numeric(length(genes)),  Sx.pvalue=numeric(length(genes))) 
 
for (i in 1:nrow(OverallSx)) { 
        df1<-cbind(geneData[,rownames(OverallSx)[i]],traits) 
        names(df1)[1]<-"gene" 
        fit<-lm(BSQ_OverallSx~factor(Sex)+gene,data = df1, na.action = na.exclude) 
        sumfit<-summary(fit) 
        OverallSx[i,"F.pvalue"]<- pf(sumfit$fstatistic[1], sumfit$fstatistic[2], 
                                     sumfit$fstatistic[3],lower.tail = FALSE) 
        OverallSx[i,"B"]<-sumfit$coefficients["gene","Estimate"] 
        OverallSx[i,"Sx.pvalue"]<-sumfit$coefficients["gene","Pr(>|t|)"] 
} 
 
OverallSx$FDR<-p.adjust(OverallSx$Sx.pvalue,method = "BH") 
OverallSx<-OverallSx[order(OverallSx$Sx.pvalue),] 
Abdominal Pain, Bloating as above 
Chapter 3 
Code for heatmaps and WGCNA mirrors Chapter 2 code using lncRNA expression data. 
Chapter 4 
Meta-analysis of TEER experiments 
Function to tabulate summary data and statistics from individual experiments 
getRes<-function(StudyName,StartDays,data,time,xvar,comp){ 
    dat2<-data[data$Time==time,] 
    varname<-xvar[1] 
    grp1<-dat2$Percent[dat2[,xvar[1]]==xvar[2]] 
    grp2<-dat2$Percent[dat2[,xvar[1]]==xvar[3]] 
    tres<-t.test(grp1,grp2) 
    se1<-sd(grp1,na.rm = T)/sqrt(length(grp1[!is.na(grp1)])) 
    se2<-sd(grp2,na.rm = T)/sqrt(length(grp2[!is.na(grp2)])) 
    baseTEERs<-lapply(c(xvar[2],xvar[3]), function(x){ 
        dat0<-data[data$Time==0,] 
        m<-format(mean(dat0$MeanR[dat0[,xvar[1]]==x]/1000),digits = 3) 
        sd<-format(sd(dat0$MeanR[dat0[,xvar[1]]==x]/1000),digits = 2) 
        msd<-paste(m," (", sd,")",sep = "") 
        return(msd) 
    }) 
    df<-data.frame(Study=StudyName, 
                   DoxStartDay=StartDays[1],InfStartDay=StartDays[2], 
                   TEER0=StartDays[3],Comparison=comp,Time=time, 
                   Grp1=xvar[2],Grp2=xvar[3], 
                   n1=length(grp1[!is.na(grp1)]),n2=length(grp1[!is.na(grp2)]), 
                   BaseTEER1=baseTEERs[[1]],BaseTEER2=baseTEERs[[2]], 
                   Mean1=tres$estimate[1],Mean2=tres$estimate[2], 
                   sd1=sd(grp1,na.rm = T),sd2=sd(grp2,na.rm = T),se1=se1,se2=se2, 
                   Estimate=tres$estimate[1]- tres$estimate[2], 
                   EstSE=(tres$conf.int[2]-tres$conf.int[1])/3.92, 
                   CIlow=tres$conf.int[1],CIhigh=tres$conf.int[2], 
                   pvalue=format(tres$p.value,digits = 3,scientific = F) 
                  ) 
    return(df) 
} 
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Example for one experiment (repeated for all with results iteratively added (rbind) to doxResp and infResp) 
load("Data/TEER_081417.rda") 
doxyrespNoOuts.081417$Time<-doxyrespNoOuts.081417$Time-min(doxyrespNoOuts.081417$Time) 
infgResp.081417$Time<-infgResp.081417$Time-min(infgResp.081417$Time) 
 
xvar<-c("Doxy","Doxy","Control") 
comp = "Dox vs No Dox AFDN-AS1" 
StudyName="Aug2017_1" 
StartDays=c(6,NA,5) 
 
res_doxyResp.081417<-lapply(c(1,2,3), function(x){ 
  return(getRes( 
    StudyName = StudyName, 
    StartDays=StartDays, 
    data = doxyrespNoOuts.081417, comp = comp, 
    time = x, xvar = xvar)) 
}) 
res_doxyResp.081417<-do.call(rbind, res_doxyResp.081417) 
doxResp<-res_doxyResp.081417 
 
StartDays=c(6,9,5) 
 
res_infResp.081417<-lapply(c(1,2,3), function(x){ 
  return(getRes(StudyName = StudyName, StartDays = StartDays, 
                data = infgResp.081417, comp = comp, 
                time = x, xvar = xvar)) 
}) 
res_infResp.081417<-do.call(rbind, res_infResp.081417) 
infResp<-res_infResp.081417 
 
resList<-list() 
resList$Doxy$Aug.14.17<-res_doxyResp.081417 
resList$Infg$Aug.14.17<-res_infResp.081417 
Create list with result data 
metaList<-list() 
metaList$Dox$`AFDN-DT`<-doxResp[doxResp$Comparison=="Dox vs No Dox AFDN-AS1",] 
metaList$Dox$EV<-doxRespEV[doxRespEV$Comparison=="Dox vs No Dox EV",] 
metaList$Dox$AFvEVdox<-doxResp[doxResp$Comparison=="AFDN-AS1 vs EV Dox",] 
metaList$Dox$AFvEVnodox<-doxResp[doxResp$Comparison=="AFDN-AS1 vs EV No Dox",] 
 
metaList$Infg$`AFDN-DT`<-infResp[infResp$Comparison=="Dox vs No Dox AFDN-AS1",] 
metaList$Infg$EV<-infRespEV[infRespEV$Comparison=="Dox vs No Dox EV",] 
metaList$Infg$AFvEVdox<-infResp[infResp$Comparison=="AFDN-AS1 vs EV Dox",] 
metaList$Infg$AFvEVnodox<-infResp[infResp$Comparison=="AFDN-AS1 vs EV No Dox",] 
Forest plots 
library(meta) 
library(forestplot) 
Functions to calculate total wells, base TEER column and meta-analysis results 
makeWells<-function(){ 
  wells <- paste(tableDat$n1 + tableDat$n2," (",tableDat$n1, 
                   "/", tableDat$n2, ")", sep = "") 
  sumWells <- paste(sum(tableDat$n1 + tableDat$n2), " (", 
                  sum(tableDat$n1), "/", sum(tableDat$n2), ")", sep = "") 
  return(c(wells, sumWells)) 
} 
 
makeBaseTEER<-function(){ 
  baseTEERs<-paste(tableDat$BaseTEER1,tableDat$BaseTEER2,sep = ", ") 
  return(c(baseTEERs,NA)) 
} 
 
calcSumRes<-function(){ 
    sumRes <- metacont( 
        n.e = tableDat$n1, 
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        mean.e = tableDat$Mean1, 
        sd.e = tableDat$sd1, 
        n.c = tableDat$n2, 
        mean.c = tableDat$Mean2, 
        sd.c = tableDat$sd2, 
        sm = "MD" 
      ) 
  return(sumRes) 
} 
Function to print plot 
plotMetaDoxAFday<-function(Time){ 
    tableDat <- doxResp[doxResp$Time==Time&doxResp$Comparison=="Dox vs No Dox AFDN-AS1",] 
    plotTitle<-paste("Response to Doxycycline: T84-TR-AFDN-DT with vs. without doxycycline\n% change in TE
ER ",Time," days post doxycycline", sep = "") 
    sumRes<-calcSumRes() 
    BaseTeer<-makeBaseTEER() 
    Wells<-makeWells() 
    tabletext <- 
      cbind( 
        c("Study",NA, as.character(tableDat$Study), "Summary"), 
        c("Dox Start", "(days post-seeding)", as.character(tableDat$DoxStartDay),NA), 
        c("n wells","Tot(Dox/No Dox)",Wells), 
        c("Baseline TEER","mean (sd), (Dox/No Dox)",BaseTeer), 
        c("Estimate","(difference)", round(c( 
          sumRes$TE, sumRes$TE.random 
        ), 2)), 
        c("p value",NA, format( 
          c(sumRes$pval, sumRes$pval.random), digits = 3 
        )) 
      ) 
    #specify formating 
    labellist<-list() 
    labellist$Row1$Col1<-gpar(cex=0.4);labellist$Row1$Col2<-gpar(cex=0.4) 
    labellist$Row1$Col3<-gpar(cex=0.4);labellist$Row1$Col4<-gpar(cex=0.4) 
    labellist$Row1$Col5<-gpar(cex=0.4);labellist$Row1$Col6<-gpar(cex=0.4) 
    labellist$Row2$Col1<-gpar(cex=0.6);labellist$Row2$Col2<-gpar(cex=0.6) 
    labellist$Row2$Col3<-gpar(cex=0.6);labellist$Row2$Col4<-gpar(cex=0.6) 
    labellist$Row2$Col5<-gpar(cex=0.6);labellist$Row2$Col6<-gpar(cex=0.6) 
    labellist$Row3$Col1<-gpar(cex=0.6);labellist$Row3$Col2<-gpar(cex=0.6) 
    labellist$Row3$Col3<-gpar(cex=0.6);labellist$Row3$Col4<-gpar(cex=0.6) 
    labellist$Row3$Col5<-gpar(cex=0.6);labellist$Row3$Col6<-gpar(cex=0.6) 
    labellist$Row4$Col1<-gpar(cex=0.6);labellist$Row4$Col2<-gpar(cex=0.6) 
    labellist$Row4$Col3<-gpar(cex=0.6);labellist$Row4$Col4<-gpar(cex=0.6) 
    labellist$Row4$Col5<-gpar(cex=0.6);labellist$Row4$Col6<-gpar(cex=0.6) 
    print( 
        forestplot( 
            labeltext = tabletext,graph.pos = 6, 
            mean = c(NA,NA, sumRes$TE, sumRes$TE.random), 
            lower = c(NA,NA, sumRes$lower, sumRes$lower.random), 
            upper = c(NA, NA,sumRes$upper, sumRes$upper.fixed), 
            ci.vertices = T,title = plotTitle,line.margin = 0, 
            colgap=unit(2,"mm"),is.summary = c(T,rep(F,4), T), 
            xlab = "Difference in % Baseline TEER",mar = unit(c(3,3,3,3),"mm"), 
            txt_gp = fpTxtGp(label=labellist,title = gpar(cex=0.7), 
                             summary = gpar(cex=0.6),xlab = gpar(cex=0.5), 
                             ticks = gpar(cex=0.5) 
                            )) 
    ) 
} 
Print plot 
png(filename = "testMeta.png", width = 6, height = 2, units = "in", res = 300) 
 plotMetaDoxAFday(3) 
dev.off() 
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RNA sequencing 
Set-up 
library(DESeq2) 
library(biomaRt) 
library(edgeR) 
DeSeq data set 
contains expression data (exprColDat), Sample data (ColDat) and annotation (RowDat) 
Expression data 
Count data were originally in one file per sample names SampleName.txt 
files1 <- dir(path = "~/read_counts/") 
df1 <- readDGE(files1, path = "~/read_counts/", header = F ) 
allDat <- as.data.frame(df1$counts) 
exprColDat<-allDat 
Sample data table 
load("pheno.rda") 
rundata<-read.csv("ReadInfo.csv", row.names = 1) 
cells<-intersect(rownames(rundata), rownames(pheno)) 
pheno<-cbind(pheno[cells,], rundata[cells,]) 
colDat<-pheno[names(allDat),] 
colDat$Group <- factor(colDat$Group, levels = c("EV","AFDN_DT")) 
colDat$Dox<- factor(colDat$Dox, levels=c("No_Doxycycline","Doxycycline")) 
colDat$GroupDox[colDat$Group=="AFDN_DT"&colDat$Dox=="Doxycycline"]<-"AF_Dox" 
colDat$GroupDox[colDat$Group=="AFDN_DT"&colDat$Dox=="No_Doxycycline"]<-"AF" 
colDat$GroupDox[colDat$Group=="EV"&colDat$Dox=="Doxycycline"]<-"EV_Dox" 
colDat$GroupDox[colDat$Group=="EV"&colDat$Dox=="No_Doxycycline"]<-"EV" 
colDat$GroupDox <- as.factor(colDat$GroupDox) 
Annotation 
notgene<- 
exprColDat[!rownames(exprColDat)%in%grep("ENSG",rownames(exprColDat),value = T),] 
 
exprColDat<- 
exprColDat[rownames(exprColDat)%in%grep("ENSG",rownames(exprColDat),value = T),] 
 
mart.hs <- useMart("ensembl", "hsapiens_gene_ensembl") 
an <- getBM(attributes = c("ensembl_gene_id", "hgnc_symbol","entrezgene" ,"description", "chromosome_name"
), filters = "ensembl_gene_id", values = row.names(exprColDat), mart = mart.hs) 
 
an<-an[!duplicated(an$ensembl_gene_id),] 
notinAn<-exprColDat[!rownames(exprColDat)%in%an$ensembl_gene_id,] 
# all deprecated - most no expression 
 
rownames(an)<-an$ensembl_gene_id 
save(an, file="ENSGhsAn.rda") 
library(dplyr) 
rowDat <- rownames_to_column(exprColDat,"ensembl_gene_id")[,1, drop=F] %>%  
  left_join(an, "ensembl_gene_id") 
save(rowDat,exprColDat,colDat, file = "CountDataAll.rda") 
Clustering identifies W16 as outlier 
For clustering, counts are transformed for linear modeling following exclusion of genes with low counts (these do not 
need to be excluded for differential expression, though genes with very low counts are removed to reduce the 
memory needed) 
dds <- DESeqDataSetFromMatrix (countData = exprColDat, 
                               colData = colDat, 
                               design = ~Group+Dox+Group:Dox) 
# remove very low count genes 
keep <-  rowSums(counts(dds)) >= 10 
dds <- dds[keep,] 
 
# remove low count genes 
countsGr10in30perfilt<-function(dds){ 
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  n30percent<-.3*dim(dds)[2] 
  countsGr10in30per<-apply(counts(dds),1,function(y){ 
    y2<-ifelse(y>10,1,0) 
    y3<-ifelse(sum(y2)>n30percent,TRUE,FALSE) 
    return(y3) 
  }) 
  ddsfilt<-dds[countsGr10in30per,] 
  return(ddsfilt) 
} 
dds<-countsGr10in30perfilt(dds) 
vs<-vst(dds,blind = FALSE) 
edata<-as.data.frame(assay(vs)) 
edata<-normalizeQuantiles(as.matrix(edata)) 
datExpr<-as.data.frame(t(edata)) 
rownames(datExpr)<-colnames(edata) 
library(WGCNA) 
sampleTree = hclust(dist(datExpr), method = "average") 
pdf(file = "SigSampClust042419.pdf") 
par(cex = 0.6); 
par(mar = c(0,4,2,0)) 
plot(sampleTree,  
     main = "Sample clustering to detect outliers",  
     sub="", xlab="", cex.lab = 1.5,  
     cex.axis = 1.5, cex.main = 2) 
dev.off() 
Remove W16 
colDat<-colDat[rownames(colDat)!="W16",] 
exprColDat<-exprColDat[,rownames(colDat)] 
save(exprColDat,colDat,rowDat,file = "CountDataAllnoW16.rda") 
Principal components plot 
dds<-dds[,dds$Sample!="W16"] 
vsd <- vst(dds) 
data <- plotPCA(vsd, intgroup = c("Group","Dox","GroupDo2","AFDTpcr"), returnData=TRUE) 
percentVar <- round(100 * attr(data, "percentVar")) 
 
library(ggplot2) 
load("/myColors.rda") 
 
ggplot(data, aes(PC1PC2, fill = GroupDox, alpha = GroupDox, size = AFDTpcr)) + 
 geom_point(shape=21) + 
    xlab(paste0("PC1: ", percentVar[1], "% variance")) + 
 ylab(paste0("PC2: ", percentVar[2], "% variance")) + 
 scale_alpha_manual(name = "Group", values = c(0.5, 1, 0.5, 1)) + 
 scale_fill_manual(name = "Group", values = c( 
        myColors$main$yellow1, myColors$main$yellow1, 
        myColors$main$blue1, myColors$main$blue1 
    ) 
  ) + 
  scale_size_continuous(name = "AFDN-DT PCR Expr.",range = c(1,10)) + 
  theme_bw() + 
  guides( 
    fill = guide_legend(order = 1,override.aes = list(size=5)), 
    alpha = guide_legend(order = 1), size = guide_legend(order = 2) 
  )  
Differential expression 
library(tidyverse) 
load("CountDataAllnoW16.rda") 
Main effects of doxycycline and cell line 
dds <- DESeqDataSetFromMatrix (countData = exprColDat, 
                               colData = colDat, 
                               rowData = rowDat, 
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                               design = ~Dox+Group) 
keep <-  rowSums(counts(dds)) >= 10 
dds <- dds[keep,] 
dds <- DESeq(dds) 
resultsNames(dds) 
# [1] "Intercept"                         
# [2] "Dox_Doxycycline_vs_No_Doxycycline" 
# [3] "Group_AFDN_DT_vs_EV"               
 
# Dox 
res<-results(dds, name = "Dox_Doxycycline_vs_No_Doxycycline") 
summary(res) 
# out of 14847 with nonzero total read count 
# adjusted p-value < 0.1 
# LFC > 0 (up)       : 3, 0.02% 
# LFC < 0 (down)     : 2, 0.013% 
# outliers [1]       : 16, 0.11% 
# low counts [2]     : 0, 0% 
# (mean count < 1) 
 
ResList<-list() 
ResList$DoxMain<-res 
 
# Group 
res<-results(dds, name = "Group_AFDN_DT_vs_EV") 
summary(res) 
# out of 14847 with nonzero total read count 
# adjusted p-value < 0.1 
# LFC > 0 (up)       : 157, 1.1% 
# LFC < 0 (down)     : 134, 0.9% 
# outliers [1]       : 16, 0.11% 
# low counts [2]     : 9771, 66% 
# (mean count < 32) 
 
ResList$GroupMain<-res 
Interaction term for dox effect in AF vs EV 
dds <- DESeqDataSetFromMatrix (countData = exprColDat, 
                               colData = colDat, 
                               rowData = rowDat, 
                               design = ~Dox+Group+Dox:Group) 
keep <-  rowSums(counts(dds)) >= 10 
dds <- dds[keep,] 
dds <- DESeq(dds) 
resultsNames(dds) 
# [1] "Intercept"                         
# [2] "Dox_Doxycycline_vs_No_Doxycycline" 
# [3] "Group_AFDN_DT_vs_EV"               
# [4] "DoxDoxycycline.GroupAFDN_DT"  
 
res<-results(dds, name="DoxDoxycycline.GroupAFDN_DT") 
summary(res) 
 
# out of 14847 with nonzero total read count 
# adjusted p-value < 0.1 
# LFC > 0 (up)       : 0, 0% 
# LFC < 0 (down)     : 0, 0% 
# outliers [1]       : 0, 0% 
# low counts [2]     : 0, 0% 
# (mean count < 0) 
 
ResList$GroupDoxInt<-res 
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Dox effect within groups, group effect within Dox 
dds <- DESeqDataSetFromMatrix (countData = exprColDat, 
                               colData = colDat, 
                               rowData = rowDat, 
                               design = ~0+GroupDox) 
keep <-  rowSums(counts(dds)) >= 10 
dds <- dds[keep,] 
dds <- DESeq(dds) 
resultsNames(dds) 
# [1] "GroupDoxAF"     "GroupDoxAF_Dox" "GroupDoxEV"     "GroupDoxEV_Dox" 
 
# AF+dox vs AF 
res<-results(dds, contrast = c("GroupDox","AF_Dox","AF")) 
summary(res) 
# out of 14847 with nonzero total read count 
# adjusted p-value < 0.1 
# LFC > 0 (up)       : 7, 0.047% 
# LFC < 0 (down)     : 9, 0.06% 
# outliers [1]       : 0, 0% 
# low counts [2]     : 13529, 91% 
# (mean count < 185) 
 
ResList$GroupDox_AF_Dox_vs_AF<-res 
 
# EV+dox vs EV 
res<-results(dds, contrast = c("GroupDox","EV_Dox","EV")) 
summary(res) 
# out of 14847 with nonzero total read count 
# adjusted p-value < 0.1 
# LFC > 0 (up)       : 0, 0% 
# LFC < 0 (down)     : 0, 0% 
# outliers [1]       : 0, 0% 
# low counts [2]     : 0, 0% 
# (mean count < 1) 
 
ResList$GroupDox_EV_Dox_vs_EV<-res 
 
#AF vs EV 
res<-results(dds, contrast = c("GroupDox","AF","EV")) 
summary(res) 
 
# out of 14847 with nonzero total read count 
# adjusted p-value < 0.1 
# LFC > 0 (up)       : 91, 0.61% 
# LFC < 0 (down)     : 57, 0.38% 
# outliers [1]       : 0, 0% 
# low counts [2]     : 12089, 81% 
# (mean count < 80) 
 
ResList$GroupDox_AF_vs_EV<-res 
 
ResAnList<-lapply(ResList, function(x){ 
  xAn<-cbind(as.data.frame(x),rowData(dds)[,2:4]) 
  xAn<-xAn[!is.na(xAn$padj),] 
  xAn<-xAn[order(xAn$pvalue),] 
  xAn$FC<-2^xAn$log2FoldChange 
  return(as.data.frame(xAn)) 
}) 
 
SigCountsTally2<-function(x){ 
  xUp=x[x$log2FoldChange>0,] 
  xDown=x[x$log2FoldChange<0,] 
  FDR10up=nrow(xUp[xUp$padj<=0.1,]) 
  FDR10down=nrow(xDown[xDown$padj<=0.1,]) 
  FDR05up=nrow(xUp[xUp$padj<=0.05,]) 
  FDR05down=nrow(xDown[xDown$padj<=0.05,]) 
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  P05up=nrow(xUp[xUp$pvalue<=0.05,]) 
  P05down=nrow(xDown[xDown$pvalue<=0.05,]) 
  return(c(FDR10=paste(FDR10up+FDR10down," (",FDR10up,"/",FDR10down,")",sep = ""), 
           FDR05=paste(FDR05up+FDR05down," (",FDR05up,"/",FDR05down,")",sep = ""), 
           P05=paste(P05up+P05down," (",P05up,"/",P05down,")",sep = ""))) 
} 
 
makeSigCountsTable2<-function(y){ 
  yFC2<-y[abs(y$log2FoldChange)>=1,] 
  return(data.frame(All=SigCountsTally2(y), 
                    FC2=SigCountsTally2(yFC2))) 
} 
 
write.csv(do.call(cbind,lapply(ResAnList, makeSigCountsTable2)), 
          "SigCountsTable.csv") 
WGCNA 
Single network 
library(WGCNA) 
options(stringsAsFactors = F) 
 
dds <- DESeqDataSetFromMatrix (countData = exprColDat, 
                               colData = colDat, 
                               design = ~Group+Dox+Group:Dox) 
keep <-  rowSums(counts(dds)) >= 10 
dds <- dds[keep,] 
dds <- DESeq(dds) 
dds<-countsGr10in30perfilt(dds) 
dim(dds) #[1] 9005   15 
vs<-vst(dds,blind = FALSE) 
edata<-as.data.frame(assay(vs)) 
edata<-normalizeQuantiles(as.matrix(edata)) 
datExpr.all<-as.data.frame(t(edata)) 
rownames(datExpr.all)<-colnames(edata) 
 
softPower=18 
netType="signed" 
deepSplit = 1 
MEDissThres = 0.25 
minModuleSize = 30 
fname.root<-"18_30_1_25_all" 
 
adjacency = adjacency(datExpr, power = softPower, type = netType); 
TOM = TOMsimilarity(adjacency); 
dissTOM = 1-TOM 
rm(adjacency) 
geneTree = hclust(as.dist(dissTOM), method = "average"); 
dynamicMods = cutreeDynamic(dendro = geneTree, distM = dissTOM, 
                            deepSplit = deepSplit, pamRespectsDendro = FALSE, 
                            minClusterSize = minModuleSize); 
dynamicColors = labels2colors(dynamicMods) 
MEList = moduleEigengenes(datExpr, colors = dynamicColors,excludeGrey = T) 
MEs = MEList$eigengenes 
MEDiss = 1-abs(cor(MEs)); 
METree = hclust(as.dist(MEDiss), method = "average"); 
merge = mergeCloseModules(datExpr, dynamicColors,  
                          cutHeight = MEDissThres,  
                          verbose = 0, getNewUnassdME = FALSE) 
mergedColors = merge$colors; 
mergedMEs = merge$newMEs 
moduleColors = mergedColors 
colorOrder = standardColors(150); 
moduleLabels = match(moduleColors, colorOrder); 
MEs = mergedMEs 
MEs0 = moduleEigengenes(datExpr, moduleColors,excludeGrey = T)$eigengenes 
MEs = orderMEs(MEs0) 
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pdf(paste("EigenNet_",fname.root,".pdf",sep = ""),width = 7, height = 6.5) 
plotEigengeneNetworks(MEs,setLabels = NULL,plotDendrograms = F,  
                      signed = T, setMargins = T) 
dev.off() 
Correlate modules with group/treatment 
load("datTraitsAll.rda") 
datTraits<-datTraits[,c(2,3,5,6,4)] 
 
datTraitsAFvEV[datTraitsGroup==1&datTraitsDox==0]<-1 
datTraitsAFvEV[datTraitsGroup==0&datTraitsDox==0]<-0 
 
datTraits<-datTraits[,c(1,6,2:5)] 
 
ylabs<-paste(labelslabel," (",labelssize,")",sep = "") 
 
moduleTraitCor = cor(MEs.all,  
                     datTraits, 
                     use = "p") 
moduleTraitPvalue = corPvalueStudent(moduleTraitCor, 
                                     nrow(datExpr.all)) 
textMatrix =  paste(signif(moduleTraitCor, 2),  
                    " (", signif(moduleTraitPvalue, 1), ")", 
                    sep = "") 
dim(textMatrix) = dim(moduleTraitCor) 
 
textMatrix2<-textMatrix 
 
for(i in 1:dim(textMatrix)[1]){ 
  for (j in 1:dim(textMatrix)[2]) { 
  if (moduleTraitPvalue[i,j]<0.05) { 
    textMatrix2[i,j]<-paste(textMatrix2[i,j],"*",sep = "") 
  }   
  } 
} 
 
xlabs<-c("Group\n(all)", 
         "Group\n(no Dox)", 
         "Dox\n(all)", 
         "Dox\n(AFDN-DT)", 
         "Dox\n(EV)", 
         "AFDN-DT\nPCR Expr.") 
 
png(file = "SingleNetTraitCorCombo.png", width = 6.5, 
    height = 3.3,units = "in",res = 300);par( 
      mar = c(2, 10, 0.5, 0.1) 
    );labeledHeatmap( 
      Matrix = moduleTraitCor,  
      textMatrix = textMatrix2, 
      xLabels = xlabs,  
      yLabels = names(MEs.all),  
      ySymbols = ylabs, 
      yColorLabels = TRUE,  
      colors = blueWhiteRed(50), setStdMargins = FALSE,  
      cex.text = 0.6, xLabelsAngle = 0, 
      cex.lab.y = 0.6,cex.legend = 0.5, 
      cex.lab.x = 0.6, 
      xLabelsAdj = c(0.5,0.5));dev.off() 
Gene info table 
notgrey<-!moduleColors=="grey" 
 
load("ENSGhsAn.rda") 
an<-an[colnames(datExpr[,notgrey]),] 
makeGeneInfo<-function(geneData,modules,geneModMemb){ 
    geneInfo0 = data.frame(ENSG = geneData$ensembl_gene_id, 
                           geneSymbol = geneData$hgnc_symbol, 
                           EntrezID = geneData$entrez, 
                           Name=geneData$description, 
                           moduleColor = modules) 
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  Modmemb<-numeric() 
  for(i in 1:nrow(geneInfo0)){ 
      modColor<-modules[i] 
      Modmemb[i]<-geneModMemb[i,modColor] 
  } 
  geneInfo0$MM<-Modmemb 
  geneOrder = order( 
      factor(geneInfo0$moduleColor,levels = names(geneModMemb)), -geneInfo0$MM) 
    geneInfo<-geneInfo0[geneOrder,] 
    geneInfo<-geneInfo[geneInfo$geneSymbol!="",] 
    return(geneInfo) 
} 
 
geneModuleMembership = as.data.frame(cor(datExpr[,notgrey], MEs, use = "p")) 
names(geneModuleMembership) = substring(names(MEs),3) 
geneInfo.all<-makeGeneInfo(an,moduleColors[notgrey],geneModuleMembership) 
write.csv(geneInfo.all, paste(fname.root,"_INFO.csv",sep = "")) 
Consensus network 
dds <- DESeqDataSetFromMatrix (countData = exprColDat, 
                               colData = colDat, 
                               rowData = rowDat, 
                               design = ~0+GroupDox) 
ddsList<-list(AF=dds[,dds$Group=="AFDN_DT"],EV=dds[,dds$Group=="EV"]) 
ddsList<-lapply(ddsList, function(x){ 
    keep<-rowSums(counts(x))>=5; return(x[keep,]) 
}) 
 
ddsDeSeqList<-lapply(ddsList, DESeq) 
 
lapply(ddsDeSeqList, dim) 
# $AF 
# [1] 15034     7 
# $EV 
# [1] 15174     8 
 
ddsDeSeqListfilt<-lapply(ddsDeSeqList, countsGr10in30perfilt) 
 
lapply(ddsDeSeqListfilt, dim) 
# $AF 
# [1] 8786    7 
#  
# $EV 
# [1] 8943    8 
 
vsList<-lapply(ddsDeSeqListfilt, function(x){ 
    y<-vst(x,blind = FALSE) 
}) 
 
edataList<-lapply(vsList, function(x){ 
    x2<-as.data.frame(assay(x)) 
    return(x2) 
}) 
 
colramp = colorRampPalette(c(3,"white",2))(20) 
 
for (i in names(edataList)) { 
    df<-edataList[[i]]   
    pdf(file = paste(i,"densplot.pdf",sep = "_")) 
    plot(density(df[,1]),col=colramp[1],lwd=3,ylim=c(0,.30)) 
    for(j in 2:8){lines(density(df[,j]),lwd=3,col=colramp[j])} 
    dev.off() 
} 
 
library(limma) 
norm_edataList<-lapply(edataList,function(x){ 
    x2<-normalizeQuantiles(as.matrix(x)) 
    return(x2) 
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}) 
 
for (i in names(norm_edataList)) { 
    df<-norm_edataList[[i]] 
    pdf(file = paste(i,"densplotNorm.pdf",sep = "_")) 
    plot(density(df[,1]),col=colramp[1],lwd=3,ylim=c(0,.30)) 
    for(j in 2:8){lines(density(df[,j]),lwd=3,col=colramp[j])} 
    dev.off() 
} 
 
datExprList<-lapply(norm_edataList, function(x){ 
    x2<-as.data.frame(t(x)) 
    rownames(x2)<-colnames(x) 
    return(x2) 
}) 
 
genes<-intersect(names(datExprList$AF), names(datExprList$EV)) #8406 
 
multiExpr<-multiData(AF=datExprList$AF[rownames(datExprList$AF)!="W16",genes], EV=datExprList$EV[,genes]) 
 
# use recommended power of 18 for <20 samples 
sp = 18; ms = 30; ds = 1; mch = 0.15; Fname<-"18_30_1_15" 
 
net = blockwiseConsensusModules( 
    multiExpr, power = sp, minModuleSize = ms, deepSplit = ds,pamRespectsDendro = FALSE, 
    networkType = "signed", mergeCutHeight = mch, numericLabels = TRUE, 
    minKMEtoStay = 0.2, verbose = 5,maxBlockSize = 20000) 
 
setLabels = c("AFDN-DT", "EV"); shortLabels = c("AF", "EV") 
consMEs = net$multiMEs 
consModuleLabels = net$colors; 
consModuleColors = labels2colors(consModuleLabels) 
consMEsC = multiSetMEs(multiExpr, universalColors = consModuleColors) 
mods<-substring(names(consMEsC$AF$data),3) 
mods<-mods[!mods%in%"grey"] 
consMEs.ConsOrder<-consensusOrderMEs(consMEsC) 
 
MyPlotEigenNets<-function(multiME){ 
    p<-plotEigengeneNetworks( 
    multiME,  
    setLabels,  
    letterSubPlots = FALSE, Letters = NULL,  
    excludeGrey = TRUE, greyLabel = "grey",  
    plotDendrograms = FALSE, plotHeatmaps = TRUE,  
    setMargins = TRUE, marDendro = NULL, 
    colorLabels = TRUE, signed = TRUE,  
    heatmapColors = NULL,  
    plotAdjacency = FALSE, 
    printAdjacency = FALSE, cex.adjacency = 0.9, 
    coloredBarplot = TRUE, barplotMeans = FALSE, barplotErrors = FALSE,  
    plotPreservation = "standard", 
    printPreservation = FALSE, cex.preservation = 0.9, 
    marHeatmap = c(3,3,2,1), 
    zlimPreservation = c(0, 1), 
    xLabelsAngle = 90) 
  print(p) 
} 
 
pdf(paste("EigNet",Fname,".pdf",sep = "")) 
MyPlotEigenNets(consMEs.ConsOrder) 
dev.off() 
Correlation with doxycycline 
load("datTraitsAll.rda") 
datTraits<-datTraits[,3:4] 
labels<-read.csv("Cons18_30_1_15_2_labels.csv") #module colors converted to names 
ylabs<-paste(labels$Label," (",labels$Size,")",sep = "") 
 
moduleTraitCorAF = cor(consMEs.ConsOrderAFdata,  
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                       datTraits[rownames(multiExprAFdata),], 
                       use = "p") 
moduleTraitPvalueAF = corPvalueStudent(moduleTraitCorAF, 
                                       nrow(multiExprAFdata)) 
textMatrixAF =  paste(signif(moduleTraitCorAF, 2),  
                    " (", signif(moduleTraitPvalueAF, 1), ")", 
                    sep = "") 
dim(textMatrixAF) = dim(moduleTraitCorAF) 
 
for(i in 1:dim(textMatrixAF)[1]){ #add * to significant results 
  for (j in 1:dim(textMatrixAF)[2]) { 
    if (moduleTraitPvalueAF[i,j]<0.05) { 
      textMatrixAF[i,j]<-paste(textMatrixAF[i,j],"*",sep = "") 
    }   
  } 
} 
 
moduleTraitCorEV = cor(consMEs.ConsOrderEVdata,  
                       datTraits[rownames(multiExprEVdata),], 
                       use = "p") 
moduleTraitPvalueEV = corPvalueStudent(moduleTraitCorEV, 
                                       nrow(multiExprEVdata)) 
textMatrixEV =  paste(signif(moduleTraitCorEV, 2),  
                      " (", signif(moduleTraitPvalueEV, 1), ")", 
                      sep = "") 
dim(textMatrixEV) = dim(moduleTraitCorEV) 
 
for(i in 1:dim(textMatrixEV)[1]){ 
  for (j in 1:dim(textMatrixEV)[2]) { 
    if (moduleTraitPvalueEV[i,j]<0.05) { 
      textMatrixEV[i,j]<-paste(textMatrixEV[i,j],"*",sep = "") 
    }   
  } 
} 
 
moduleTraitCor<-cbind(moduleTraitCorAF[1:23,],moduleTraitCorEV[1:23,]) 
textmatrix<-cbind(textMatrixAF[1:23,],textMatrixEV[1:23,]) 
 
xlabs<-c("Doxycycline\n(AFDN-DT)", 
         "AFDN-DT\nPCR Expr.\n(AFDN-DT)", 
         "Doxycycline\n(EV)", 
         "AFDN-DT\nPCR Expr.\n(EV)") 
 
png(file = "ConsTraitCorComb.png", width = 6.5, 
    height = 3.5,units = "in",res = 300);par( 
      mar = c(1.6, 11, .1, 0.1) 
      );labeledHeatmap( 
        Matrix = moduleTraitCor,  
        textMatrix = textmatrix, 
        xLabels = xlabs,  
        yLabels = names(consMEs.ConsOrderAFdata)[1:23],  
        ySymbols = ylabs, 
        yColorLabels = TRUE,  
        colors = blueWhiteRed(50), setStdMargins = FALSE,  
        cex.text = 0.6, xLabelsAngle = 0, 
        cex.lab.y = 0.6,cex.legend = 0.5, 
        cex.lab.x = 0.55, 
        xLabelsAdj = c(0.5,0.5));dev.off() 
GO enrichment 
See Chapter 2 code, page 200. 
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Chapter 5 
Basic process for RNA seq data 
• counts downloaded from recount project (https://jhubiostatistics.shinyapps.io/recount/) 
• scale counts 
• DeSeq 
• limit to genes with counts > 10 in at least 30% 
• vst (DeSeq2) 
• normalizeQuantiles (limma) 
Creation of expression matrices 
#source('http://bioconductor.org/biocLite.R') 
#biocLite('recount') 
library('recount') 
library('DESeq2') 
library(limma) 
Colon 
load("rse_geneSig34.rda") 
rse<-rse_geneSig34 
rseSig <- scale_counts(rse_geneSig34) 
Scale counts with recount package 
rse <- scale_counts(rse) 
Run DESeq 
control for RIN and batch 
dds <- DESeqDataSet(rse, design = ~as.numeric(smrin)+smgebtch) 
dds <- DESeq(dds) 
Filter to counts>10 in 30% 
n30percent<-.3*dim(rse)[2] 
countsGr10in30per<-apply(counts(dds),1,function(x){ 
  x2<-ifelse(x>10,1,0) 
  x3<-ifelse(sum(x2)>n30percent,TRUE,FALSE) 
  return(x3) 
}) 
 
dds <- dds[ countsGr10in30per, ] 
Variance stabilization 
vsd <- vst(dds, blind = FALSE) 
edata=as.data.frame(assay(vsd)) 
Scatter plot and normalization 
colramp = colorRampPalette(c(3,"white",2))(20) 
plot(density(edataSig[,1]),col=colramp[1],lwd=3,ylim=c(0,.30)) 
for(i in 2:73){lines(density(edataSig[,i]),lwd=3,col=colramp[i])} 
 
norm_edataSig = normalizeQuantiles(as.matrix(edataSig)) 
plot(density(norm_edataSig[,1]),col=colramp[1],lwd=3,ylim=c(0,.30)) 
for(i in 2:73){lines(density(norm_edataSig [,i]),lwd=3,col=colramp[i])} 
 
datExprSig<-as.data.frame(t(norm_edataSig)) 
rownames(datExprSig)<-rse_geneSig34$Person 
Repeat for Brain 
cortFilt<-rse_geneCortex$Person%in%samps # limit to samples with sigmoid data 
rse_geneCort34<-rse_geneCortex[,cortFilt] 
dim(rse_geneCort34) #[1] 58037    34 
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rseCort34<-scale_counts(rse_geneCort34) 
ddsCort<-DESeqDataSet(rseCort34,~as.numeric(smrin)) 
ddsCort<-DESeq(ddsCort) 
 
n30percent<-.3*dim(rseCort34)[2] 
countsGr10in30per<-apply(counts(ddsCort),1,function(x){ 
  x2<-ifelse(x>10,1,0) 
  x3<-ifelse(sum(x2)>n30percent,TRUE,FALSE) 
  return(x3) 
}) 
 
ddsCort <- ddsCort[ countsGr10in30per, ] 
nrow(ddsCort) #24048 
vsdCort <- vst(ddsCort, blind = FALSE) 
edataCort=as.data.frame(assay(vsdCort)) 
colramp = colorRampPalette(c(3,"white",2))(20) 
 
plot(density(edataCort[,1]),col=colramp[1],lwd=3,ylim=c(0,.30)) 
for(i in 2:33){lines(density(edataCort[,i]),lwd=3,col=colramp[i])} 
 
norm_edataCort = normalizeQuantiles(as.matrix(edataCort)) 
plot(density(norm_edataCort[,1]),col=colramp[1],lwd=3,ylim=c(0,.30)) 
for(i in 2:33){lines(density(norm_edataCort[,i]),lwd=3,col=colramp[i])} 
 
datExprCort<-as.data.frame(t(norm_edataCort)) 
rownames(datExprCort)<-rseCort34$Person 
Remove X and Y chromosome genes 
load("genedataAllcolon.rda") # probes 
 
ensemblIDs <- sapply( strsplit( as.character(genedataAll$Probe), split="\\." ), "[", 1 ) 
 
library( "biomaRt" ) 
ensembl = useMart( "ensembl", dataset = "hsapiens_gene_ensembl" ) 
genemap <- getBM( attributes = c("ensembl_gene_id", "entrezgene", "hgnc_symbol", "description","chromosome
_name"), 
                  filters = "ensembl_gene_id", 
                  values = ensemblIDs, 
                  mart = ensembl ) 
idx <- match( ensemblIDs, genemap$ensembl_gene_id ) 
genedataAll<-data.frame(Probe=genedataAll$Probe, ENS=ensemblIDs,EntrezID=genemap$entrezgene[idx],Symbol=ge
nemap$hgnc_symbol[idx], Name=genemap$description[idx],Chr=genemap$chromosome_name[idx]) 
 
noXY<-as.character(genedataAll$Probe[!genedataAll$Chr%in%c("X","Y")]) 
 
datExprSigNoXY<-datExprSig[,names(datExprSig)%in%noXY] 
datExprSigNoXYconsSamp<-datExprSigNoXY[ConsensusSample,] 
 
datExprCortNoXY<-datExprCort[,names(datExprCort)%in%noXY] 
datExprCortNoXYconsSamp<-datExprCortNoXY[ConsensusSample,] 
save(datExprCortNoXY,file = "datExprCortNoXY.rda") 
save(datExprCortNoXYconsSamp,file = "datExprCortNoXYconsSamp.rda") 
 
Genes<-intersect(names(datExprCortNoXYconsSamp),names(datExprSigNoXYconsSamp)) 
datExprBrain<-datExprCortNoXYconsSamp[,Genes] 
datExprColon<-datExprSigNoXYconsSamp[,Genes] 
multiExpr<-multiData(Colon=datExprColon, Brain=datExprBrain) 
Of the 34 samples with sigmoid colon and cerebral cortex there are 29 that are not outliers in either (outliers based on 
sample clustering in WGCNA) 
Softpower threshold 9 worked for both brain and colon. For signed network, power is doubled. 
WGCNA 
Tissue-specific and consensus networks 
Run WGCNA as in Chapter 4 (Tissue-specific: page 210, Consensus: page 212) with the following parameters (used 
for both tissue specific and consensus analyses) 
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library(WGCNA) 
options(stringsAsFactors = FALSE) 
allowWGCNAThreads() 
 
#parameters----- 
softPower = 18 
netType = "signed" 
minModuleSize = 80 
deepSplit = 1 
MEDissThres = 0.15 
Unified network 
Combine top 10,000 by max variance 
load("datExprSigNoXYconsSamp.rda") 
load("datExprCortNoXYconsSamp.rda") 
 
c<-datExprSigNoXYconsSamp 
b<-datExprCortNoXYconsSamp 
 
names(c)<-paste("c",names(c),sep = "_") 
names(b)<-paste("b",names(b),sep = "_") 
 
tb<-as.data.frame(t(b)) 
tb$var<-apply(tb,1,var) 
tb<-tb[order(tb$var,decreasing = TRUE),] 
topVarB<-rownames(tb)[1:10000] 
b<-b[,names(b)%in%topVarB] 
 
tc<-as.data.frame(t(c)) 
tc$var<-apply(tc,1,var) 
tc<-tc[order(tc$var,decreasing = TRUE),] 
topVarC<-rownames(tc)[1:10000] 
c<-c[,names(c)%in%topVarC] 
 
datExpr<-cbind(b,c) 
Run WGCNA 
# parameters 
softPower = 12 
netType = "signed" 
minModuleSize = 80 
deepSplit = 1 
MEDissThres = 0.15 
Gene Ontology Enrichment 
See Chapter 2 code, page 200. 
 
 
 
 
 
 
